UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, 2009

Commission File Number: 000-50470

CERAGENIX PHARMACEUTICALS, INC.

(Exact name of registrant as Specified in its Charter)

Delaware		84-1561463
(State or Other Jurisdiction of Incorporation or Organization)		(Internal Revenue Service Employer Identification Number)

1444 Wazee Street, Suite 210, Denver, Colorado		80202
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (720) 946-6440

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $.0001 par value per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes x No o

Indicate by checkmark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). o Yes o No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment of this Form 10-K: x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer o

Non-accelerated filer o		Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes o No x

The aggregate market value of the voting and non-voting common stock ($.0001 par value) held by non-affiliates was approximately $2,177,175 as of June 30, 2009 based upon the average bid and asked price of the registrant’s common stock on the Nasdaq Electronic Bulletin Board.

As of April 12, 2010, the registrant had 18,303,293 shares of its common stock ($.0001 par value) outstanding.

Table of Contents

Table of Contents

		Page

Forward Looking Statements		1
	PART I	1
Item 1.	Description of Business	1
	The Company	1
	Our Strategy	2
	Our Technology	4
	Product and Product Candidates	8
	Product Markets	9
	Sales and Marketing	10
	Competition	10
	License Agreements and Proprietary Rights	11
	Trademarks	12
	Government Regulation	12
	Employees	14
Item 1A.	Risk Factors	14
Item 1B.	Unresolved Staff Comments	24
Item 2.	Properties	24
Item 3.	Legal Proceedings	24
Item 4.	Submission of Matters to a Vote of Security Holders	24
Executive Officers of the Registrant		25

Item 5.	Market for the Company’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	25
Item 6.	Selected Financial Data	26
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	35
Item 8.	Financial Statements and Supplementary Data	35
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	61
Item 9A.	Controls and Procedures	61
Item 9B.	Other Information	61

	PART III
Item 10.	Directors, Executive Officers and Corporate Governance	62
Item 11.	Executive Compensation	65
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	71
Item 13.	Certain Relationships and Related Transactions, and Director Independence	72
Item 14.	Principal Accountant Fees and Services	74

	PART IV
Item 15.	Exhibits	74
SIGNATURES		77

Table of Contents

FORWARD LOOKING STATEMENTS

Our disclosure and analysis in this Annual Report on Form 10-K (this “Form 10-K”), in other reports that we file with the Securities and Exchange Commission (“SEC”), in our press releases and in public statements of our officers contain forward-looking statements. Forward-looking statements are based on the current expectations of or forecasts of future events made by our management. Forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Form 10-K, for example general economic conditions, governmental regulation and competition in our industry, will be important in determining future results. No forward-looking statement can be guaranteed, and actual results may vary materially from those anticipated in any forward-looking statement.

You can identify forward-looking statements by the fact that they do not relate strictly to historical or current events. They use words such as “anticipate,” “estimate,” “expect” “will,” “may,” “intent,” “plan,” “believe,” and similar expressions in connection with discussion of future operating or financial performance. These include statements relating to future actions, prospective products or product approvals, future performance or results of anticipated products, expenses, financial results or contingencies.

Although we believe that our plans, intentions and expectations reflected in these forward-looking statements are reasonable, we may not achieve these plans or expectations. Forward-looking statements in this Form 10-K will be affected by several factors, including the following: the ability of the Company to raise sufficient capital to finance its planned activities including completing development of its Ceragenin™ technology; the ability of the Company to meet its obligations under the supply and distribution agreement with Dr. Reddy’s Laboratories; the ability of the Company to service its outstanding convertible debt obligations; the ability of the Company to maintain its intellectual property rights including its ability to pay its obligations under the license agreements within the timeframes required by the agreements; receiving the necessary marketing clearance approvals from the United States Food and Drug Administration (the “FDA”); successful clinical trials of the Company’s planned products including the ability to enroll the studies in a timely manner, patient compliance with the study protocol, and a sufficient number of patients completing the studies; the ability of the Company to commercialize its planned products; the ability of the Company to successfully manufacture its products in commercial quantities (through contract manufacturers); market acceptance of the Company’s planned products, the Company’s ability to successfully develop its licensed compounds, alone or in cooperation with others, into commercial products, the Company’s ability to successfully prosecute and protect its intellectual property, and the Company’s ability to hire, manage and retain qualified personnel. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained in this Form 10-K. In particular, this Form 10-K sets forth important factors that could cause actual results to differ materially from our forward-looking statements. These and other factors, including general economic factors, business strategies, the state of capital markets, regulatory conditions, and other factors not currently known to us, may be significant, now or in the future, and the factors set forth in this Form 10-K may affect us to a greater extent than indicated. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this Form 10-K and in other documents that we file from time to time with the SEC including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to be filed in 2010. Except as required by law, we do not undertake any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

PART I

Item 1. Business

THE COMPANY

Ceragenix Pharmaceuticals, Inc., a Delaware corporation, is an emerging medical device company focused on infectious disease and dermatology. We have two base technology platforms each with multiple applications: Ceragenins™ (also known as cationic steroid antibiotics or “CSAs”) and barrier repair (“Barrier Repair”). References to “the Company,” “we,” “our,” or “us” in this Form 10-K refer to Ceragenix Pharmaceuticals, Inc. and Ceragenix Corporation.

Our Ceragenin™ technology, licensed from Brigham Young University, covers the composition of matter and use of a broad class of small molecule, positively charged aminosterol compounds. These patented compounds mimic the activity of the naturally occurring antimicrobial peptides that form the body’s innate immune system and several of these candidates are currently in pre-clinical development. Ceragenin™ compounds are electrostatically attracted to bacteria, viruses, fungi and cancers that all share in common the presence of negatively charged phospholipids on their cell membrane surfaces. The compounds are believed to primarily act via induction of apoptosis by rapid depolarization of the cell membranes (by tearing holes in the cell walls). Unlike most antibiotics which are bacteriastatic (prevents the reproduction of bacteria cells), the Ceragenins™ are bacteriacidal (kills the bacterial cells). Our Ceragenin™ technology has shown activity against bacteria, and certain viruses, fungi and cancers in a variety of in vitro tests. While Ceragenins™ have the potential to be developed for a broad range of applications, we intend to focus our efforts on

Table of Contents

developing them as an antimicrobial treatment for medical devices such as endotracheal tubes, catheters and implantable devices to help combat the growing number of hospital acquired infections in the United States and throughout the world.

To that end, during 2009, we entered into three development agreements with potential commercialization partners that provide these partners with an exclusive period of time to test, evaluate and negotiate commercialization terms for specific devices using our Ceragenin™ technology. We anticipate entering into several similar agreements during 2010. It is our expectation that we will be able to generate revenue from the Ceragenin™ technology prior to receiving FDA approvals in the form of upfront and milestone payments under development and sublicense agreements.

Further, during 2009, the National Institutes of Health (the “NIH”) awarded two grants aggregating approximately $4.5 million to third parties for the development of our Ceragenin™ technology. One of these grants is for the development of CSA-13 as an oral drug to treat Clostrdium difficile and Shigella two common and potentially deadly gastrointestinal infections. The grant will fund the preclinical development, formulation, toxicology and cGMP scale up to 1 kilogram of CSA-13. While our stated focus is on developing our anti-infective technology as a coating for medical devices, we are interested in letting others pursue drug applications if it does not require significant financial resources from the Company. The other grant will evaluate the use of a CSA-13 based coating for orthopedic implants in a preclinical model to evaluate the safety and efficacy of this approach in preventing and eradicating bacterial biofilm. Bacterial biofilms on implanted orthopedic medical devices is a major medical concern, as such bacterial contamination may lead to serious infections necessitating removal of the implant and treatment with extended courses of antibiotics. We anticipate that both of these grants will advance the knowledge, understanding, and testing of CSA-13 in ways that may be beneficial to our efforts to create the needed data package to allow regulatory review of Cerashield™ coated or treated devices in the future. Most, if not all, of our Cerashield™ coating applications involve use of CSA-13 as the active ingredient. As CSA-13 has no prior approved use, it is viewed as a New Chemical Entity by the FDA as well as foreign regulatory bodies. Therefore, data developed under these grants that helps to address the safety and efficacy of CSA-13, as well as cGMP manufacturing of CSA-13, is potentially very valuable to the Company.

We have also licensed patents from the Regents of the University of California for a Barrier Repair technology that is a specific combination of ceramides, cholesterol and fatty acids which are able to create a human-like skin barrier and thus provide patients with a more normal skin barrier function. This patented Barrier Repair technology is the invention of Dr. Peter Elias, Chairman of our Scientific Advisory Board, and the author of over 500 peer reviewed journal articles. Our first developed product using this technology is EpiCeram®.

EpiCeram® is a prescription only product intended for use to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including atopic dermatitis (“eczema”), irritant contact dermatitis, and radiation dermatitis. All of these conditions share in common a defective or incomplete skin barrier, and we believe current therapies are viewed as either lacking effectiveness or in need of improvement. In April 2006, we received marketing clearance from the FDA to sell EpiCeram® as a medical device pursuant to a 510(k) filing. The clearance received from the FDA allows us to market EpiCeram® for all of the above listed conditions. In April 2007, we announced the results of a 113 person clinical trial which demonstrated that EpiCeram® had comparable efficacy to a mid strength steroid in treating the symptoms associated with eczema after 28 days of treatment. In November 2007, we entered into an exclusive distribution and supply agreement with Dr. Reddy’s Laboratories, Inc. (“DRL”) for the commercialization of EpiCeram® in the United States (the “DRL Agreement”). Under the terms of the DRL Agreement, we are responsible for manufacturing (through a contract manufacturer) and supplying the product while DRL is responsible for distribution, marketing and sales. During September 2008, we shipped the first commercial quantities of EpiCeram® to DRL and DRL officially launched sales and marketing efforts during October 2008.

During 2009, we entered into several exclusive international distribution and supply agreements for EpiCeram®. Commercialization efforts were launched in Canada under one of these agreements during the latter part of 2009, and we expect commercialization activities to commence in certain Asian countries, certain European countries and Israel during 2010. Further, we anticipate entering into additional international agreements during 2010.

Our executive offices are located at 1444 Wazee Street, Suite 210, Denver, Colorado 80202. Our telephone number is (720) 946-6440

OUR STRATEGY

Our principal objective is to be a leading provider of technology used in the prevention and treatment of infectious disease. More specifically, we want our Cerashield™ antimicrobial coatings to be utilized by leading manufacturers to coat their catheters, implantables and devices to prevent the bacterial colonization of such products. Bacterial colonization of indwelling medical devices is a leading cause of nosocomial (hospital acquired) infections. Leading healthcare organizations such as the World Health Organization and the U.S. Centers for Disease Control (the “CDC”) have recognized that the growing number of multidrug resistant

Table of Contents

bacterial infections poses a major worldwide health risk. According to the CDC, during 2002, there were approximately 1.7 million nosocomial infections in the United States resulting in 99,000 deaths (up from 13,000 in 1992). The NIH now estimates that nosocomial infections add between $28 billion and $32 billion annually to health care costs in the United States. Over half of these infections were attributable to bacterial growth on medical devices and the greatest risk of mortality is associated with multidrug resistant bacterial infections. In August of 2007, the Center for Medicare Services (CMS) issued a ruling that it will no longer reimburse hospitals for certain hospital acquired infections including those related to urinary tract infections (associated with urinary catheters) and certain central venous line related bloodstream infections. This ruling went into effect in October 2008. Each year CMS expects to add additional nosocomial infections to its exclusionary list. As a result, hospitals and third party payors are seeking solutions from device makers to help reduce the incidence of nosocomial infections.

We believe that our Ceragenin™ class of compounds has the potential to be a solution for combating nosocomial infections. Our Cerashield™ technology (utilizing CSA-13) is being developed in a variety of forms: (i) as a coating in combination with a polyurethane polymer which may be dip coated onto a broad range of polymeric and metallic medical devices which allows CSA-13 to elute out over time; (ii) as a covalent attachment to polymers (including textiles) and metals to provide a shield against bacterial colonization that does not migrate from the surface; and (iii) by direct incorporation into polymers (during the melt process) to create catheters and other components of medical devices that have antimicrobial activity built into the device without the need for an exterior coating. Our primary strategy is to license Cerashield™ on a device by device basis to the manufacturers of such devices. We are evaluating retaining one or more niche applications of the technology to commercialize ourselves once our financial and managerial resources make such approach a viable option. We believe that antimicrobial treated devices with demonstrated ability to prevent or reduce bacterial colonization can demand premium pricing in the market based on cost savings to payors and/or reduction in morbidity and/or mortality rates. Our goal is to establish Cerashield™ as the most efficacious antimicrobial technology available for medical devices. We believe that current antimicrobial approaches (such as silver) are of limited efficacy and duration. We plan to target Cerashield™ development for several devices with high incidences of infection such as endotracheal tubes, urinary catheters, and central venous catheters as well as those devices associated with less frequent but catastrophic infections. We believe that there is a broad range of medical devices that would benefit from use of our Cerashield™ technology and we are pursuing collaboration arrangements with medical device manufacturers. As discussed previously in “The Company”, during 2009, we entered into three formal collaboration agreements with medical device manufacturers and anticipate entering into several new agreements during 2010.

While our in-vitro testing activities have demonstrated that one or more of our lead Ceragenin™ compounds may have efficacy as a pharmaceutical therapy against key pathogens associated with various diseases (e.g. multidrug resistant Pseudomonas aeuroginosa associated with respiratory infections in Cystic Fibrosis patients), we plan to focus on Cerashield™ applications that will be regulated as medical devices as opposed to pharmaceutical therapies which would require regulation as new drugs. We have based this decision on the following considerations:

· Anticipated development costs;

· Projected timeframes associated with regulatory approvals;

· Heightened awareness on the part of payors, physicians and patients of nosocomial infections;

· Anticipated market demand;

· Currently available and anticipated competitive products; and

· Projected financial resources available to the Company.

However, as discussed previously in “The Company”, during 2009, a consortium of research institutions were awarded a $2.87 million grant to fund the pre-clinical development of a Ceragenin™ based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella. The grant will fund the preclinical development, formulation, toxicology and cGMP scale up to 1 kilogram of CSA-13. While our stated focus is on developing our anti-infective technology as a coating for medical devices, we are interested in letting others pursue drug applications if it does not require significant financial resources from the Company as the preclinical testing may result in data that can be valuable in developing our coatings business and may also result in licensing opportunities for the drug.

We believe that we can partially fund the development costs for our Ceragenin™ technology through cash flows generated from sales of EpiCeram®. While revenues from EpiCeram® are not yet sufficient to make the Company profitable, we believe that EpiCeram® revenues can provide a significant contribution to defraying operating costs by 2011.

Table of Contents

A key component of our current business strategy has been to operate as a fairly “virtual” company until such time as the business requires a more robust infrastructure. We believe this strategy has been successful as it allowed us to direct a greater percentage of our financial resources into product development and provided us with greater flexibility by limiting the size of our corporate infrastructure and workforce. While it is possible that we will hire additional management and staff resources during 2010 to develop our business, we believe we can keep our corporate and development staff to levels that are substantially lower than found in traditional medical device companies by carefully leveraging third party expertise.

OUR TECHNOLOGY

We have two base technology platforms; Ceragenins™ and Barrier Repair. Our primary focus in the future will be on Ceragenin™ development given the remaining patent life of the Barrier Repair technology (4.5 years). See “License Agreements and Proprietary Rights.” A discussion of both technologies follows below.

Ceragenins™

As discussed above, we plan to utilize our Ceragenin™ technology to develop new generation antimicrobial protection for medical devices. Ceragenins™ are small molecule, positively charged compounds that have shown promising activity against bacteria, and certain viruses, fungi and cancers in a variety of preclinical tests. These patented compounds mimic the activity of the naturally occurring antimicrobial peptides that form the body’s innate immune system. The compounds are electrostatically attracted to bacteria, viruses, and certain lines of cancer cells that all share in common the presence of negatively charged phospholipids on their cell membrane surfaces. The compounds are believed to primarily act via induction of apoptosis by rapid depolarization of the cell membranes (tearing holes in the cell walls). Unlike most antibiotics which are bacteriastatic (preventing the reproduction of bacteria cells), the Ceragenins™ are bacteriacidal (kills the bacterial cells). Other efforts to duplicate the naturally occurring antimicrobial peptides have proven not to be commercially viable because of the inability to stabilize and cost effectively produce bulk quantities of such compounds. Ceragenins™, however, are neither peptides nor steroids, but rather cationic steroid shaped small molecules that we believe are far simpler, more stable and inexpensive to produce in bulk quantities.

Since May 2005, we have accomplished the following developments related to our Ceragenin™ technology:

In vitro testing

·	Demonstrated that a Ceragenin™ based coating prevented bacterial colonization on titanium surfaces and eradicated staphylococcus aureus and E. coli bacteria in the fluid surrounding the coated disk;

·	Presented data at a meeting of the American Academy of Dermatology showing that use of one of our Ceragenin™ compounds (CSA-8) when used in combination with mupirocin (a commonly used topical antibiotic active against gram-positive bacteria) was able to expand mupirocin’s spectrum of activity to include gram-negative bacteria such as E. coli, salmonella and kleibsiella;

·	Demonstrated that our leading Ceragenin™ pre-clinical compound, CSA-13, was highly effective against vancomycin-resistant staphylococcus aureus (“VRSA”), vancomycin-resistant enterococci (“VRE”), vancomycin intermediate resistant staph aureus (“VISA”), hospital acquired MRSA, and community associated MRSA (“CA-MRSA”) at minimum inhibitory concentrations (“MIC”) of under .25 micrograms/ml;

·	Demonstrated that compound CSA-13 was highly effective in vitro against strains of pseudomonas infections isolated from cystic fibrosis patients (MIC values of 1 to 3 micrograms/ml) that are highly resistant to tobramycin (mics of over 80 micrograms/ml are required);

·	Demonstrated that compound CSA-13 was highly effective in vitro against pseudomonas aueroginosa, E. coli;

·	Demonstrated that compound CSA-13 was highly effective in vitro against bioterrorism surrogate strains of anthrax, listeria and plague;

·	Demonstrated that compounds CSA’s -8, -13 and -54 possessed activity similar to human angiostatins in vitro and that the compounds had been accepted by the National Cancer Institute’s developmental therapeutics program to evaluate potential activity in inhibiting the growth of tumor blood supply;

·	Demonstrated that compound CSA-54 was highly active against Epstein-Barr virus;

Table of Contents

·	Demonstrated that compound CSA-13 was highly active in vitro against the vaccinia virus;

·	Demonstrated that compound CSA-54 showed potent virucidal activity testing against multiple strains of HIV;

·	Demonstrated that CSA-13 and CSA-54 showed the ability to inhibit angiogenesis at low micromolar concentrations in testing performed by the National Cancer Institute;

·	Demonstrated that CSA-13 was 100 times more effective in eradicating a MRSA biofilm than vancomycin;

·	Demonstrated that CSA-13 was able to significantly inhibit bladder cancer growth with minimal toxicity to normal cells;

·	Demonstrated that CSA-13 was able to prevent influenza infection by H3N2, one of the common strains of Type A Influenza;

·	Developed a prototype contact lens disinfectant solution that demonstrated the ability to virtually eradicate the bacterial and fungal strains that the FDA specifies for testing pursuant to its published guidance document;

·	Demonstrated that Ceragenin™ treated hemodialysis catheters were able to virtually prevent bacterial colonization in a 21 day study;

·	Demonstrated in a series of experiments that CSA-13 shows promise as a potential therapy to treat multidrug resistant Pseudomonas aeuroginosa infections which are a leading cause of morbidity and mortality in patients with cystic fibrosis;

·	Demonstrated in a series of experiments that CSA-13 showed rapid killing activity and synergistic activity with conventional antibiotics against multidrug resistant Pseudomonas aeuroginosa bacterial strains. P. aeuroginosa is a leading cause of morbidity and mortality in patients with pneumonia and other respiratory diseases;

·	Demonstrated in a series of experiments that prototype Cerashield™ coated endotracheal tube segments were able to completely prevent bacterial adhesion and biofilm formation in a 21 day continuous challenge test;

·	Demonstrated that Cerashield™ coated silicone urinary catheters provided complete protection against E.Coli bacterial colonization for the entire duration of the 21 day study when challenged with daily inocula of 1,000 colony forming units of E. Coli;

·	Demonstrated that a silicone intravaginal ring incorporating CeraShield™ achieved 224 days of continuous antimicrobial efficacy when soaked in artificial urine with a fresh inoculum of at least 1,000 colony forming units per ml of E. coli on a daily basis;

·	Demonstrated that CSA-13 was effective in preventing biofilm growth on disks of material used in dentistry for artificial teeth (hydoxyappetitate); and

·	Demonstrated that CSA-13 was effective against H.pylori, a common pathogen linked to stomach ulcers, stomach cancer and various other diseases.

In vivo-testing

·	Demonstrated in a pilot study (sheep), that Cerashield™ treated surgical screws did not have any adverse biological, histological or hematological effects on bone tissue healing or remodeling compared to untreated screws. However, given the small number of animals (n=2), the study did not allow for extended interpretations or provide statistically conclusive data;

	Given our limited financial resources, our ability to expand testing is primarily limited to:

·	Testing performed by individual investigators (usually in academic settings) to whom we have sent compound at little or no cost;

·	Testing performed by potential commercialization partners under material transfer agreements or formal development agreements; or

·	Testing performed under NIH grants.

Table of Contents

During 2010, we expect to continue testing under the arrangements described above as well as commence testing under new but similar agreements that are not yet identified.

Barrier Repair

Our Barrier Repair technology is a specific combination of epidermal lipids which are able to create a human-like skin barrier and thus provide patients with a more normal skin barrier function. Defects in the skin’s barrier function play critical roles in the pathogenesis of certain skin diseases such as eczema. The skin’s barrier is composed of a thin sheet of epidermal lipids about half the thickness of a piece of notebook paper. This thin, flexible, strong combination of lipid components forms a mechanical defense against skin irritants and bacterial infections while also helping to retain skin moisture. Persons with a deficient skin barrier suffer from higher levels of moisture evaporating through their skin also known as trans-epidermal water loss (“TEWL”). TEWL leads to dry, itchy, cracked skin which can then lead to further degradation of the skin’s barrier. Deficient skin barrier function can be caused by both internal factors (i.e. genetic predisposition and/or immune system related misregulation) and external factors (i.e. radiation treatment and other skin irritants).

Since May 2005, we accomplished the following developments related to our Barrier Repair technology:

· Received 510(k) marketing clearance from the FDA for EpiCeram®, our first prescription barrier product candidate;

· Demonstrated that EpiCeram® accelerated skin barrier recovery in eczema patients afflicted with moderate to severe symptoms compared to untreated patients in a small but statistically significant third party study. The objective measurement of this study showed that there was 100% reduction in itch, an over 50% reduction in dry skin, over 36% reduction in scaliness and an over 37% reduction in irritation/inflammation (each at the 3 and 6 hour measurement points after applying EpiCeram®);

· Completed a 113 person clinical study to compare the efficacy of EpiCeram® to Cutivate®, a commonly prescribed mid strength steroid, in children with moderate to severe eczema. In the study, we demonstrated that there was no significant statistical difference in efficacy between EpiCeram® and Cutivate® in treating the symptoms of eczema after 28 days of treatment. More detailed study results were as follows:

Study Design

The study was an investigator-blinded, randomized controlled study conducted at five centers which evaluated a total of 113 patients in two groups of children (ages 6 months to 18 years) with moderate-to-severe eczema treated with either Cutivate® Cream, a mid-potency topical steroid, or EpiCeram®. The study was primarily conducted during the winter months of December (‘06), January (‘07) and February (‘07).

Primary and Secondary Outcome Measures

According to the protocol, the primary outcome measure was the change in mean SCORAD score measured at Day 28 as compared to the baseline. The protocol’s secondary efficacy parameters were:

· Percentage of subjects reaching clear or almost clear on Investigator’s Global Assessment (IGA) at Day 28;

· Change in patient reported assessments of pruritus (itch); and

· Change in patient reported assessment of disturbance of sleep habits.

Table of Contents

Study Results

Primary Outcome Measure (change in mean SCORAD score measured at Day 28 compared to Baseline)

Daily (twice) applications of both Cutivate® Cream and EpiCeram® produced significant reductions in SCORAD scores at Day 28 compared to baseline values. Daily (twice) applications of EpiCeram® produced statistically significant improvement of eczema after 28 days with a reduction in SCORAD scores of 56.41% from baseline. Daily (twice) applications of the comparator product, Cutivate® cream, also produced statistically significant improvement of eczema after 28 days with a reduction in SCORAD scores of 68.77%. Statistical comparison of the treatment effects (SCORAD scores) showed no statistically significant difference between treatment effects after 28 days of treatment.

Secondary Outcome Measures

A. Percentage of subjects reaching clear or almost clear on IGA at Day 28

Assessment of the disease progression showed significant improvements in the IGA scores over time for both EpiCeram® and Cutivate® cream with 61.1% of the EpiCeram® patients assessed as clear or almost clear after 28 days of treatment and 76.2% of the Cutivate® cream patients being assessed as clear or almost clear at Day 28. Comparison of the disease progression results for both treatments showed no statistically significant difference between EpiCeram® and Cutivate® cream after 28 days of treatment.

B. Assessment of Pruritus

Patient reported assessments of pruritus also showed significant improvement from baseline after 28 days of treatment for both EpiCeram® (3.54 change from baseline) and Cutivate® cream (3.75 change from baseline). No statistically significant differences were found between treatments after 28 days of treatment.

C. Assessment of Sleep Habits

Patient reported assessments of sleep habits also showed significant improvement from baseline after 28 days of treatment for both EpiCeram® (2.63 change from baseline) and Cutivate® cream (2.81 change from baseline). No statistically significant differences were found between treatments after 28 days of treatment.

Safety

The investigators concluded that use of EpiCeram® was safe for use under the conditions of the study. There were no serious adverse events reported in the study, all but one of the reported adverse events was either mild or moderate and all were consistent with the symptoms of eczema. The investigators recommended that four EpiCeram® patients experiencing adverse events temporarily discontinue use of the product. Two of these patients fully resolved. The investigators made no recommendation that any of the Cutivate® patients discontinue use.

Completed a 38 person clinical study to compare the efficacy of EpiCeram® to Elidel®, a commonly prescribed non steroidal therapy, in children with mild to moderate eczema. In the study, we demonstrated that both EpiCeram® and Elidel® produced significant improvement after four weeks of treatment. More detailed study results were as follows:

Study Design

The study was an investigator-blinded, randomized controlled study conducted at two centers which evaluated a total of 38 patients in two groups of children (ages 6 months to 12 years) with mild-to-moderate eczema treated with either Elidel® (pimecrolimus 1%), an immunosuppressant cream, or EpiCeram®. The study was conducted from April 2007 to January 2008.

Primary and Secondary Outcome Measures

According to the protocol, the primary outcome measure was the change in median Eczema Area and Severity Index (“EASI”) scores measured at Day 28 as compared to the baseline. The protocol’s secondary efficacy parameters were:

· Percentage of subjects reaching clear or almost clear on IGA at Day 28; and

· Change in patient reported assessments of pruritus (itch).

Table of Contents

Study Results

Primary Outcome Measure (change in median EASI score measured at Day 28 compared to Baseline)

Daily (twice) applications of Elidel® produced significant reductions in EASI scores at Day 28 compared to baseline. While twice daily applications of EpiCeram® did not produce statistically significant improvement in EASI scores at Day 28, the overall improvement produced by EpiCeram® was not statistically different from that produced by Elidel®. Additionally, there were no statistically significant differences between EpiCeram® and Elidel® in the proportion of subjects with either greater than 50% improvement in EASI scores or greater than 75% improvement in EASI scores at Day 28.

Secondary Outcome Measures

A. Percentage of subjects reaching clear or almost clear on IGA at Day 28

Both treatments demonstrated statistically significant reductions in eczema symptoms as measured by IGA at Day 28. Assessment of the disease progression showed significant improvements in the IGA scores over time with 27% of the EpiCeram® patients assessed as clear or almost clear after 28 days of treatment and 44% of Elidel® patients being assessed as clear or almost clear at Day 28. Comparison of these disease progression results for both treatments showed no statistically significant difference between EpiCeram® and Elidel® after 28 days of treatment.

B. Assessment of Pruritus

Patient reported assessments of pruritus also showed significant improvement from baseline after 28 days of treatment for both EpiCeram® and Elidel®. No statistically significant differences were found between treatments after 28 days of treatment.

Safety

The investigators concluded that use of EpiCeram® was safe for use in the patient population studied. There were no serious adverse events reported in the study and both treatments had similar rates of adverse events.

· Entered into the DRL Agreement to commercialize EpiCeram® in the United States;

· Commenced shipment of EpiCeram® for commercial launch in the United States;

· Entered into exclusive distribution and supply agreements for commercialization of EpiCeram® in Southeast Asia; Canada, Europe, Israel, Taiwan, Hong Kong, and South Korea; and

· Commenced shipment of EpiCeram® for commercial launch in Canada and Southeast Asia.

PRODUCTS AND PRODUCT CANDIDATES

Nearly all of our product candidates will require clearance by the FDA and in certain cases extensive clinical evaluation before we can sell them either directly or via partners. Any product or technology under development may not result in the successful introduction of a new product.

Cerashield™ Antimicrobial Technology

We believe that our Ceragenin™ class of compounds has the potential to be a solution for combating nosocomial infections. For information on our Cerashield™ technology, see the discussion under the heading “Our Strategy.” We believe that Cerashield™ coatings can receive regulatory approval as medical devices under Pre-Market Approval (“PMA”) regulatory filings or in certain applications under 510(k) (see Government Regulation). However, there is no assurance that the FDA will agree with our conclusions.

Table of Contents

We do not plan on doing any new drug development unless that development is funded by potential collaboration partners, existing grants or potential grant applications. As discussed previously under “The Company”, the NIH has approved a grant to fund development of CSA-13 as an oral drug for Clostrdium difficile and Shigella.

Barrier Repair

EpiCeram®

NeoCeram®

NeoCeram® is a pediatric barrier repair cream intended to help create a skin barrier in premature infants and neonates. Infants born prematurely enter the world without fully formed skin barriers. As lung surfactant therapy has pushed back the age of viability to 23 weeks of gestational age, the lack of an adequate skin barrier is now of critical importance to morbidity and mortality in this at-risk population. We believe that by providing the topical equivalent of a skin barrier, these infants will develop more rapidly, be at lower risk for bacterial infections and sepsis, and spend less time in the neonatal intensive care unit thereby significantly reducing the costs incurred by the health care system to care for these infants. We had intended to utilize our 510(k) approval for EpiCeram® to market NeoCeram® using an identical formulation packaged for single dose use. However, based on a recent feedback we have received, we believe that we will likely have to file a new 510(k) application for the product. Development activities for NeoCeram® are currently on hold pending additional financing. There is no assurance that we will ever commercialize NeoCeram®.

PRODUCT MARKETS

Ceragenin™ Based Products

Cerashield™ Antimicrobial Coatings

Every year, approximately 1 million Americans acquire infections while hospitalized as the result of implantation of medical devices such as urinary catheters, central venous catheters, endotracheal tubes, pacemakers, orthopedic implants and fixator pins. These devices act as focal points for bacterial adhesion, growth and infection. Certain of these infections have lethal consequences resulting in over 50,000 deaths each year while non-lethal infections prolong hospital stays, complicate recoveries and increase costs. It has been estimated that the cost of treating medical-device related infections run into the billions of dollars annually. Medical device related infections are becoming of even greater concern in recent years as a result of the development of an increased number of multiple drug resistant bacterial strains particularly in the hospital setting, which are proving increasingly difficult to safely and successfully treat. Nearly every implantable medical device is susceptible to infections by a variety of pathogens, with implantable devices estimated to account for over 50% of all nosocomial infections. Depending on the length of time a medical device is present in the body, the likelihood for a biofilm related infection increases, and biofilm based infections typically require dramatically higher antibiotic concentrations to treat. For example, it has been estimated that up to 90% of bloodstream infections in the hospital setting are related to the use of some type of intravascular medical device. While many factors contribute to the medical device related infection rate, including health care worker hand washing and training procedures, sterilization protocols, and prophylactic use of antibiotics, the development of catheter wound dressings and antimicrobial technology for medical devices aimed at helping to prevent the development of device-related infections is an area of growing interest. Current antimicrobial coatings are extremely limited and in general do not provide very effective long-lasting antimicrobial protection.

Medical device markets are large, and we believe that currently available methods for combating the higher incidence of infection associated with those devices lack effectiveness. For example, each of the following segments of the medical device market has annual sales over $100 million and has also been reported to have infection rates in the 1% to 30% range: urinary catheters, central venous catheters, dental implants, fracture fixation (including fixator pins and orthopedic implants), and pacemakers. There are a variety of additional attractive market segments with unmet antimicrobial coating needs including segments such as endotracheal tubes, needleless connectors, antimicrobial medical sponges, and wound dressings. We believe that there is a large opportunity for introducing a new generation catheter, wound dressing or antimicrobial coating that is safe, effective and provides longer lasting protection than available product offerings.

Table of Contents

Barrier Repair Products

EpiCeram®

Atopic Dermatitis

An estimated 15 million Americans suffer from the disease Atopic Dermatitis, which is commonly known as eczema. Eczema is the leading skin disease of childhood and 65% of those affected show clinical symptoms by 6 months of age. The skin of eczema patients becomes extremely itchy and inflamed, causing redness, swelling, cracking and scaling. The skin can become so severely irritated, patients often scratch themselves until they bleed, leading to a secondary infection. Histological analysis of the skin of eczema patients reveals a global deficiency in epidermal lipids (ceramides, cholesterol and essential fatty acids) with a marked deficiency of ceramides. This lack of epidermal lipids leads to a defective skin barrier. Normalizing the barrier is the key to successful treatment. The work of Dr. Elias has shown that topical application of an optimal molar ration of these epidermal lipids can correct the skin barrier abnormality. We believe that EpiCeram® will greatly reduce skin irritation, quickly reduce itch, and help to restore a more normal skin barrier than currently available products. While there are multiple products and treatments for eczema, the most commonly prescribed treatments are immune system suppressants or steroids both of which have well recognized undesirable side effects. Immunomodulator drugs used for treating eczema recently received a black box safety warning from the FDA that is resulting in a substantial decline in sales for these products since 2004, when they combined had over $500 million in sales. EpiCeram® is non steroidal and is not an immunomodulator The current market size for eczema treatments is believed to be between $800 million and $900 million annually in the U.S. alone.

NeoCeram®

It is estimated that 80,000 infants a year are born in the U.S. under 32 weeks of gestational age. Infants under 32 weeks lack a fully developed skin barrier. Pre-term infants spend an average of 56 days in the neonatal intensive care unit (“NICU”) at a total cost estimated to be $18 billion annually in the United States. The lack of a fully formed barrier increases the risk of infections (sepsis) and other medical complications due to excessive trans-epidermal water loss. Pre term infants who develop sepsis (20%) spend an additional 19 days in the NICU. NICUs receive capitated payments for treating premature infants so any reduction in the length of stay positively affects the institution’s profitability. At present, the standard of care for such infants is to place them in a warmer in a high humidity environment. We believe that if the data shows a significant benefit in the use of NeoCeram® (for example, reduction of length of stay in the NICU or reduction of bacterial infections), then there is the possibility of rapid adoption of it by the more than 600 neonatologists in the United States. In order to generate the data required to successfully market NeoCeram®, we will need to conduct a clinical study to determine the efficacy of NeoCeram® and obtain regulatory clearance. We have not filed for regulatory clearance for NeoCeram®. Once clearance is received, we believe the duration of such a study will take approximately one year. Our ability to conduct this trial is dependent upon receiving IRB approval, which cannot be assured, and having sufficient financial resources to pay for the study. Under the terms of the DRL Agreement, we have retained the rights to market NeoCeram®.

SALES AND MARKETING

We currently do not have any sales and marketing personnel. We do not anticipate hiring a significant number of sales and marketing personnel unless we choose to commercialize products using an internal sales force.

COMPETITION

Ceragenins™

The pharmaceutical industry is highly competitive and includes a number of established, large and mid-size companies, as well as smaller emerging companies, whose activities are directly focused on our target markets. We face significant competition from pharmaceutical and biotechnology companies that are designing and selling products designed to treat bacterial infections. Many major pharmaceutical companies, such as GlaxoSmithKline, Pfizer, Bayer, Merck and Sanofi Aventis have already established significant positions in the antibiotic market. Additionally, many smaller companies, such as Cubist Pharmaceuticals, Oscient Therapeutics, Polymedix, NovaBay Pharmaceuticals, Inc. and Inhibitex have either marketed antibiotics and/or are attempting to enter this market by developing novel and potentially more potent antibiotics that are intended to be effective against drug-resistant bacterial strains.

Table of Contents

We expect our Cerashield™ technology to compete primarily with other anti-infective coating technologies designed to reduce the infection rates. Competitive product offerings would include the following products: products from C.R. Bard such as Agento Endotracheal Tubes; Bardex IC Foley Catheters with Bacti-Guard® silver and hydrogel coating; Bardex® IC Catheters with a silver hydrogel coating; and Lubri-Sil® Foley Catheter line of silicone catheters with an antimicrobial and hydrogel coating. Competitive entries from Angiotech, Inc. include their recently cleared central venous catheter based on 5-FU and other 5-FU products under development. Competitive entries from The Kendall Company include their DOVER® 100% Silicone Foley Catheters as well as their DOVER Silver catheters which incorporates OMNION® silver ion technology coupled with a hydrogel coating. Competitive entries from Rochester Medical include their RELEASE-NF® Catheter line which has a nitrofurazone coating. Competitive offerings from Arrow International Inc. include their Gard I and Gard II coatings containing chlorhexidine + silver sulfadiazine. Competitive offerings from Cook Critical Care include their SPECTRUM® line of antimicrobial polyurethane catheters containing minocycline and rifampin. The omiganan pentahydrochloride gel under development by Cadence Pharmaceuticals as well as a variety of other new antibiotic or antimicrobial coating based products which may be under development at other firms could also become future competitors. While we expect to compete based primarily on the greater spectrum of efficacy against infectious agents and longer duration of activity, it is too early to know whether the Cerashield™ technology under development will be approved for use in target medical device segments of greatest interest and unmet medical needs.

Barrier Repair

We expect to compete on, among other things, the efficacy of our products, the reduction in adverse side effects experienced when compared with certain current therapies, and more desirable patient treatment regimens. Competing successfully will depend on our ability to demonstrate efficacy of our products through clinical trials, our ability to convince opinion leaders and prescribing physicians of the advantages of our products, and having sufficient financial resources to adequately market our products. In addition, our ability to compete may be affected by our ability to obtain reimbursement from third-party payors. The clearance of EpiCeram® as a 510(k) medical device also limits the type of claims initially associated with the promotion of the product until such time as additional clinical trials, the outcomes of which cannot yet be certain, have been concluded supporting broader claims.

Our first product, EpiCeram®, is indicated for use to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including atopic dermatitis, irritant contact dermatitis, radiation dermatitis, and dry skin. Accordingly, we compete with well established products such as Elidel® from Novartis AG, Protopic® from Fujisawa, Atopiclair® from Sinclair Pharmaceuticals, MimyX® from Steifel Laboratories as well as a variety of topical steroids and skin emollients. We believe that the limitations established by the FDA on prescribing steroids and immunosuppressants to children under the age of two years of age will provide EpiCeram® with a competitive advantage in the market to children in this age category with symptoms of eczema.

LICENSE AGREEMENTS AND PROPRIETARY RIGHTS

License Agreement with the Regents of the University of California

Osmotics Corporation (“Osmotics”) entered into an exclusive license agreement with the Regents of the University of California (the “Regents”) for the Barrier Repair technology on June 28, 2000. The license agreement grants exclusive U.S. and international rights to issued patent 5,634,899 — “Lipids for epidermal moisturization and repair of barrier function.” The patent expires in July 2014. In connection with the merger of Ceragenix Corporation (f/k/a Osmotics Pharma, Inc.) and the Company in May 2005 (the “Merger”), Ceragenix Corporation was substituted in place of Osmotics as the licensee under the agreement. The license agreement provides Ceragenix Corporation with the worldwide exclusive right to commercially develop, use and sell therapeutic and cosmetic applications for the Barrier Repair technology. Under the terms of a sublicense agreement with Osmotics, Ceragenix Corporation agreed that Osmotics will retain the license rights for all cosmetic, non-prescription applications (as defined in the sublicense agreement). The rights of Ceragenix Corporation under the license agreement are subject to a non-exclusive, irrevocable, royalty free license to the U.S. Government with the power to grant a license for all governmental purposes. Unless terminated earlier by Ceragenix Corporation for any reason or by the Regents due to Ceragenix Corporation’s breach, the license agreement continues until the date of expiration of the last to expire patent licensed under this agreement. Ceragenix Corporation is obligated to pay the Regents, on an annual basis, the greater of $50,000 or five percent of net sales (as defined in the agreement) of products derived from the Barrier Repair technology. Upfront and milestone payments received from sub licensed products are subject to a 15% royalty. In addition, the agreement requires Ceragenix Corporation to reimburse the Regents for legal expenses associated with patent protection and expansion.

Table of Contents

License Agreement with the Brigham Young University

On May 1, 2004, Osmotics Corporation and Ceragenix Corporation entered into an exclusive license agreement with Brigham Young University (“BYU”) for the intellectual property rights to the Ceragenin™ technology. The exclusive license agreement grants the U.S. and international rights to U.S. composition of matter patents: 6,350,738, 6,486,148 and 6,767,904 which are in effect until 2022. In connection with the Merger, Osmotics was removed as a co-licensee and Ceragenix Corporation is now the sole licensee under the agreement. The license agreement provides Ceragenix Corporation with the worldwide exclusive right to develop, use and sell all applications based on the Ceragenin™ technology until May 1, 2006. After May 1, 2006, the exclusive license extends only to those applications for which Ceragenix Corporation has conducted research or engaged in substantial commercialization efforts, including research or commercialization by strategic partners and sublicensees. To date, we have conducted research related to the Ceragenin™ technology for use as an antibiotic, antiviral agent, anticancer agent and antifungal agent. We believe such research meets the application definition to preserve exclusivity under the agreement. The rights of Ceragenix Corporation under the license agreement are subject to the right of BYU and the Church of Jesus Christ of Latter day Saints and the Church Education System to use the technology for continuing research and non-commercial academic and ecclesiastical uses without cost.

The BYU License requires us to pay quarterly research and development support fees of $22,500 and royalty payments equal to 2% - 10% of adjusted gross sales (as defined in the agreement) on any product we sell using the licensed technology. The royalty is subject to an annual minimum royalty. The minimum annual royalty was $100,000 in 2008, $200,000 in 2009, and $300,000 in 2010 and each year thereafter. We have not made the payment which was due in 2009 nor have we made the quarterly support fee payments that were due on August 1, 2009, November 1, 2009, and February 1, 2010. These delinquent payments represent a technical default under the terms of the BYU License. We are also obligated to reimburse BYU for any legal expenses associated with patent protection and expansion. During the year ended December 31, 2009, we did not reimburse BYU for these legal fees in accordance with the required timeframes set forth in the BYU License agreement. These delinquent payments also represent a technical default under the terms of the BYU License. On April 7, 2010, BYU declared us in breach of the agreement. Under the terms of the BYU License, we have 30 days to cure the breach. If we cannot cure the breach, the BYU License will be terminated. Further, a default under the BYU License would also constitute a default under our convertible debt obligations. Unless terminated earlier by Ceragenix Corporation for any reason or by BYU due to Ceragenix Corporation’s breach, the license agreement terminates on the date of expiration of the last valid claim of any patent included in the technology.

The underlying patents and license agreements with the Regents and BYU are critically important to the Company’s business prospects. We have no proprietary technologies outside of these agreements. The loss of either of these license agreements, or if the underlying patents were declared invalid or could not be protected, would result in a material adverse effect on the Company.

TRADEMARKS

We believe that trademark protection is an important part of establishing product and brand recognition. The United States Patent and Trademark Office has approved EpiCeram® and NeoCeram® as registered trademarks and the following applications for registration subject to final approval of statements of use: Ceracide™, Ceragenins™, Ceragenin™ and Cerashield™. United States federal registrations for trademarks remain in force for ten years and may be renewed every ten years after issuance, provided the mark is still being used in commerce. We have also received trademark protection for EpiCeram® in Korea, the Philippines and Singapore, and we have filed for EpiCeram® trademark protection in the European Union, Canada, Malaysia, Indonesia, and the Russian Federation. However, any such trademark or service mark registrations may not afford us adequate protection, and we may not have the financial resources to enforce our rights under any such trademark or service mark registrations. If we are unable to protect our trademarks or service marks from infringement, any value developed in such trademarks and service marks could be impaired.

GOVERNMENT REGULATION

Government authorities in the U.S., at the federal, state, and local level, and foreign countries extensively regulate, among other things, the following areas relating to our product and product candidates:

· Research and development;

· Testing, manufacture, labeling and distribution;

· Advertising, promotion, sampling and marketing; and

· Import and export

We expect that all of our prescription pharmaceutical products will require regulatory approval by governmental agencies before we can commercialize them. The nature and extent of the review process for our potential products will vary depending on the

Table of Contents

regulatory categorization of particular products. Prescription products can be cleared as either medical devices or new drugs. The clearance process for medical devices is typically shorter and less expensive than for a new drug. Within the medical device category, there are two approval paths: 510(k) or PMA. Typically, the 510(k) path is shorter and less expensive than the PMA. The 510(k) process is an abbreviated approval process that typically does not require clinical studies.

The FDA determines whether a product is a drug or device based on its primary mode of action. If a product is determined to be a device, in order to qualify for the 510(k) process, it must be demonstrated that the product is substantially equivalent to a previously approved device. If a product is determined to be a device, but not substantially equivalent to a previously approved device, then it would be subject to the PMA. A PMA application requires clinical studies and the approval time is longer (typically several years from filing).

We received marketing clearance for EpiCeram® under 510(k). We currently plan on marketing NeoCeram® (if and when development is completed and a clinical trial is completed with favorable results) as a 510(k) medical device. We have not filed a separate 510(k) for NeoCeram® as of the date of this Form 10-K nor can we provide an anticipated filing date. Our ability to complete development of NeoCeram® and seek regulatory clearance is dependent upon our financial resources which are currently inadequate to proceed with our planned development.

We believe that the appropriate approval path for our Cerashield™ antimicrobial coatings will be through the process established for medical devices. We base this belief on the guidelines published by the FDA as well as the approval paths followed by other antimicrobial coatings. In June 2006, the FDA notified us that a Ceragenin™ wound dressing would be regulated as a device and we believe that the same fact pattern would apply to antimicrobial coatings. However, there is no assurance that the FDA will agree that Cerashield™ coated devices should be regulated as medical devices. Systemic, topical and inhaled applications of the Ceragenins™ will be considered new drugs by the FDA and require the submission of an Investigational New Drug Application and a NDA.

Our products will also be subject to foreign regulatory requirements governing human clinical trials, manufacturing and market approval for pharmaceutical products. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement are similar, but not identical, to FDA requirements, and they vary widely from country to country. Product development and approval within this regulatory framework, and subsequent compliance with appropriate federal and foreign statutes and regulations, takes a number of years and involves the expenditure of substantial resources.

Manufacturing

The FDA regulates and inspects equipment, facilities, and processes used in the manufacturing of pharmaceutical products before providing approval to market a product. If after receiving clearance from the FDA, we make a material change in manufacturing equipment, location, or process, we may have to undergo additional regulatory review. We must apply to the FDA to change the manufacturer we use to produce any of our products. We and our contract manufacturers must adhere to current Good Manufacturing Practices (“cGMP”) and product-specific regulations enforced by the FDA through its facilities inspection program. The FDA also conducts regular, periodic visits to re-inspect equipment, facilities, and processes after the initial approval. If, as a result of these inspections, the FDA determines that our (or our contract manufacturers’) equipment, facilities, or processes do not comply with applicable FDA regulations and conditions of product approval, the FDA may seek sanctions and/or remedies against us, including suspension of our manufacturing operations. We do not plan on manufacturing any of our products using in-house facilities. Rather, we will outsource the manufacturing to experienced contractors with approved, cGMP facilities.

Post-Approval Regulation

The FDA continues to review marketed products even after granting regulatory clearances, and if previously unknown problems are discovered or if we fail to comply with the applicable regulatory requirements, the FDA may restrict the marketing of a product or impose the withdrawal of the product from the market, recalls, seizures, injunctions or criminal sanctions. In its regulation of advertising, the FDA from time to time issues correspondence to pharmaceutical companies alleging that some advertising or promotional practices are false, misleading or deceptive. The FDA has the power to impose a wide array of sanctions on companies for such advertising practices.

Pharmacy Boards

It is possible that we could be required to be licensed with the state pharmacy boards as a manufacturer, wholesaler, or wholesale distributor. Many of the states allow exemptions from license if our products are distributed through a licensed wholesale distributor. We believe that we will be exempt from registration for EpiCeram® as a result of DRL’s distribution licenses. The regulations of each state are different, and receiving a license in one state will not authorize us to sell our products in other states.

Table of Contents

Accordingly, we will have to undertake an annual review of our license status to ensure compliance with the state pharmacy board requirements. We are currently not licensed with any state pharmacy board.

Fraud and Abuse Regulations

We are subject to various federal and state laws pertaining to health care “fraud and abuse,” including anti-kickback laws and false claims laws. The Office of Inspector General (“OIG”) of the U.S. Department of Health and Human Services has provided guidance that outlines several considerations for pharmaceutical manufacturers to be aware of in the context of marketing and promotion of products reimbursable by the federal health care programs. The federal anti-kickback statute places constraints on business activities in the health care sector that are common business activities in other industries, including sales, marketing, discounting, and purchase relations. Practices that may be common or longstanding in other businesses are not necessarily acceptable or lawful when soliciting federal health care program business. Specifically, anti-kickback laws make it illegal for a prescription drug manufacturer to solicit or to offer or pay anything of value for patient referrals, or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease or ordering of, any item or service that is reimbursable in whole or part by a federal health care program, including the purchase or prescription of a particular drug. The federal government has published regulations that identify “safe harbors” or exemptions for certain payment arrangements that do not violate the anti-kickback statutes. We will seek to comply with the safe harbors where possible.

False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third party payors (including Medicare and Medicaid) claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Our planned activities relating to the sale and marketing of our products may be subject to scrutiny under these laws.

Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as the possibility of exclusion from federal health care programs (including Medicare and Medicaid).

EMPLOYEES

As of April 12, 2009, we had five full-time employees. We do not carry key man life insurance on any of our employees. We are not part of any collective bargaining agreement. There have been no work stoppages and we believe our employee relations are good.

Item 1A. Risk Factors

An investment in our securities is speculative and involves a high degree of risk. Please carefully consider the following risk factors, as well as the possibility of the loss of your entire investment, before deciding to invest in our securities. Any of the following risks, either alone or taken together, could materially and adversely affect an investment in our securities and our business, financial position or future prospects. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, our actual results may vary materially from what we have projected. There may be additional risks that we do not presently know or that we currently believe are immaterial which could also materially affect an investment in our securities and our business, financial position or future prospects. Accordingly, you should evaluate all forward-looking statements with the understanding of their inherent uncertainty. Due to the following factors, we believe that quarter-to-quarter comparisons of our results of operations are not a good indication of our future performance.

Risks Related to Our Business

Our securities represent a highly speculative investment.

We are an early stage company with a limited operating history. As of December 31, 2009, we had an accumulated deficit of approximately $19.7 million. We have incurred losses since inception and we anticipate that we will continue to incur operating losses, in the aggregate and on a per share basis, for the next several years. These losses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity, net current assets and working capital. While we currently project that these losses will shrink over time as EpiCeram® revenues increase, there is no assurance that EpiCeram® will have the commercial success that we currently anticipate. We have not had sufficient capital to fund all of our capital resource needs since our formation, and you cannot assume that our plans will either materialize or prove successful. There is no assurance that our operations will ever produce sufficient revenue to fund our capital resource needs. If our plans are unsuccessful, the price and liquidity of our common stock will be adversely affected and you could lose your entire investment.

Our auditors have included a “going concern” emphasis paragraph in their report which expresses substantial doubt about our ability to continue as a going concern.

Table of Contents

We believe that existing cash on hand in combination with projected cash receipts and actions to delay or defer payment to certain vendors will allow us to maintain a positive cash balance into April 2010. Accordingly, we will require additional funding by April 30, 2010. However, the actions we have taken to extend our short-term cash balance may result in negative near and long-term consequences to the Company. As of the date of this Form 10-K, we believe that we have an agreement in principal to provide short-term funding for the Company, however, it is dependent upon cooperation from our secured creditors which cannot be assured. Further, we have no firm commitments for raising additional capital and as described in further detail in Management’s Discussion and Analysis “Liquidity and Capital Resources,” our ability to access the capital markets may be severely limited for a variety of reasons that we do not see changing in the near term. There is no assurance that we will be able to raise additional capital within the timeframe described above. Even if we are successful, it could be on terms that substantially dilute our current shareholders. If we are unsuccessful in raising additional capital we may not be able to continue our business operations and our securities may have little or no value.

If we are unable to meet our needs for additional funding in the future, we will be required to limit, scale-back or cease operations

We do not currently have the funding resources necessary to carry out all of our proposed short and long-term operating activities. Our projection of future capital needs is based on our operating plan, which in turn is based on assumptions that may prove to be incorrect. Our future capital requirements will depend on many factors, including:

· The commercial success of EpiCeram® both domestically and internationally;

· The ability to enter into additional international distribution agreements for EpiCeram® on commercially attractive terms;

· The cost of raw materials, and payment terms for such materials, for EpiCeram®;

· The cost associated with completing the development, regulatory filings, and clinical trials for NeoCeram®;

· Progress with preclinical experiments and development of our Ceragenin™ technology;

· The success, timing, and financial consequences of our existing and any future collaborative, licensing and other arrangements for our Ceragenin™ technology;

· Our ability to restructure the terms of our convertible debt securities, if even possible;

· The conditions in the capital markets and the biopharmaceutical industry that make raising capital or entering into strategic arrangements difficult or expensive;

· Ongoing general and administrative expenses related to being a reporting company;

· The cost, timing, and results of regulatory reviews and approvals;

· The maintenance of our existing licenses with the University of California and Brigham Young University;

· The cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

· Technological and market developments; and

· The timing and level of sales of any new products for which we may obtain marketing approval.

These factors could result in variations from our currently projected operating and liquidity requirements. Additional funds may not be available when needed, or, if available, we may not be able to obtain such funds on terms acceptable to us. If adequate funds are unavailable, we will further delay, scale-back or eliminate certain of our planned development activities, or cease operations.

Funding, especially on terms acceptable to us, may not be available to meet our future capital needs because of the deterioration of the credit and capital markets.

Global market and economic conditions have been, and continue to be, disruptive and volatile. The debt and equity capital markets have been impacted by significant write-offs in the financial services sector and the re-pricing of credit risk in the broadly syndicated market, among other things. These events have negatively affected general economic conditions and it is uncertain when the credit and capital markets will stabilize or improve.

In particular, the cost of raising money in the debt and equity capital markets has increased substantially while the availability of funds from those markets has diminished significantly. Also, as a result of concern about the stability of the financial markets generally and the solvency of counterparties specifically, the cost of obtaining money from the credit markets has increased as many lenders and institutional investors have increased interest rates, enacted tighter lending standards and reduced and, in some cases, ceased to provide funding to borrowers. Low valuations and decreased appetite for equity investments, among other factors, may make the equity markets difficult to access on acceptable terms or unavailable altogether.

If funding is not available when needed, or is available only on unfavorable terms, meeting our capital needs or otherwise taking advantage of business opportunities may become challenging, which could have a material adverse effect on our business plans.

Table of Contents

Future financings may result in dilution to our shareholders and restrictions on our business operations.

Given the state of the capital markets described above, if we are successful in raising additional funds by issuing equity or convertible debt securities, further dilution to our shareholders will occur and could be substantially dilutive to existing shareholders. Additionally, we may grant registration rights to investors purchasing equity or debt securities. Debt financing, if available, may involve pledging some or all of our assets and may contain restrictive covenants with respect to raising future capital and other financial and operational matters. If we are unable to obtain necessary additional capital, we may be unable to execute our business strategy, which would have a material adverse effect on our business, financial position and future prospects.

The existence of our convertible debt will make it difficult to raise additional capital

We will require additional capital to execute our business plan and continue as a going concern. As of December 31, 2009, we had $9,738,812 outstanding in secured convertible debt. Repayment of these obligations is secured by a first lien on all of our assets, including all of our intellectual property rights and intellectual property licenses. We have amended the terms of the debt several times but the convertible debt agreements still contain a number of provisions which new investors could find problematic and could deter investment. We do not believe it is possible to raise additional capital without further modification of the debt. See discussion in Management’s Discussion and Analysis “Liquidity and Capital Resources” for a discussion of the specific terms of the convertible debt agreements that new investors could find problematic. If we default on any of the covenants or other requirements of our debt agreements, the debt holders will be able to foreclose on our assets by which their debts are secured which would likely cause you to lose your entire investment. Such foreclosure would likely force us out of business. Furthermore, if the debt holders choose to convert their debt into shares of common stock it is possible that the sale of such shares could have a depressive effect on the share price of our common stock.

The DRL Agreement will increase our cash requirements

Under the terms of the DRL Agreement, we are responsible for manufacturing (through a contract manufacturer) and supplying EpiCeram®. This results in us having to pay our vendors for the cost of the product prior to receiving payment from DRL. This creates a working capital requirement which is expected to increase over time as sales of EpiCeram® increase. We may not have sufficient cash on hand to meet all purchase orders from DRL. If we cannot provide product to DRL within the timeframes called for under the DRL Agreement, DRL could assume manufacturing responsibilities which will serve to reduce the profits we earn on the sale of EpiCeram®. During 2009, DRL worked with us to mitigate the working capital requirements by prepaying a number of purchase orders placed with us. However, this arrangement expired during 2009, and we do not expect DRL to agree to similar payment terms in the future.

Under the terms of our amended convertible debt agreements, all of our net revenue (as defined in the agreements) from the DRL Agreement is required to be used to service the debt. Accordingly, we will not be able to utilize cash flows from the DRL Agreement for operations until such time that the convertible debt is paid in full.

Our ability to register securities sold in private placements is extremely limited.

Our ability to register securities sold in private placements transactions qualified for registration on resale registration statements pursuant to Rule 415(a)(1)(x) is extremely limited . Until such time as Osmotics consummates its planned exchange offering (see discussion below), our public float for Rule 415 purposes excludes the 12,004,569 shares of common stock Osmotics has placed in escrow. The implication is that unless an investor is willing to wait for Rule 144 eligibility, we will have to raise capital through registered offerings which can be more time consuming and more expensive. As a result, this may serve to further limit our ability to raise capital through private placements or result in the investors in such transactions seeking additional economic compensation. If we are unable to raise additional capital in private placement transactions, it could have a material adverse affect on our liquidity and business prospects.

A substantial number of our outstanding common shares are controlled by one shareholder.

Osmotics is the owner of record of 12,162,170 shares, or 67%, of our outstanding common stock. Osmotics has placed 12,004,569 of these shares into escrow for a planned common stock exchange with their security holders. Pursuant to a registration rights agreement we have with Osmotics, we were obligated to register such shares with the SEC. We filed such a registration statement in February 2007, however, based on discussions with the SEC, we withdrew such registration statement. After subsequent discussions with the SEC, we believe that we will have to register the Osmotics exchange transaction on Form S-4 in order to avoid Rule 415 limitations. We cannot file the S-4 until Osmotics comes to an agreement with its debtholders regarding how many of the escrowed shares will be used to satisfy their debt obligations. We do not know when Osmotics will complete this negotiation. Osmotics has signed a limited standstill agreement which requires that the shares currently held in escrow be released into the trading

Table of Contents

market over a 24 month period commencing on the later of June 30, 2008 or the consummation of the planned exchange. Once these shares have been registered and distributed by Osmotics, such shares will be freely tradable and could have a depressive effect on the price of our stock. The recipients of these shares will be subject to the provisions of the limited standstill agreement. Additionally, the planned release of these shares into the trading market could prevent or limit our ability to raise additional capital during this time period.

Our convertible debt agreements contain repricing provisions.

Our secured convertible debt agreements contain provisions that provide for the conversion price of the debt and exercise price of common stock purchase warrants to be reduced under certain circumstances. In the event that the conversion price of such debt, or the exercise price of the warrants, is reduced, the holders will receive more shares of our common stock upon conversion of the debt, or the exercise of warrants, than they would with the current conversion price. This would result in current shareholders experiencing dilution to their holdings and could result in a depressive effect on the share price of our common stock. There is no assurance that conversion price reductions will not take place in the future.

Our near term revenues will be dependent upon the efforts of DRL.

The commercial success of EpiCeram® will in large part be dependent upon the efforts of DRL. While we believe that DRL is committed to providing the necessary resources to promote and market EpiCeram® to prescribing physicians and patients, there is no assurance that DRL will do so. We cannot terminate the agreement if sales do not reach our expectations.

We do not know whether EpiCeram® will be reimbursed by third party payors.

The market acceptance of EpiCeram® will in part depend upon the amount of reimbursement coverage third party payors will provide for EpiCeram®. Under the terms of the DRL Agreement, DRL is responsible for managing the reimbursement process. If third party payors do not provide sufficient reimbursement for EpiCeram®, it may inhibit physicians from prescribing and/or prevent certain patients from purchasing the product. Additionally, inadequate reimbursement coverage could result in DRL having to reduce the sales price per unit. All of these factors would result in reducing our revenues from EpiCeram®.

The patents underlying our Barrier Repair technology have relatively short patent lives remaining.

The patents underlying EpiCeram® will expire in July 2014, which will likely serve to limit the revenues we will be able to generate from this product.

Our anti-infective products are at a very early stage of development.

Our Ceragenin™ technology is at a very early stage of development. While we have received encouraging results from testing the technology in vitro, and several in vivo models, there is substantial additional development to be done as well as preclinical and clinical testing before we, or a commercialization partner, can market a product. We currently do not have sufficient cash on hand to develop this technology as rapidly or extensively as we would like. Accordingly, there may be delays in developing this technology. Additionally, as of the date of this Form 10-K, we have very limited data on toxicity. See the discussion under the heading “Government Regulation.” As we progress through the development and approval process of different applications of the Ceragenin™ technology, there are numerous factors that could prevent us from ever generating revenue from the Ceragenin™ technology. Accordingly, there is no assurance that the Ceragenin™ technology will ever generate revenue for us.

We have limited human resources; we need to attract and retain highly skilled personnel; and we may be unable to manage our growth with our limited resources effectively.

We expect that the expansion of our business will place a significant strain on our limited managerial, operational, and financial resources. We will be required to expand our operational and financial systems significantly and to expand, train and manage our work force in order to manage the expansion of our operations. Our future success will depend in large part on our ability to attract, train, and retain additional highly skilled executive level management with experience in the pharmaceutical industry. Competition is intense for these types of personnel from more established organizations, many of which have significantly larger operations and greater financial, marketing, human, and other resources than we have. We may not be successful in attracting and retaining qualified personnel on a timely basis, on competitive terms or at all. If we are not successful in attracting and retaining these personnel, our business, prospects, financial condition and operating results would be materially adversely affected. Further, our ability to manage our growth effectively will require us to continue to improve our operational, financial and management controls, reporting systems and procedures, to install new management information and control systems and to train, motivate and manage employees. If we are unable to manage growth effectively and new employees are unable to achieve adequate performance levels, our business, financial condition and prospects could be materially adversely affected.

Table of Contents

We depend on licenses from others for all of our products.

All of our products and product candidates are based upon licenses from either the University of California or Brigham Young University. If either or any of these license agreements are properly terminated, our business will be materially adversely affected. These agreements may be terminated if we fail to perform our obligations under these licenses in accordance with their terms including, but not limited to, our ability to make all payments due under such agreements. During 2009, we failed to make all of the payments due to Brigham Young University in accordance with the time frames called for in the agreement, and on April 7, 2010, Brigham Young University declared us in breach. We can provide no assurance that we will have the financial resources to cure the breach. Even if we can cure the breach, there is no assurance that we will be able to make all future payments owed to Brigham Young University when due, and we can provide no assurance that Brigham Young University will accommodate our financial constraints in the future. Further, in March 2010, we became in technical default under the license with the University of California for failure to make certain payments when due. Should the University of California declare us to be in breach of the agreement, we will have 60 days to cure the breach or otherwise risk termination of the agreement.

In addition to these licensing agreements, we rely on the expertise of Dr. Paul Savage, a professor of chemistry at Brigham Young University and Dr. Peter Elias, a professor of dermatology. Dr. Elias is the Chairman of our Scientific Advisory Board and we utilize Dr. Savage’s services under a consulting agreement. If our agreements with either or both Drs. Savage and Elias were terminated, our ability to advance our product candidates or develop new products may be adversely affected. We are delinquent in our payments to both Drs. Savage and Elias.

If clinical trials of our current or future product candidates do not produce results necessary to support regulatory approval in the United States or elsewhere, we will be unable to commercialize these products.

To receive regulatory approval for the commercial sale of our product candidates that we may develop or out-license, we, or our potential partners, must conduct, adequate and well controlled clinical trials to demonstrate efficacy and safety in humans. Clinical testing is expensive, takes many years and has an uncertain outcome. Clinical failure can occur at any stage of the testing. Our clinical trials may produce negative or inconclusive results, and we, or our partners, may decide, or regulators may require us, to conduct additional clinical and/or non-clinical testing. Our failure to adequately demonstrate the efficacy and safety of any product candidate that we may develop or out-license would prevent receipt of regulatory approval and, ultimately, the commercialization of that product candidate.

Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.

Even if U.S. regulatory approval or clearance is obtained, the FDA can impose significant restrictions on a product’s indicated uses or marketing or may impose ongoing requirements for potentially costly post-approval studies. Any of these restrictions or requirements could adversely affect our potential product revenues. Our product candidates will also be subject to ongoing FDA requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information on the drug. In addition, approved products, manufacturers and manufacturers’ facilities are subject to continual review and periodic inspections. If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If our product candidates fail to comply with applicable regulatory requirements, such as cGMP, a regulatory agency may:

·	issue warning letters or untitled letters;
·	require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;
·	impose other civil or criminal penalties;
·	suspend regulatory approval;
·	suspend any ongoing clinical trials;
·	refuse to approve pending applications or supplements to approved applications filed by us;
·	impose restrictions on operations, including costly new manufacturing requirements; or
·	seize or detain products or require a product recall.

Even if regulatory authorities approve our product candidates, they may not be commercially successful.

Our product candidates may not be commercially successful because physicians, government agencies and other third-party payors may not accept them. Third parties may develop superior products or have proprietary rights that preclude us from marketing our products. We also expect that most of our products will be premium priced, if approved. If we do obtain regulatory approval for any of our product candidates, we will need to achieve physician and patient acceptance and demand in order to be commercially successful. Acceptance and demand for our product candidates will depend on many factors, including but not limited to, the extent,

Table of Contents

if any, of reimbursement by government agencies and other third party payors, pricing, the safety and effectiveness of alternative products, and the prevalence of hospital acquired infections. If we do not achieve product acceptance and sufficient demand, we will not be able to sell our products and our operating results and financial condition will be materially adversely affected.

Our ability to successfully commercialize our products will greatly depend on the success of our clinical trials.

Our commercialization efforts will be greatly dependent upon our ability, or the ability of our partners, to demonstrate product efficacy in clinical trials. Without compelling supporting data, hospitals, pharmacies and other dispensing facilities will be reluctant to order our products, and medical practitioners will be reluctant to prescribe our products. While we believe that our products will be effective for our planned indications, there is no assurance that this will be proven in clinical trials. The failure to demonstrate efficacy in our clinical trials, or a delay or failure to complete our clinical trials, would have a material adverse effect on our business, prospects, financial condition and operating results.

Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our product candidates.

Delays in the commencement or completion of clinical testing could significantly affect our product development costs. Our clinical trials for EpiCeram® took longer to complete than planned and our NeoCeram™ clinical trial has not yet commenced as originally planned. Accordingly, any future clinical trials may not begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials requires us to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs for the same indication as our product candidates or may not be eligible to participate in or may be required to withdraw from a clinical trial as a result of changing standards of care. The commencement and completion of clinical trials can be delayed for a variety of other reasons, including delays related to:

·	reaching agreements on acceptable terms with prospective clinical research organizations, or CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
·	obtaining regulatory approval to commence a clinical trial;
·	obtaining institutional review board approval to conduct a clinical trial at a prospective site;
·	recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for the same indication as our product candidates; and
·	retaining patients who have initiated a clinical trial but may be prone to withdraw due to the treatment protocol, lack of efficacy, personal issues, side effects from the therapy or who are lost to further follow-up.

A clinical trial may be suspended or terminated by us, the FDA or other regulatory authorities due to a number of factors.

A clinical trial may be suspended or terminated by us, the FDA or other regulatory authorities due to a number of factors, including:

·	failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
·	inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;
·	unforeseen safety issues or any determination that a trial presents unacceptable health risks; or
·	lack of adequate funding to continue the clinical trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional trials and studies and increased expenses associated with the services of our CROs and other third parties.

Additionally, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to institutional review boards for reexamination, which may impact the cost, timing or successful completion of a clinical trial. If we experience delays in the completion of, or if we terminate, our clinical trials, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Even if we are able to ultimately commercialize our product candidates, other therapies for the same indications may have been introduced to the market and established a competitive advantage.

Some of our ingredients come from sole source providers.

While we have supply agreements in place for certain key ingredients used in the formulation of EpiCeram®, two of these ingredients come from sole source providers. To date, we have not had any difficulties in acquiring any of these ingredients. While we believe that similar ingredients are available from other sources, there is no assurance that they will work as well as the ingredients

Table of Contents

currently used, and in certain cases, a change in ingredients could require us to receive clearance from the FDA. Further, our ability to mitigate cost increases for these ingredients may be limited, thus reducing our margins. Any delays in manufacturing resulting from an inability to purchase ingredients or waiting on FDA clearance could have a material adverse effect on our business prospects, financial condition and operating results. Further, any reduction in product efficacy resulting from using alternative ingredients could also have a material adverse effect on our business prospects, financial condition and operating results. Such delays or reduction in efficacy could result in DRL terminating the DRL Agreement.

If we lose the support of our key scientific collaborators, it may be difficult to establish products using our technologies as a standard of care for various indications, which may limit our revenue growth and profitability.

We have established relationships with leading scientists around the world. We have formalized certain of these relationships by establishing a scientific advisory board. We believe that such relationships are key to establishing products using our technologies as commercially viable for various indications. We have entered into consulting agreements with our scientific advisory board members, but such agreements provide for termination with 30 days notice. Additionally, there is no assurance that our current research partners will continue to work with us or we will be able to attract additional research partners. The inability to maintain and build on our existing scientific relationships could have a material adverse effect on our business, prospects, financial condition and operating results.

We may not be able to successfully manufacture Ceragenins™ in commercial quantities.

To date, we have only produced Ceragenin™ compound in a laboratory. We do not know whether we will be able to produce quantities sufficient for commercial use in a cGMP manufacturing facility. If we cannot manufacture these compounds in commercial quantities it could have a material adverse effect on our business prospects.

If the government or third-party payors fail to provide coverage and adequate coverage and payment rates for our future products, if any, or if hospitals choose to use therapies that are less expensive, our revenue and prospects for profitability will be limited.

In both domestic and foreign markets, our sales of any future products will depend in part upon the availability of coverage and reimbursement from third-party payors. Such third-party payors include government health programs such as Medicare, managed care providers, private health insurers and other organizations. In particular, many U.S. hospitals receive a fixed reimbursement amount per procedure for certain surgeries and other treatment therapies they perform. Because this amount may not be based on the actual expenses the hospital incurs, hospitals may choose to use therapies which are less expensive when compared to our product candidates. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to the satisfaction of hospitals, other target customers and their third-party payors. Such studies might require us, or our partners, to commit a significant amount of management time and financial and other resources. Our future products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.

Healthcare reform measures could adversely affect our business

The business and financial condition of pharmaceutical companies is affected by the efforts of governmental and third party payors to contain or reduce the costs of healthcare. In the U.S. and in foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the healthcare system. For example, in some countries other than the U.S., pricing of drugs and devices are subject to governmental price controls. The implementation of such additional controls could have the effect of reducing what we are able to charge for any products that we may develop. While we believe that our Ceragenin™ technology will result in lower costs to the healthcare system as a whole by reducing infections and the associated costs to treat them, there is no assurance that we will be able to demonstrate this through clinical trials or, even if demonstrated, that healthcare reform will not serve to reduce what we can charge even with demonstrated economic benefit.

None of our potential products may reach the commercial market for a number of reasons.

Successful research and development of pharmaceutical products is highly risky. Most products and development candidates fail to reach the market. Our success depends on the discovery of new drugs or devices that we can commercialize. It is possible that our potential products may never reach the market for a number of reasons. They may be found to be toxic, ineffective or may cause harmful side effects during pre-clinical testing or clinical trials or fail to receive necessary regulatory approvals. We may find that certain products cannot be manufactured on a commercial scale basis and, therefore, they may not be economical to produce. Our products could also fail to achieve market acceptance or be precluded from commercialization by proprietary rights of third parties. We have a number of product candidates in various stages of development, but do not expect the majority of them to be commercially available for a number of years, if at all. If our competitors succeed in developing products and technologies that are more effective

Table of Contents

than our own, or if scientific developments change our understanding of the potential scope and utility of our products, then our products and technologies may be rendered less competitive.

We will face significant competition from industry participants that are pursuing similar products and technologies that we are pursuing and are developing pharmaceutical products that are competitive with our planned products and potential products.

Nearly all of our industry competitors have greater capital resources, larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval and pharmaceutical product manufacturing and marketing than we do. With these additional resources, our competitors may be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster than we can. Our future success will depend in large part on our ability to maintain a competitive position with respect to these technologies. Rapid technological development, as well as new scientific developments, may result in our compounds, products or processes becoming obsolete before we can recover any of the expenses incurred to develop them. For example, changes in our understanding of the appropriate population of patients who should be treated with a targeted therapy we are developing may limit the product’s market potential if it is subsequently demonstrated that only certain subsets of patients should be treated with the targeted therapy.

Our reliance on third parties, such as clinical research organizations, may result in delays in completing, or a failure to complete, clinical trials if they fail to perform under our agreements with them.

In the course of product development, we may engage clinical research organizations to conduct and manage clinical studies and to assist us in guiding our products through the FDA review and approval process. If we engage clinical research organizations to help us obtain market approval for our drug candidates, many important aspects of this process have been and will be out of our direct control. If the clinical research organizations fail to perform their obligations under our agreements with them or fail to perform clinical trials in a satisfactory manner, we may face delays in completing our clinical trials, as well as commercialization of one or more drug candidates. Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion of our clinical trials and the market approval of drug candidates.

If the manufacturers upon whom we rely fail to produce our product candidates in the volumes that we require on a timely basis, or to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our products and may lose potential revenues.

We do not manufacture any of our product candidates, and we do not currently plan to develop any capacity to do so. Any problems or delays we experience in manufacturing of EpiCeram® or any other product candidate may impair our ability to manufacture commercial quantities, which would adversely affect our business. For example, our manufacturers will need to produce specific batches of our product candidates to demonstrate acceptable stability under various conditions and for commercially viable lengths of time. Furthermore, if our commercial manufacturers fail to deliver the required commercial quantities of bulk drug or device substance or finished product on a timely basis and at commercially reasonable prices, we would likely be unable to meet demand for our products and we would lose potential revenues.

The manufacturing of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Our manufacturers may not perform as agreed. If our manufacturers were to encounter any of these difficulties, our ability to provide product to commercialization partners or product candidates to patients in our clinical trials would be jeopardized. In addition, all manufacturers of our product candidates must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers’ compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to our manufacturers’ failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.

We will rely on third parties to market our products.

We currently plan on licensing our planned products to third parties and/or utilizing third parties to market our planned products. In such cases, the amount of revenue we receive will be dependent upon the success of such third parties. In all likelihood, our products will not be the only products sold or marketed by such parties and they may not devote the necessary resources to

Table of Contents

successfully sell our products. Accordingly, these arrangements may result in our products not reaching their full revenue potential which could have an adverse affect on our operations, liquidity and business prospects.

We may suffer losses from product liability claims

Any of our products or product candidates could cause adverse events to patients, such as immunologic or allergic reactions. These reactions may not be observed in clinical trials, but may nonetheless occur after commercialization. If any of these reactions occur, they may render our products or product candidates ineffective in some patients and our sales would suffer.

We may be susceptible to product liability lawsuits, from events arising out of the use of products or product candidates in clinical studies or products sold in the market. Product liability claims may also require us to limit commercialization of our products. Our business exposes us to potential product liability risks, which are inherent in the testing, manufacturing, marketing and sale of pharmaceutical products. We may not be able to avoid product liability claims. If product liability lawsuits are brought against us, we may incur substantial liabilities that exceed the coverage of our product liability insurance, and as a result, our business may fail.

The approval path for our Ceragenin™ technology contains regulatory uncertainty

Our Ceragenin™ technology is a new chemical entity that we intend to combine with medical devices. While we believe that regulatory clearances for these combination devices should be made pursuant to 510(k) or PMA filings based on published guidance and prior communications with the FDA, there is no assurance that the FDA will concur with our belief. Accordingly, regulatory clearances for these devices may take longer and cost more money than we, or our commercialization partners, currently anticipate. Uncertain regulatory approval paths could deter potential commercialization partners from entering into commercialization arrangements with us, or result in less favorable financial terms than we would otherwise expect to receive under such arrangements.

Our future success depends, in part, on the continued service of our management team.

Our success is dependent in part upon the availability of our senior executive officers and our scientific advisors. The loss or unavailability to us of any of these individuals or key research, development, sales and marketing personnel, particularly, if lost to competitors, could have a material adverse effect on our business, prospects, financial condition, and operating results. We have no key man insurance on any of our employees.

The difficulty and cost of protecting our proprietary rights makes it difficult to ensure their protection.

Our commercial success will depend in part on maintaining patent protection and trade secret protection for our products, as well as successfully defending these patents against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the United States. The patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.

The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:

·	our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;
·	our licensors might not have been the first to file patent applications for these inventions;
·	others may independently develop similar or alternative technologies or duplicate any of our product candidates or technologies;
·	it is possible that none of the pending patent applications licensed to us will result in issued patents;
·	the issued patents covering our product candidates may not provide a basis for commercially viable active products, may not provide us with any competitive advantages, or may be challenged by third parties;
·	we may not develop additional proprietary technologies that are patentable; or
·	patents of others may have an adverse effect on our business.

In the event that a third party has also filed a U.S. patent application relating to our product candidates or a similar invention, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office to determine priority of

Table of Contents

invention in the United States. The costs of these proceedings could be substantial and it is possible that our efforts would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. It is also possible that we may not have the financial resources to pursue infringement actions on a timely basis, if at all. Furthermore, we may not have identified all U.S. and foreign patents or published applications that affect our business either by blocking our ability to commercialize our drugs or by covering similar technologies that affect our drug market.

In addition, some countries, including many in Europe, do not grant patent claims directed to methods of treating humans, and in these countries patent protection may not be available at all to protect our drug or device candidates. Even if patents issue, we cannot guarantee that the claims of those patents will be valid and enforceable or provide us with any significant protection against competitive products, or otherwise be commercially valuable to us.

We may also rely on trade secrets to protect our technology, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. While we use reasonable efforts to protect our trade secrets, our licensors, employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.

If our licensors or we fail to obtain or maintain patent protection or trade secret protection for our products, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability.

If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in any litigation would harm our business.

Our ability to develop, manufacture, market and sell our products depends upon our ability to avoid infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we infringe on their products or technology, we could face a number of issues, including:

·	infringement and other intellectual property claims which, with or without merit, can be expensive and time consuming to litigate and can divert management’s attention from our core business;
·	substantial damages for past infringement which we may have to pay if a court decides that our product infringes on a competitor’s patent;
·	a court prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it is not required to do;
·	if a license is available from a patent holder, we may have to pay substantial royalties or grant cross licenses to our patents; and
·	redesigning our processes so they do not infringe which may not be possible or could require substantial funds and time.

Our corporate charter places certain limitations on director liability.

Our Certificate of Incorporation provides, as permitted by Delaware law, that our directors shall not be personally liable to the corporation or our stockholders for monetary damages for breach of fiduciary duty as a director, with certain exceptions. These provisions may discourage stockholders from bringing suit against a director for breach of fiduciary duty and may reduce the likelihood of derivative litigation brought by stockholders on behalf of us against directors. In addition, our Certificate of Incorporation and bylaws provide for mandatory indemnification of directors and officers to the fullest extent permitted by Delaware law.

Members of our management have conflicts of interest.

Our directors, are, or may become in their individual capacity, officers, and directors, controlling shareholders and/or partners of other entities engaged in a variety of businesses. Thus, the involvement of these individuals with such other business entities may create conflicts of interest including, among other things, time, effort, and corporate opportunity. The amount of time that our directors will devote to our business will be limited. Additionally, our Chief Executive Officer retains a significant ownership interest in Osmotics (approximately 10%) and is married to the Chief Executive Officer of Osmotics. Accordingly, he is conflicted in all Company matters dealing with Osmotics. Further, a certain other director also retains a small ownership interest in Osmotics (less than 1%). It is possible that Osmotics may have interests that are in conflict with our best interests.

Table of Contents

There are trading risks for low priced stocks.

Our common stock is currently traded in the over the counter market on the “Electronic Bulletin Board” of the National Association of Securities Dealers, Inc. As a consequence, an investor could find it more difficult to dispose of, or to obtain accurate quotations as to the price of, our securities.

The Securities Enforcement and Penny Stock Reform Act of 1990 requires additional disclosure, relating to the market for penny stocks, in connection with trades in any stock defined as a penny stock. The Securities and Exchange Commission (the “SEC”) recently adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. Such exceptions include any equity security listed on NASDAQ and any equity security issued by an issuer that has (i) net tangible assets of at least $2,000,000, if such issuer has been in continuous operation for three (3) years, (ii) net tangible assets of at least $5,000,000, if such issuer has been in continuous operation for less than three (3) years, or (iii) average annual revenue of at least $6,000,000, if such issuer has been in continuous operation for less than three (3) years. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated therewith.

If our securities are not quoted on NASDAQ, or we do not have $2,000,000 in net tangible assets, trading in our securities will be covered by Rules 15(g)(1) through 15(g)(6) promulgated under the Exchange Act for non NASDAQ and nonexchange listed securities. Under such rules, broker dealers who recommend such securities to persons other than established customers and accredited investors must make a special written suitability determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement in connection with any transaction. Securities are exempt from these rules if the market price of the common stock is at least $5.00 per share.

Our ability to issue additional securities without shareholder approval could have substantial dilutive and other adverse effects on existing stockholders and investors in this offering.

We have the authority to issue additional shares of common stock and to issue options and warrants to purchase shares of our common stock without shareholder approval. Future issuance of common stock could be at values substantially below the exercise price of the warrants, and therefore could represent further substantial dilution to you as an investor in this offering. In addition, we could issue large blocks of voting stock to fend off unwanted tender offers or hostile takeovers without further shareholder approval. As of December 31, 2009, we had outstanding options exercisable to purchase up to 5,611,750 shares of common stock at a weighted average exercise price of $1.51 per share, and outstanding warrants exercisable to purchase up to 10,747,609 shares of common stock at a weighted average exercise price of $.99 per share. Exercise of these warrants and options could have a further dilutive effect on existing stockholders and potential investors.

Item 1B. Unresolved Staff Comments

Not applicable.

Item 2. Properties

Our principal offices are located at 1444 Wazee Street, Suite 210, Denver, Colorado 80202. Our telephone number is (720) 946-6440. We currently utilize office space provided by Osmotics pursuant to a shared services agreement under which we pay Osmotics $5,000 per month for office space and certain administrative services. The shared services agreement expires on December 31, 2010. We believe that our facility is adequate for its intended purpose. Should we increase our staffing levels or should the shared services agreement expire without being extended, we will be required to locate additional or substitute office space, which we believe is readily available to us. As manufacturing is contracted to third parties, we do not have, nor do we require, property for that purpose.

Item 3. Legal Proceedings

We are not currently involved in any legal proceedings that we believe will result in a material obligation to the Company.

Item 4. Submission of Matters to a Vote of Security Holders

Not applicable.

Table of Contents

EXECUTIVE OFFICERS OF THE REGISTRANT

The following table shows information about our executive officers as of April 1, 2010.

Name	Age	Position	Director/Officer Since
Steven S. Porter	60	Chief Executive Officer, Chairman and Director	2005
Jeffrey Sperber	45	Chief Financial Officer and Director	2005
Russell L. Allen	63	Vice President of Corporate Development	2005

Steven S. Porter has served as the Company’s Chief Executive Officer and Chairman since May 2005. Prior to joining us, he served as Chief Executive Officer and Chairman of the Board of Osmotics from its inception in August 1993 until May 2005. He served as a director of Osmotics Corporation through December 2007. He has served as Chief Executive Officer and Chairman of Ceragenix Corporation since February 2002. In January 1986, Mr. Porter and two other individuals founded GDP Technologies, Inc. (GDP), a medical imaging company, completing major strategic partnerships with Olympus Optical, Japan, GE Medical and Bruel & Kjaer, Denmark. From that time until August 1993, Mr. Porter served as Executive Vice President of GDP. Prior to 1986, Mr. Porter was the National Sales Manager for Protronyx Research, Inc., a large scale scientific computer systems company, working with the United States Department of Energy, United States Department of Defense, Boeing and the National Security Agency. Mr. Porter has a Bachelor of Arts degree in Economics from UCLA.

Jeffrey S. Sperber has served as the Company’s Chief Financial Officer since May 2005. Prior to joining us, he served as the Chief Financial Officer of Osmotics Corporation from June 2004 until May 2005. He has served as Chief Financial Officer of Ceragenix Corporation since June 2004. From January 2004 through May 2004, Mr. Sperber worked as an independent consultant for various companies, including Osmotics Corporation. From March 2001 through January 2004, Mr. Sperber served as the Vice President and Controller of TeleTech Holdings, Inc., a $1 billion, global, public company which provides outsourced call center services primarily to the Fortune 1000. From October 1997 through March 2001, he served as the Chief Financial Officer of USOL Holdings, Inc., a publicly traded broadband provider focused on multi family housing communities. At USOL, Mr. Sperber led a successful public offering of USOL’s common stock. From August 1995 through September 1997, Mr. Sperber served as a business unit controller for Tele Communications, Inc., which was subsequently acquired by Comcast. From September 1991 through August 1995, he served in various financial positions for Concord Services, Inc., an international conglomerate, most recently as the Chief Financial Officer of its manufacturing and processing business unit where he oversaw both public and private entities. From September 1986 through September 1991, Mr. Sperber was employed by Arthur Andersen LLP in Denver, Colorado. Mr. Sperber received a CPA license in the State of Colorado, which has since expired. Mr. Sperber was appointed as an outside director of Omni Bio Pharmaceutical Corporation in October 2009 where he also serves as Audit Committee Chair.

Russell L. Allen was appointed as our Vice President of Corporate Development in June 2005. Prior to joining us, he worked as an independent consultant. Previously, he served from 2002 to 2004 as Senior Vice President Corporate Development for Cellular Genomics Inc., a private drug discovery biopharmaceutical firm. From 1997 to 2001, he served as Vice President, Corporate Development and Strategic Planning at Ligand Pharmaceuticals, where he was responsible for concluding a wide variety of business development transactions including major strategic alliances with pharmaceutical firms. Between 1985 and 1996, Mr. Allen held senior positions with Sanofi Winthrop (including preceding corporate entities Sterling Winthrop and Eastman Pharmaceuticals), including being General Manager for Central American pharmaceutical operations and holding Vice President and Director level positions in business development and strategic planning. Prior experience includes more than 10 years of marketing and business development related positions with Bristol Myers Squibb and Procter & Gamble in Rx, OTC, and nutritional products. Mr. Allen received his B.A. from Amherst College and his MBA from the Harvard Graduate School of Business Administration.

PART II

Item 5.

Market for the Company’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

PRICE RANGE OF OUR COMMON STOCK

Our shares of common stock commenced trading on the OTC Bulletin Board (“OTCBB”) on February 3, 2004. Prior to June 27, 2005, our trading symbol was “OSCE.” On June 27, 2005, to reflect our new name, our trading symbol was changed to “CGXP.” The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter equity securities. An OTCBB equity security generally is any equity that is not listed or traded on NASDAQ or a national securities exchange. The reported high and low bid and ask prices for the common stock are shown below for each quarterly period from January 1, 2008 through December 31, 2009 as derived from NASDAQ trading reports.

Table of Contents

	Bid				Ask
	High		Low		High		Low
2008 Fiscal Year
Jan. 1 — Mar. 31, 2008	$	1.05	$	0.76	$	1.13	$	0.80
Apr. 1 — June 30, 2008	$	0.96	$	0.58	$	1.01	$	0.65
July 1 — Sept. 30, 2008	$	0.98	$	0.53	$	1.25	$	0.63
Oct. 1 — Dec. 31, 2008	$	0.65	$	0.16	$	0.70	$	0.19

2009 Fiscal Year
Jan. 1 — Mar. 31, 2009	$	0.85	$	0.17	$	0.90	$	0.23
Apr. 1 — June 30, 2009	$	0.61	$	0.27	$	0.69	$	0.37
July 1 — Sept. 30, 2009	$	0.50	$	0.25	$	0.55	$	0.33
Oct. 1 — Dec. 31, 2009	$	0.65	$	0.35	$	0.70	$	0.39

The bid and ask prices of our common stock as of April 12, 2010 were $.21 and $.33, respectively, as reported on the Bulletin Board. The Bulletin Board prices are bid and ask prices which represent prices between broker dealers and do not include retail mark ups and mark downs or any commissions to the broker dealer. The prices do not reflect prices in actual transactions. As of April 1, 2010, there were approximately 800 record owners of our common stock.

Our common stock is subject to rules adopted by the SEC regulating broker dealer practices in connection with transactions in “penny stocks.” Those disclosure rules applicable to “penny stocks” require a broker dealer, prior to a transaction in a “penny stock” not otherwise exempt from the rules, to deliver a standardized list disclosure document prepared by the Securities and Exchange Commission. That disclosure document advises an investor that investment in “penny stocks” can be very risky and that the investor’s salesperson or broker is not an impartial advisor but rather paid to sell the shares. The disclosure contains further warnings for the investor to exercise caution in connection with an investment in “penny stocks,” to independently investigate the security, as well as the salesperson with whom the investor is working and to understand the risky nature of an investment in this security. The broker dealer must also provide the customer with certain other information and must make a special written determination that the “penny stock” is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. Further, the rules require that, following the proposed transaction, the broker provide the customer with monthly account statements containing market information about the prices of the securities.

These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for our common stock. Many brokers may be unwilling to engage in transactions in our common stock because of the added disclosure requirements, thereby making it more difficult for stockholders to dispose of their shares.

Dividend Policy

We have not declared or paid cash dividends on our common stock since our inception. We intend to retain all future earnings, if any, to fund the operation of our business, and, therefore, do not anticipate paying dividends in the foreseeable future. The terms of our convertible debt securities prevent the payment of common stock dividends. Future cash dividends, if any, will be determined by our board of directors.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Issuer Purchases of Equity Securities

None.

Item 6. Selected Financial Data

Not Applicable

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity and cash flows of the Company for the fiscal years ended December 31, 2009 and December 31, 2008. The following discussion and analysis should be read in conjunction with the consolidated financial statements of the Company and the notes thereto included elsewhere in this Form 10-K. This discussion and analysis may contain forward-looking information based on current expectations that involve risks and uncertainties. Our actual results may differ materially as a result of various factors, including those set forth under “Risk Factors” or elsewhere in this Form 10-K.

Table of Contents

BUSINESS OVERVIEW

We are an emerging medical device company focused on dermatology and infectious disease. We have two base technology platforms each with multiple applications: Barrier Repair and Ceragenins™ (also known as cationic steroid antibiotics or “CSAs”). Our Barrier Repair platform represents near term revenue opportunities for prescription skin care products to treat a variety of skin disorders all characterized by a disrupted skin barrier. In April 2006, we received clearance from the United States Food and Drug Administration (“FDA”) to market EpiCeram® our first commercial product using the Barrier Repair technology. EpiCeram® is a prescription-only topical cream intended to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses including eczema, irritant contact dermatitis, and radiation dermatitis. All of these conditions share in common a defective or incomplete skin barrier function. In November 2007, we entered into an exclusive distribution and supply agreement with Dr. Reddy’s Laboratories, Inc. (“DRL”) for the commercialization of EpiCeram® in the United States (the “DRL Agreement”). Under the terms of the DRL Agreement, we are responsible for manufacturing (through a contract manufacturer) and supplying the product while DRL is responsible for distribution, marketing and sales. DRL launched sales and marketing efforts during October 2008. During 2009, we entered into supply and distribution agreements to commercialize EpiCeram® in Canada (the “Canadian Agreement”), certain Southeast Asian countries (the “Asian Agreement”), the European Union (the “EU Agreement”), and Israel (collectively the “International Agreements”). Sales and marketing efforts under the Canadian Agreement commenced during the fourth quarter of 2009. In January 2010, we entered into a supply and distribution agreement to commercialize EpiCeram® in Hong Kong and Taiwan, and we expect to consummate additional international agreements during the remainder of 2010.

Our Ceragenin™ technology represents near, mid and long-term revenue opportunities for treating infectious disease. Ceragenins™ are small molecule, positively charged, aminosterol compounds that have shown activity against both gram negative and gram positive bacteria, certain viruses, certain fungi and certain cancers in preclinical testing. These patented compounds mimic the activity of the naturally occurring antimicrobial peptides that form the body’s innate immune system. We are initially pursuing activities in antimicrobial medical device coatings. We have not applied for, nor have we received, approval from the FDA to market any product using our Ceragenin™ technology. However, it is our expectation that we will be able to generate revenue from the Ceragenin™ technology prior to receiving FDA approvals in the form of upfront and milestone payments under development and sublicense agreements.

Since our inception in February 2002, we have incurred significant cash and operating losses and as of December 31, 2009, we had a stockholders’ deficit of $19,631,693 and a working capital deficit of $3,631,833. We have relied upon proceeds from the sale of convertible debt securities, proceeds received from the exercise of common stock purchase warrants, and milestone payments from the DRL Agreement to fund our operations. We will require additional capital to execute our business plan and continue as a going concern. As of December 31, 2009, we had $9,738,812 outstanding in secured convertible debt. Repayment of these obligations is secured by a first lien on all of our assets, including all of our intellectual property rights and intellectual property licenses. We have amended the terms of the debt several times but the convertible debt agreements still contain a number of provisions which new investors could find problematic and could deter investment. We do not believe it is possible to raise additional capital without further modification of the debt. If we default on any of the covenants or other requirements of our debt agreements, the debt holders will be able to foreclose on our assets by which their debts are secured which would likely cause you to lose your entire investment. Such foreclosure would likely force us out of business. Furthermore, if the debt holders choose to convert their debt into shares of common stock it is possible that the sale of such shares could have a depressive effect on the share price of our common stock.

Our future success will be highly dependent on the commercial success of EpiCeram® as well as our ability to develop, test and commercialize our Ceragenin™ technology as an antimicrobial coating for medical devices. We plan on commercializing our Ceragenin™ through licensing agreements with device manufacturers. In order to control the timing and direction of the development of the Ceragenin™ technology, we will require capital resources beyond what we currently have on hand or expect to generate from EpiCeram® sales. Currently, we rely on the efforts of potential commercialization partners to advance the testing of the Ceragenin™ technology. Our ability to raise additional capital will be dependent upon many factors including, but not limited to, our ability to amend the terms of our convertible debt securities, the commercial success of EpiCeram®, successful testing of the Ceragenin™ technology and global market and economic conditions. If funding is not available when needed, or is available only on unfavorable terms, meeting our capital needs or otherwise taking advantage of business opportunities may become challenging, which could have a material adverse effect on our business plans.

CERTAIN EVENTS AND RESULTS OF OPERATIONS

During 2009, we announced the following significant events:

In February 2009, we entered into an exclusive distribution and supply agreement with Hyphens Marketing & Technical Services PTE. LTD (“Hyphens”), to commercialize EpiCeram® in Singapore, Malaysia, the Philippines, Vietnam, Indonesia and Brunei.

Table of Contents

In the fourth quarter of 2009, we shipped product to Hyphens under this agreement. Hyphens has advised us that they expect to launch EpiCeram® in the second quarter of 2010.

In February 2009, we entered into an exclusive distribution and supply agreement with Pediapharm Inc. (“Pediapharm”), to commercialize EpiCeram in Canada. During the fourth quarter of 2009, we shipped product to Pediapharm and they launched commercialization activities.

In March 2009, the National Institutes of Health (“NIH”) awarded a $1.66 million grant to the University of Utah to fund research evaluating a Cerashield™ coating to reduce orthopedic implant infections. The grant will fund preclinical evaluation of orthopedic implants coated with CSA-13, the active ingredient in Cerashield™ coatings.

In April 2009, we entered into a Joint Development Agreement (“JDA”) with MAST BioSurgery Inc. (“MAST”) for the development of one or more new surgical products incorporating our CeraShield™ antimicrobial technology. Under the terms of the JDA, MAST has exclusive rights to develop specified products and negotiate commercialization terms for such products through June 2010, as extended.

In May 2009, we entered into an exclusive evaluation and option to license agreement with a global, multi-billion dollar healthcare company covering the use of our Cerashield™ antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections. For competitive reasons, neither the name of the company nor the precise area of interest was publicly disclosed. Under the terms of the agreement, the company has an exclusive period to evaluate, negotiate commercialization terms and license the specified product application through April 2010, as extended.

In May 2009, we entered into an exclusive distribution and supply agreement with Davi II - Farmaceutica S.A., a Portuguese company, (“Davi “), to commercialize EpiCeram® in Europe. Davi has advised us that they expect the first country launch to occur in the third quarter of 2010.

In July 2009, we entered into an exclusive evaluation and option to license agreement with Nobel Biocare (“Nobel”), a world leader in innovative restorative and esthetic dental solutions. Under terms of the agreement, Nobel will have an exclusive period to evaluate, negotiate commercialization terms and license Cerashield™ for certain oral and cranial maxillofacial applications through October 6, 2010.

In July 2009, we entered into an exclusive distribution and supply agreement with Megapharm Ltd., an Israeli company, (“Megapharm”), to commercialize EpiCeram® in Israel and the Palestinian territories. We expect Megapharm to launch EpiCeram® in the latter half of 2010.

In August 2009, we announced that pre-clinical testing of a silicone medical device incorporating our CeraShield™ antimicrobial technology demonstrated 224 days of continuous antimicrobial efficacy in preventing bacterial colonization in an in vitro test using a fresh inoculum of at least 1,000 colony forming units per ml of E. coli on a daily basis in artificial urine.

In September 2009, we announced that the NIH awarded a $2.87 million grant to fund the pre-clinical development of a Ceragenin™ based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella. The grant will fund the preclinical development, formulation, toxicology and cGMP scale up to 1 kilogram of CSA-13. The research grant has been awarded to a consortium of research institutions led by Brigham Young University (“BYU”) and including SRI International (Menlo Park, CA), Southwest Research Institute (SwRI, San Antonio, TX) and McMaster University (Hamilton, Ontario, Canada).

Critical Accounting Policies

We have identified the policies described below as critical to our business and results of operations. For further discussion on the application of these and other accounting policies, see Note 3 to the consolidated financial statements contained elsewhere in this Form 10-K. Our reported results are impacted by the application of the following accounting policies, certain of which require management to make subjective or complex judgments. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact quarterly or annual results of operations. For all of these policies, management cautions that future events rarely develop exactly as expected, and the best estimates routinely require adjustment. Specific risks associated with these critical accounting policies are described in the following paragraphs.

Revenue Recognition

We recognize revenue when there is persuasive evidence that an arrangement exists, when title has passed, the price is fixed

Table of Contents

or determinable, and we are reasonably assured of collecting the resulting receivable. Revenue arrangements that include multiple deliverables are divided into separate units of accounting if the deliverables meet certain criteria. To date, we have not recognized product revenues net of revenue reserves such as sales returns and allowances as we have not experienced, nor do we anticipate experiencing, such returns. In the event that our future experience with returns differs from our historical experience, we will modify our revenue recognition practice. This accounting policy for revenue recognition may have a substantial impact on our reported results and relies on certain estimates that can require difficult, subjective and complex judgments on the part of management.

For the year ended December 31, 2008, our sole source of revenue was the sale of EpiCeram® in the United States pursuant to the DRL Agreement. For the year ended December 31, 2009, sale of EpiCeram® under the DRL Agreement was our primary source of revenue, however, we also recognized revenue under the Canadian and Asian Agreements. We record (or will record) revenue under our supply and distribution agreements for EpiCeram® as follows:

Advance Fees — Certain of our agreements call for non-sales milestone payments based on the accomplishment of specific events including the launch of the product or regulatory approval. We believe that the payment of these fees and our continuing performance obligation related to supplying EpiCeram® are an integrated package. Accordingly, we record receipt of advance fees as deferred revenue and recognize revenue systematically over the periods that the fees are earned. We are recognizing revenue on a straight-line basis over the period of our performance obligations under these agreements which range from 15 to 20 years.

Product Sales —We recognize revenue for product sales when title passes to our customers. Under certain agreements, the supply price of EpiCeram® includes a percentage of the net sales realized by our customers (as defined in the agreements) (“Net Sales Component Revenue”). We recognize Net Sales Component Revenue during the period our customers’ sales occur based upon reports provided by our customers, subject to minor true-up adjustments.

Net Sales Milestones — Certain agreements provide for the payment of milestone payments based on cumulative net sales over the life of the agreement. We will recognize revenue from net sales milestones once the amount can be reliably estimated based upon reports provided by our customer or when our customer communicates to us that an additional milestone payment has been triggered if reliable estimates cannot be provided.

Other Nonrefundable Fees - We recognize revenue from non refundable up-front fees on a straight-line basis over the contractual term of the arrangement.

Derivatives

Our derivative instruments (including certain derivative instruments embedded in other contracts) are recorded in the balance sheet as either an asset or liability measured at its fair value, with changes in the derivative’s fair value recognized currently in earnings unless specific hedge accounting criteria are met. We value these derivative securities under the fair value method at the end of each reporting period (quarter), and their value is marked to market at the end of each reporting period with the gain or loss recorded against earnings. We continue to revalue these instruments each quarter to reflect their current value in light of the current market price of our common stock. We utilize the Black-Scholes option-pricing model to estimate fair value. Key assumptions of the Black-Scholes option-pricing model include applicable volatility rates, risk-free interest rates and the instrument’s expected remaining life. These assumptions require significant management judgment.

Share-Based Payments

We account for stock option compensation costs at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest, using the modified prospective method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results differ from our estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We consider various factors when estimating expected forfeitures, including historical experience. Actual results may differ substantially from these estimates.

We determine the fair value of stock options granted to employees and directors using the Black-Scholes valuation model, which considers the exercise price relative to the market value of the underlying stock, the expected stock price volatility, the risk-free interest rate and the dividend yield, and the estimated period of time option grants will be outstanding before they are ultimately exercised. Had we made different assumptions about our stock price volatility or the estimated time option and warrant grants will be outstanding before they are ultimately exercised, the related stock based compensation expense and our net loss and net loss per share amounts could have been significantly different in 2009 and 2008.

Table of Contents

YEAR ENDED DECEMBER 31, 2009 COMPARED TO YEAR ENDED DECEMBER 31, 2008

Revenue

For the years ended December 31, 2009 and 2008, revenue consists of the following components:

	2009		2008
Product revenue	$	1,840,285	$	642,037
Milestone recognition	258,020		114,187
Other	8,000		—
	$	2,106,305	$	756,224

The increase in revenue between years is primarily the result of a complete year of EpiCeram® sales in the United States during the year ended December 31, 2009 compared to a partial year for the year ended December 31, 2008. EpiCeram® was launched in the United States in late September 2008. Further, during the fourth quarter of 2009, we commenced shipment of EpiCeram® to Canada and certain Southeast Asian countries which also contributed to the increase in revenue between years.

Cost of Goods Sold

For the years ended December 31, 2009 and 2008, cost of goods sold as a percentage of revenue was as follows:

		2009		2008
		60.5	%	73.9	%

The reduction in cost of goods sold as a percentage of revenue between periods is primarily the result of (1) an increase in the proportion of EpiCeram® Net Sales Component revenue which has no associated cost and (2) the introduction of international revenue during 2009 which had a higher gross margin associated with it than domestic revenue.

Licensing Fees and Royalties

We pay licensing fees and royalties under separate license agreements with two entities: The Regents of the University of California (for Barrier Repair technology) and Brigham Young University (for Ceragenin™ technology). For the years ended December 31, 2009 and 2008, licensing fees and royalties were as follows:

	2009		2008
Ceragenin™ Technology	$	290,000	$	206,667
Barrier Repair Technology	92,014		36,269
	$	382,014	$	242,936

The increase in fees paid for the Ceragenin™ technology is the result of an increase in the minimum amount due under the Brigham Young University license agreement during 2009. The increase in Barrier Repair technology royalties is due to the increase in product revenue between years.

Research and Development

Research and development expense was approximately the same for the years ended December 31, 2009 and 2008. Our ability to conduct research and development activities is greatly dependent upon our financial resources. Because of our limited financial resources, we do not expect to incur significant research and development costs during 2010. In order to develop Cerashield™ and NeoCeram® in a more timely manner, we will require additional financial resources. No assurance can be given that necessary additional financing will be available on terms acceptable to us, if at all. If adequate additional funds are not available when required, we may have to delay, scale-back or eliminate certain aspects of our research, testing and/or development activities.

General and Administrative

General and administrative expenses for the year ended December 31, 2009, decreased by $1,167,891 or approximately 25% compared to the year ended December 31, 2008. The decrease in expense between years was primarily due to decreases in bonuses, stock compensation, investor relations, legal, and travel and entertainment expenses. There were no bonuses awarded during 2009. Stock compensation expense decreased as the result of certain stock options issued in prior years becoming fully vested during 2008 combined with no new grants during 2009. Investor relations expense decreased primarily due to a reduction in stock compensation expense related to investor relations services combined with a reduction in monthly cash retainers paid for these services. Legal and travel expenses decreased as a result of our focus on reducing such expenditures.

Table of Contents

Loss from Operations

As a result of the factors described above, the loss from operations for the year ended December 31, 2009 decreased by $1,670,995 compared to the year ended December 31, 2008.

Other Expense

Other expense for the year ended December 31, 2009 increased by $3,746,055 compared to the year ended December 31, 2008. The increase in other expense between years is the net result of recording a loss on fair value of derivative liabilities during 2009 compared to a gain during 2008, partially offset by a reduction in interest expense during 2009 compared to 2008. Included in interest expense for the year ended December 31, 2008, are charges for recording the fair value of consideration paid to the holders of our convertible debt securities in exchange for amending the terms of the debt.

Net Loss

As a result of the factors described above, the net loss for year ended December 31, 2009 increased by $2,075,060 compared to the year ended December 31, 2008.

Preferred Stock Dividends

We did not record preferred stock dividends during the year ended December 31, 2009 as a result of the conversion of Series A Preferred Stock into common shares during the second quarter of 2008. Preferred stock dividends were $80,000 for the year ended December 31, 2008.

Loss Attributable to Common Shareholders

As a result of the factors described above, the loss attributable to common shareholders increased by $1,995,060 for the year ended December 31, 2009 compared to the year ended December 31, 2008.

Historical Cash Flows

Operating Activities

As of December 31, 2009, we had $104,442 of cash and cash equivalents. During the year ended December 31, 2009, $445,360 of cash was used in operating activities compared to $1,574,156 used in the year ended December 31, 2008. The decrease in cash used in operating activities between years is the result of a decrease in the Company’s cash operating loss which we define as the net loss adjusted for all non-cash items.

Investing Activities

During the year ended December 31, 2009, there was no cash used in or provided by investing activities. As of December 31, 2009, we had no material commitments for capital expenditures.

Financing Activities

During the year ended December 31, 2009, $64,655 of cash was used in financing activities primarily representing principal payments made to Osmotics under a promissory note agreement.

LIQUIDITY AND CAPITAL RESOURCES

Our consolidated financial statements for 2009 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on our consolidated financial statements as of and for each of the years ended December 31, 2009 and 2008, includes a “going concern” emphasis paragraph describing that conditions exist that raise substantial doubt about the Company’s ability to continue as a going concern.

Raising sufficient capital to fund our business activities has historically been, and continues to be, our most significant challenge. Typically, we have never had more than 12 to 15 months of cash on hand at any given time and often we have had much less. The costs and time associated with developing a technology into an FDA cleared medical device or new drug is substantial. Because of our limited capital resources we have not been able to advance development of our technologies as broadly or as rapidly as otherwise possible with greater resources. Our capital resource constraints have also impacted our business strategy as follows:

Table of Contents

· We are focusing our development efforts on products that can be regulated as medical devices instead of new drugs;

· We plan to commercialize our products primarily through out-license and/or supply and distribution agreements with third parties instead of fielding an internal sales force; and

· We are willing to enter into out-license agreements or collaboration arrangements at early stages of development.

While this strategy will serve to reduce the amount of capital required by the Company, it also may serve to limit the value we create for our shareholders from our technologies.

Our ability to raise additional capital is constrained by the following factors related to our capital structure and market for our common stock:

· The existence and terms of our convertible debt securities (see discussion provided under Note 5 to the consolidated financial statements included elsewhere in this Form-10K) contain a number of provisions which many new investors may find problematic including the following:

· The conversion price of the debt and warrants is to be adjusted downward under a number of circumstances which creates uncertainty for new investors;

· We are required to utilize a significant portion of our future revenue streams to service and retire debt. New investors would likely prefer that these cash flows be retained by the Company to defray or fund our operating costs;

· As of December 31, 2009, there were 21,032,725 common shares underlying the conversion of the debt and exercise of warrants held by the debt holders. This represents a significant overhang and creates uncertainty for new investors;

· Under most circumstances, we would be required to obtain approval from the debtholders in order to execute a future funding transaction; and

· Any, or all, of these provisions could result in a new investor seeking a waiver, or permanent amendment, to the debt agreements in order to consummate a funding transaction. There is no assurance that the debtholders would agree to a waiver or any change to the terms of the debt agreements.

· The existence of 12,004,569 shares of our common stock held by Osmotics for exchange with their shareholders and debtholders creates uncertainty for new investors particularly as to how the market for our common stock will be impacted when that exchange transaction takes place;

· The recent trading price of our common stock is below the conversion price of the convertible debt creating the following issues:

· Any transaction at or near market price would result in an adjustment to the conversion price of the convertible debt securities and warrants (unless waived by the existing debt holders) resulting in immediate substantial dilution to our current shareholders and new investors; and

· We would likely have to issue a number of shares that would/could result in the new investors owning a significant percentage of our common shares, which may result in a change of control. Many investors do not want, or are prohibited from, owning such a significant percentage of an investee.

· Changes in the interpretation of Rule 415(a)(1)(x) by the SEC have limited the number of shares of common stock that

we can register for new investors that are sold pursuant to private placement transactions. Until such time that Osmotics completes its planned exchange transaction, the shares they hold in escrow are excluded from our float for purposes of Rule 415 calculations which further exacerbates this limitation; and

· The average trading volume of our common stock on the OTC Bulletin Board is not significant. Our common stock is subject to rules adopted by the SEC regulating broker dealer practices in connection with transactions in “penny stocks.” These rules make it more difficult to buy and sell shares of our common stock. Additionally, we have a limited public float which has also contributed to the limited trading volume. Further, many retail investors will not, and many institutional investors cannot, invest in stocks that trade on the OTC Bulletin Board. Investors typically want to be assured that they can sell their shares of common stock without adversely impacting the market for such common stock

Table of Contents

and we currently cannot provide such assurances.

All of the above factors serve to limit the number of potential investors available to the Company. We do not see these conditions changing in the near term.

We have two series of convertible debt instruments which may affect our future liquidity. For more information on the Convertible Notes and the Convertible Debentures, see the descriptions in Note 5 to our audited financial statements included elsewhere in this Form 10-K.

Outlook

As of December 31, 2009, we had cash of $104,442. We believe that we can maintain a positive cash balance into April 2010 based on expected cash receipts and by delaying payments to certain vendors including those critical to our ability to manufacture EpiCeram® and the universities from which we have licensed our proprietary technologies. The Company will require additional funding by April 30, 2010 in order to remain a viable business. The Company has been actively pursuing funding alternatives and believes that it has reached an agreement in principal with a third party for a $3 million secured note (the “Note Transaction”). The Company believes that the proceeds from the Note Transaction should be adequate to fund the Company’s activities through the end of 2010 and allow sufficient time for the Company to attempt to raise additional capital. However, in order to consummate the Note Transaction, the holders of the Company’s convertible debt securities (the “Secured Creditors”) will be required to release certain liens related to the manufacture and sale of EpiCeram® in the United States. The Company has been in active dialog with the Secured Creditors regarding this transaction but the Secured Creditors have not yet agreed to the transaction. Additionally, the Company is aware of certain third parties (the “Third Parties”) who are attempting to acquire the “Convertible Notes” (defined below) and the “2006 Debentures” (defined below”) in order to consummate an effective acquisition of the Company. Based on the Company’s limited understanding of the proposal being made by the Third Parties, the Company’s Board of Directors believes that it significantly undervalues the Company and it would not be in the best interest of the Company’s shareholders for such a transaction to be consummated. The Company believes that the efforts by these Third Parties to purchase the Company’s convertible debt from the Secured Creditors has served to delay and hinder its ability to execute the Note Transaction.

The Company is in discussions with several parties regarding a financing transaction that would fund the Company’s activities beyond 2010 and provide for the retirement of the convertible debt on terms the Company believes are more favorable than those being proposed by the Third Parties to the Secured Creditors. The Company is working vigorously to demonstrate to the Secured Creditors that the Company’s strategy is credible but ultimately, the Secured Creditors will make their own determination. There is no assurance that the Company will be successful in convincing the Secured Creditors to pursue the plan being proposed by the Company nor is there any assurance that the Company’s financing efforts will be successful assuming the Secured Creditors consent to the Note Transaction.

As a result of the actions taken to extend its cash balance, the Company is currently facing the following risks and uncertainties:

· As of December 31, 2009, the Company owed Brigham Young University (“BYU”) $339,663 in license, maintenance and legal fees the majority of which are delinquent. These delinquent fees constitute grounds for BYU to terminate the patent sublicense agreement between BYU and the Company. On April 7, 2010, BYU declared us in breach of the BYU license with 30 days to cure the breach. A loss of the BYU license would have a material adverse affect on the Company’s business prospects.

· The Company is also delinquent in making its 2010 minimum annual royalty payment as well as the December 31, 2009 quarterly royalty payment to the Regents of the University of California (the “Regents”) under its patent sublicense agreement. The delinquent payments aggregate to approximately $78,656. In the event that the Regents declare the Company to be in breach of the agreement, the Company will have 60 days to cure the breach. A loss of the license agreement with the University of California would have a material adverse affect on the Company’s operations, liquidity and business prospects.

· The Company is also at risk of not meeting certain commercial obligations related to outstanding purchase orders for EpiCeram®. Further, future international launch dates for EpiCeram® could also be in jeopardy as a result of the Company’s current lack of liquidity. There is no assurance that even if the Note Transaction is consummated that we will be able to meet our commercial obligations within the required timeframes. This could result in a disruption of supply for EpiCeram®.

As of the date of this Form 10-K, we have no firm commitments for funding and our ability to access the capital markets may be severely limited due to the following reasons:

Table of Contents

· The existence and terms of our convertible debt securities (see discussion provided under Note 5 below) contain a number of provisions which could deter new investment including the following:

· The conversion price of the debt and warrants is to be adjusted downward under a number of circumstances which creates uncertainty for new investors;

· As of December 31, 2009, there were 21,032,726 common shares underlying the conversion of the debt and exercise of warrants held by the debt holders. This represents a significant overhang and creates uncertainty for new investors;

· Under most circumstances, we would be required to obtain approval from the debtholders in order to execute a future funding transaction; and

· The existence of 12,004,569 shares of our common stock held by Osmotics for exchange with their shareholders creates uncertainty for new investors particularly as to how the market for our common stock will be impacted when that exchange transaction takes place;

· The recent trading price of our common stock is below the conversion price of the convertible debt creating the following issues:

· Changes in the interpretation of Rule 415(a)(1)(x) by the SEC have limited the number of shares of common stock that we can register for new investors that are sold pursuant to private placement transactions. Until such time that Osmotics completes its planned exchange transaction, the shares they hold in escrow are excluded from our float for purposes of Rule 415 calculations which further exacerbates this limitation; and

· Our limited operating history and lack of profitable operations; and

· The economic downturn and uncertainty in the U.S. financial markets.

There is no assurance that we will be able to raise additional capital within the timeframe described above. Even if we are successful, it will likely be on terms that substantially dilute our current shareholders. In the event that we cannot raise sufficient capital within the required timeframe, it will have a material adverse effect on the Company’s liquidity, financial condition and business prospects or force the company out of business.

Table of Contents

Contractual Obligations

We had the following contractual obligations at December 31, 2009, which require us to raise additional capital to meet the obligations that exceed the current capital resources of the Company:

Contractual Obligations	Less Than 1 Year		1-3 years		3-5 years		Over 5 years		Total
Debt	$	1,190,898	$	8,941,944	$	12,724	$	—	$	10,145,566
License Agreements	685,000		880,000		830,000		3,120,000		5,515,000
Purchase Commitments	868,831		—		—		—		868,831
	$	2,744,729	$	9,821,944	$	842,724	$	3,120,000	$	16,529,397

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

OTHER

We have entered into employment agreements with various executives. These agreements provide for severance arrangements and accelerated vesting of equity compensation awards in the event that the executive is terminated by us other than for cause or disability or if the executive resigns for good reason.

RECENT ACCOUNTING PRONOUNCEMENTS

For a discussion of the recent accounting pronouncements relevant to our operations, please refer to the information provided under Note 3 to our audited consolidated financial statements included elsewhere in this Form 10-K.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

Market risk represents the risk of loss that may impact our consolidated financial position, consolidated results of operations, or consolidated cash flows due to adverse changes in financial and commodity market prices and rates. As of December 31, 2009 we do not believe we are exposed to significant market risks due to changes in U.S. interest rates or foreign currency exchange rates as measured against the U.S. dollar.

Item 8. Financial Statements and Supplementary Data

CONTENTS

	Page
Consolidated Financial statements for the years ended December 31, 2009 and December 31, 2008:
Report of Independent Registered Public Accounting Firm	36
Consolidated Balance Sheets	37
Consolidated Statements of Operations	38
Consolidated Statements of Cash Flows	39
Consolidated Statements of Stockholders’ Equity (Deficit)	40
Notes to Consolidated Financial Statements	41

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have audited the accompanying consolidated balance sheets of Ceragenix Pharmaceuticals, Inc. and subsidiary as of December 31, 2009 and 2008, and the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the years then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Ceragenix Pharmaceuticals, Inc. and its subsidiary as of December 31, 2009 and 2008, and the results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has not generated cash flows from operations since inception, has incurred continuing losses and has a stockholders’ deficit at December 31, 2009. In addition, the Company is in technical default under the terms of a significant license agreement related to one of the Company’s primary technologies, and the licensor has declared the Company in breach of the agreement. If the Company cannot cure this breach, the license may be terminated, which could have a material adverse effect on the Company. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ GHP Horwath, P.C.

GHP Horwath, P.C.
Denver, Colorado
April 14, 2010

Table of Contents

CERAGENIX PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2009 AND 2008

	2009			2008
ASSETS

Current assets:
Cash	$	104,442		$	614,457
Accounts receivable	264,363			261,615
Inventory	431,824			164,628
Related party receivables	5,829			44,135
Prepaid expenses, deposits and other	253,029			91,768
Total current assets	1,059,487			1,176,603

Property and equipment, net	5,042			11,927
Other asset	435,375			—
Total assets	$	1,499,904		$	1,188,530

LIABILITIES AND STOCKHOLDERS’ DEFICIT

LIABILITIES:
Current liabilities:
Trade accounts payable	$	339,633		$	159,403
Customer deposits	776,881			—
Accrued compensation	591,000			591,000
Accrued interest	334,082			11,694
Accrued licensing fees	245,000			—
Other accrued liabilities	532,326			277,437
Current portion of deferred revenue	304,869			205,663
Current portion of note payable, related party	84,996			—
Current portion of Convertible Notes	395,782			—
Current portion of 2006 Debentures, net of discount of $120,083	590,037			—
Derivative liabilities	496,714			—
Total current liabilities	4,691,320			1,245,197

Deferred revenue, less current portion	4,545,543			3,670,775
Note payable, related party, less current portion	321,758			—
Convertible Notes, less current portion	3,089,562			3,252,575
2006 Debentures, less current portion, net of discount of $937,390 (2009) and $1,586,210 (2008)	4,605,958			4,248,740
Derivative liabilities	3,877,456			819,226
Total liabilities	21,131,597			13,236,513

STOCKHOLDERS’ DEFICIT:

Series B Preferred stock, no par value, 495,000 shares authorized; 60,000 (2009) and 315,000 (2008) shares issued and outstanding; liquidation preference of $135,000 (2009) and $708,750 (2008)	135,000			708,750
Common stock, $.0001 par value; 100,000,000 shares authorized; 18,183,293 (2009) and 17,808,293 (2008) shares issued and outstanding	1,819			1,781
Additional paid-in capital	19,858,764			18,459,423
Accumulated deficit	(39,627,276		)	(31,217,937		)
Total stockholders’ deficit	(19,631,693		)	(12,047,983		)
Total liabilities and stockholders’ deficit	$	1,499,904		$	1,188,530

The accompanying notes are an integral part of these financial statements.

Table of Contents

CERAGENIX PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2009 AND 2008

	2009			2008

REVENUE:
Product	$	1,840,285		$	642,037
Milestone recognition	258,020			114,187
Other	8,000			—
Total revenue	2,106,305			756,224

COST OF GOODS SOLD	1,273,993			558,857

GROSS MARGIN	832,312			197,367

OPERATING EXPENSES:
Licensing fees and royalties	382,014			242,936
Research and development	224,544			231,781
General and administrative	3,440,606			4,608,497
	4,047,164			5,083,214

Loss from operations	(3,214,852		)	(4,885,847		)

OTHER INCOME (EXPENSE):
Interest and other, net	(1,639,543		)	(9,757,931		)
(Loss) gain on value of derivative liabilities	(3,554,944		)	8,309,499
	(5,194,487		)	(1,448,432		)

NET LOSS	(8,409,339		)	(6,334,279		)

PREFERRED STOCK DIVIDENDS	—			(80,000		)

LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(8,409,339	)	$	(6,414,279	)

WEIGHTED AVERAGE SHARES OUTSTANDING:
Basic and diluted	18,032,430			17,255,582

LOSS PER SHARE:
Basic and diluted	$	(0.47	)	$	(0. 37)

The accompanying notes are an integral part of these financial statements.

Table of Contents

CERAGENIX PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2009 AND 2008

	2009			2008
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(8,409,339	)	$	(6,334,279	)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss (gain) on value of derivative liability	3,554,944			(8,309,499		)
Amortization of debt discount	528,737			1,485,961
Stock-based compensation expense	831,992			1,392,712
Interest expense added to convertible debt balance	651,288			485,336
Fair value of adjustment to exercise price of convertible debt and warrants	—			6,450,384
Fair value of warrants issued for amending debt agreements	—			920,091
Warrants issued for services	16,137			1,467
Depreciation and amortization expense	87,510			11,860
Inventory obsolescence expense	3,589			—
Increase in accounts receivable	(2,748		)	(261,615		)
Increase in inventory	(270,785		)	(164,628		)
Increase in prepaid expenses, deposits and other	(54,243		)	(13,236		)
Increase in accounts payable and accrued liabilities	866,703			375,477
Increase in customer deposits	776,881			—
Increase in deferred revenue	973,974			2,385,813
Net cash used in operating activities	(445,360		)	(1,574,156		)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	—			(7,577		)
Net cash used in investing activities	—			(7,577		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments under promissory note to Osmotics	(65,459		)	(50,000		)
Repayments from Osmotics under promissory note	—			25,000
Borrowings under insurance financing agreement	88,454			84,434
Payments under insurance financing agreement	(87,650		)	(76,898		)
Net cash used in financing activities	(64,655		)	(17,464		)
Net decrease in cash	(510,015		)	(1,599,197		)
Cash at the beginning of year	614,457			2,213,654
Cash at the end of year	$	104,442		$	614,457

The accompanying notes are an integral part of these financial statements.

Table of Contents

CERAGENIX PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED DECEMBER 31, 2009 AND 2008

	Preferred Stock				Preferred Stock
	Series A				Series B					Common Stock			Additional			Accumulated
	Shares		Amount		Shares		Amount			Shares	Amount		Paid in Capital			Deficit			Total

BALANCES, December 31, 2007	1,000,000		$	—	375,000		$	843,750		16,393,724	$	1,639	$	17,299,917		$	(24,883,658	)	$	(6,738,352	)

Stock-based compensation expense	—		—		—		—			—	—		823,181			—			823,181
Conversion of preferred shares and accrued dividends into common shares	(1,000,000	)	—		(60,000	)	(135,000		)	1,364,569	137		374,863			—			240,000
Conversion of accrued interest into common stock	—		—		—		—			50,000	5		39,995			—			40,000
Warrants issued for services	—		—		—		—			—	—		1,467			—			1,467
Net loss	—		—		—		—			—	—		—			(6,334,279		)	(6,334,279		)
Preferred stock dividends			—		—		—			—	—		(80,000		)	—			(80,000		)
BALANCES, December 31, 2008	—		—		315,000		708,750			17,808,293	1,781		18,459,423			(31,217,937		)	(12,047,983		)

Stock-based compensation expense	—		—		—		—			—	—		539,496			—			539,496
Conversion of preferred shares to common shares	—		—		(375,000	)	(843,750		)	375,000	38		843,712			—			—
Issuance of preferred shares for services	—		—		120,000		270,000			—	—		—			—			270,000
Warrants issued for services	—		—		—		—			—	—		16,133			—			16,133
Net loss	—		—		—		—			—	—		—			(8,409,339		)	(8,409,339		)
BALANCES, December 31, 2009	—		$	—	60,000		$	135,000		18,183,293	$	1,819	$	19,858,764		$	(39,627,276	)	$	(19,631,693	)

The accompanying notes are an integral part of these financial statements.

Table of Contents

CERAGENIX PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2009

(1) BUSINESS AND OVERVIEW

Ceragenix Pharmaceuticals, Inc. (the “Company”) is an emerging medical device company focused on dermatology and infectious disease. We have two base technology platforms each with multiple applications: Barrier Repair and Ceragenins™ (also known as cationic steroid antibiotics or “CSAs”). Our Barrier Repair platform represents near term revenue opportunities for prescription skin care products to treat a variety of skin disorders all characterized by a disrupted skin barrier. In April 2006, we received clearance from the United States Food and Drug Administration (“FDA”) to market EpiCeram® our first commercial product using the Barrier Repair technology. EpiCeram® is a prescription-only topical cream intended to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses including eczema, irritant contact dermatitis, and radiation dermatitis. All of these conditions share in common a defective or incomplete skin barrier function. In November 2007, we entered into an exclusive distribution and supply agreement with Dr. Reddy’s Laboratories, Inc. (“DRL”) for the commercialization of EpiCeram® in the United States (the “DRL Agreement”). Under the terms of the DRL Agreement, we are responsible for manufacturing (through a contract manufacturer) and supplying the product while DRL is responsible for distribution, marketing and sales. DRL launched sales and marketing efforts during October 2008. During 2009, we entered into supply and distribution agreements to commercialize EpiCeram® in Canada (the “Canadian Agreement”), certain Southeast Asian countries (the “Asian Agreement”), the European Union (the “EU Agreement”), and Israel (collectively the “International Agreements”). Sales and marketing efforts under the Canadian Agreement commenced during the fourth quarter of 2009. In January and February 2010, we entered into supply and distribution agreements to commercialize EpiCeram® in Hong Kong, Taiwan and South Korea, and we expect to consummate additional international agreements during the remainder of 2010.

(2) GOING CONCERN AND MANAGEMENT’S PLANS

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since our inception in February 2002, we have incurred significant cash and operating losses and as of December 31, 2009, we had a stockholders’ deficit of $19,631,693 and a working capital deficit of $3,631,833. We have relied upon proceeds from the sale of convertible debt securities, proceeds received from the exercise of common stock purchase warrants, and milestone payments from the DRL Agreement to fund our operations.

As of December 31, 2009, we had cash of $104,442. We believe that we can maintain a positive cash balance into April 2010 based on expected cash receipts and by delaying payments to certain vendors including those critical to our ability to manufacture EpiCeram® and the universities from which we have licensed our proprietary technologies. The Company will require additional funding by April 30, 2010 in order to remain a viable business. The Company has been actively pursuing funding alternatives and believes that it has reached an agreement in principal with a third party for a $3 million secured note (the “Note Transaction”). The Company believes that the proceeds from the Note Transaction should be adequate to fund the Company’s activities through the end of 2010 and allow sufficient time for the Company to attempt to raise additional capital. However, in order to consummate the Note Transaction, the holders of the Company’s convertible debt securities (the “Secured Creditors”) will be required to release certain liens related to the manufacture and sale of EpiCeram® in the United States. The Company has been in active dialog with the Secured Creditors regarding this transaction, but the Secured Creditors have not yet agreed to the transaction. Additionally, the Company is aware of certain third parties (the “Third Parties”) who are attempting to acquire the “Convertible Notes” (defined below) and the “2006 Debentures” (defined below) in order to consummate an effective acquisition of the Company. Based on the Company’s limited understanding of the proposal being made by the Third Parties, the Company’s Board of Directors believes that it would not be in the best interest of the Company’s shareholders for such a transaction to be consummated.

Table of Contents

As a result of the actions taken to extend its cash balance, the Company is currently facing the following risks and uncertainties:

· As of December 31, 2009, the Company owed Brigham Young University (“BYU”) $339,663 in license, maintenance and legal fees, the majority of which are delinquent. These delinquent fees constitute grounds for BYU to terminate the patent sublicense agreement between BYU and the Company. On April 7, 2010, BYU declared us in breach of the BYU license with 30 days to cure the breach. A loss of the BYU license would have a material adverse affect on the Company’s business prospects.

As of the date of this Form 10-K, we have no firm commitments for funding and our ability to access the capital markets may be severely limited due to the following reasons:

· The existence and terms of our convertible debt securities (see discussion provided under Note 5 below) contain a number of provisions which could deter new investment including the following:

· The conversion price of the debt and warrants is to be adjusted downward under a number of circumstances which creates uncertainty for new investors;

· Under most circumstances, we would be required to obtain approval from the debtholders in order to execute a future funding transaction; and

· The existence of 12,004,569 shares of our common stock held by Osmotics for exchange with their shareholders creates uncertainty for new investors, particularly as to how the market for our common stock will be impacted when that exchange transaction takes place;

· The recent trading price of our common stock is below the conversion price of the convertible debt creating the following issues:

· Any transaction at or near market price would result in an adjustment to the conversion price of the convertible

Table of Contents

debt securities and warrants (unless waived by the existing debt holders) resulting in immediate substantial dilution to our current shareholders and new investors; and

· Our limited operating history and lack of profitable operations; and

· The economic downturn and uncertainty in the U.S. financial markets.

(3) BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Ceragenix Corporation. All inter-company accounts and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. Actual results may differ from these estimates.

Accounts Receivable

Accounts receivable are stated at net realizable value. We review accounts receivable on a quarterly basis for slow paying or uncollectible accounts to determine whether we need to establish an allowance for doubtful accounts. Based on our analysis, we do not believe an allowance for doubtful accounts was necessary at December 31, 2009 or 2008.

Inventory

Inventory is stated at the lower of cost or market value using the first-in, first-out method of accounting. At December 31, 2009 and 2008, inventory consisted of the following items:

	December 31, 2009			December 31, 2008

Raw materials	$	234,681		$	164,628
Work in process	127,022			—
Finished goods	73,710			—
	435,413			164,628
Reserve for obsolescence	(3,589		)	—
	$	431,824		$	164,628

Table of Contents

We review inventory on a quarterly basis for spoiled, obsolete and slow moving items. Based on our analysis, during 2009 we established a reserve for obsolescence. For the year ended December 31, 2009, activity in the inventory obsolescence reserve was as follows:

Balance, January 1, 2009	$	—
Additions	3,589
Write-offs	—
Balance, December 31, 2009	$	3,589

Property and Equipment

We state property and equipment at cost less accumulated depreciation. We calculate depreciation using the straight-line method over the estimated useful lives of the assets of three to five years. A detail of property and equipment is set forth below:

	Years ended December 31,
	2009			2008
Laptops and computers	$	9,249		$	27,335
Server	5,841			5,841
	15,090			33,176
Accumulated depreciation	(10,048		)	(21,249		)
	$	5,042		$	11,927

Long-Lived Assets

We evaluate the carrying value of long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. An asset is considered to be impaired when the anticipated undiscounted future cash flows of an asset group are estimated to be less than its carrying value. The amount of impairment recognized is the difference between the carrying value of the asset group and its fair value. Fair value estimates are based on assumptions concerning the amount and timing of estimated future cash flows.

Customer Deposits

Customer deposits consist of advance payments of purchase orders made by our customers. As of December 31, 2009, the majority of our deposits are from DRL. From March 2009 through September 2009, DRL agreed to prepay a portion of all purchase orders placed during this period. Prepayments made by DRL bear interest at 6% per annum from the time the prepayment is made until such time that product is received by DRL under each respective purchase order. The prepaid purchase orders do not contain any right of offset.

Deferred Revenue

We record amounts billed and received, but not earned, as deferred revenue. These amounts are recorded as short-term or long-term liabilities on the accompanying consolidated balance sheets based on the date such amounts will be recognized as revenue.

Table of Contents

Derivatives

The applicable accounting rules require that each derivative instrument (including certain derivative instruments embedded in other contracts) be recorded in the balance sheet as either an asset or liability measured at its fair value, with changes in the derivative’s fair value recognized currently in earnings unless specific hedge accounting criteria are met. We value these derivative securities under the fair value method at the end of each reporting period (quarter), and their value is marked to market at the end of each reporting period with the gain or loss recognition recorded against earnings. We continue to revalue these instruments each quarter to reflect their current value in light of the current market price of our common stock. We utilize the Black-Scholes option-pricing model to determine fair value. Key assumptions of the Black-Scholes option-pricing model include applicable volatility rates, risk-free interest rates and the instrument’s expected remaining life. These assumptions require significant management judgment.

We have three classes of securities that contain embedded derivatives. For a further description of these securities, see Note 5 below. At December 31, 2009 and 2008, the fair value of the derivative liabilities associated with these securities, using the Black-Scholes option-pricing model, was as follows:

	December 31,		December 31,
	2009		2008
Convertible debt conversion features	$	2,386,009	$	420,298
Convertible debt warrants	1,953,751		393,659
Placement and finder warrants	34,410		5,269
	$	4,374,170	$	819,226

We classify derivatives as either current or long-term in the balance sheet based on the classification of the underlying convertible debt instrument.

Revenue Recognition

We recognize revenue when there is persuasive evidence that an arrangement exists, when title has passed, the price is fixed or determinable, and we are reasonably assured of collecting the resulting receivable. Revenue arrangements that include multiple deliverables are divided into separate units of accounting if the deliverables meet certain criteria. To date, we have not recognized product revenues net of revenue reserves such as sales returns and allowances as we have not experienced, nor do we anticipate experiencing, such returns. In the event that our future experience with returns differs from our historical experience, we will modify our revenue recognition practice. This accounting policy for revenue recognition may have a substantial impact on our reported results and relies on certain estimates that can require difficult, subjective and complex judgments on the part of management.

Other Nonrefundable Fees - We recognize revenue from non refundable up-front fees on a straight-line basis over the contractual term of the arrangement.

Table of Contents

Research and Development Costs

Research and development costs are expensed as incurred.

Income Taxes

We account for income taxes by recognizing deferred tax assets and liabilities for the expected future income tax consequences of transactions that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Gross deferred tax assets then may be reduced by a valuation allowance for amounts that do not satisfy specified realization criteria.

Accounting rules also prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We are required to recognize in the financial statements the impact of a tax position if that position is more likely than not of being sustained on audit, based on the technical merits of the position.

We currently have a full valuation allowance against our net deferred tax assets and have not recognized any benefits from tax positions in earnings. We will recognize potential interest and penalties related to income tax positions as a component of the provision for income taxes on the consolidated statements of operations in any future periods in which we must record a liability. Since we have not recorded a liability at December 31, 2009, there is no impact to our effective tax rate. We file income tax returns in the U.S. federal jurisdiction and several state jurisdictions. We do not believe there will be any material changes in our unrecognized tax positions over the next 12 months.

Share-Based Payments

We account for stock option compensation costs at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results differ from our estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We consider various factors when estimating expected forfeitures, including historical experience. Actual results may differ substantially from these estimates.

Earnings (Loss) Per Share

Earnings (loss) per share are computed by dividing the Company’s income (loss) attributable to common shareholders by the weighted average number of common shares outstanding. The impact of any potentially dilutive securities is excluded. Diluted earnings per share are computed by dividing the Company’s income (loss) attributable to common shareholders by the weighted average number of common shares and dilutive potential common shares outstanding during the period. In calculating diluted earnings per share, we utilize the “treasury stock method” for all stock options and warrants and the “if converted method” for all other convertible securities. For all periods presented, the basic and diluted loss per share is the same as the impact of potential dilutive common shares is anti-dilutive.

Warrants, options and convertible securities excluded from the calculation of diluted loss per share are as follows:

	Years ended December 31,
	2009	2008

Warrants	10,747,609	10,842,609
Options	5,611,750	5,796,750
Convertible debt	12,173,515	11,359,407
Preferred stock	60,000	315,000

Table of Contents

Concentration of Credit Risk and Significant Customer

Our financial instruments that are at times exposed to concentration of credit risks consist primarily of cash and accounts receivable. We maintain our cash in bank accounts which exceed federally insured limits. We have not experienced any losses in such accounts. We believe that our bank is well capitalized and has not been significantly impacted by the recent banking crisis. Accordingly, we believe we are not exposed to significant credit risk on cash.

For the years ended December 31, 2009 and 2008, Promius Pharmaceuticals (“Promius”), a wholly owned subsidiary of DRL, was our largest customer, accounting for 92% and 100%, respectively, of our consolidated revenue. Additionally, at December 31, 2009, Promius comprised 85% of our accounts receivable balance. To date, we have not experienced any bad debts from Promius and all receivables have been collected in a timely manner. While DRL does not report separate Promius financial results, we have reviewed the financial condition of DRL and based on that analysis believe they have the financial wherewithal to fulfill their payment obligations. We will continue to evaluate the financial condition of DRL on a periodic basis. We currently do not believe that this represents a significant collections risk. Considerable management judgment is involved in estimating bad debts.

Segment Information

We operate in one business segment. The determination of reportable segments is based on the way management organizes financial information for making operating decisions and assessing performances. While we sell to distributors outside of the United States, all of our operations are located in the United States.

Fair Value of Financial Instruments

The fair value of cash, accounts receivable, and accounts payable approximate their carrying amounts due to the short term maturities of these instruments. The conversion features of convertible debt securities and derivative liabilities have been stated at fair value using the Black-Scholes option-pricing model

Supplemental Disclosures of Cash Flow Information

Cash paid during the year for:

	Years ended December 31,
	2009		2008
Interest	$	212,550	$	513,364
Income taxes	—		—

Supplemental disclosures of noncash investing and financing activities:

	Years ended December 31,
	2009		2008

Assets acquired in exchange for note payable, related party	$	516,000	$	—
Related party receivables applied to note payable, related party	49,606		—
Preferred stock issued for service agreements	270,000		—
Conversion of accrued interest to common stock	—		40,000
Accrual of preferred stock dividends	—		80,000
Conversion of preferred stock and accrued dividends into common stock	843,750		240,000

Codification of US GAAP

In June 2009, the Financial Accounting Standards Board (the “FASB”) issued Statement No. 168, The FASB Accounting Standards CodificationTM and the Hierarchy of Generally Accepted Accounting Principles—a replacement of FASB Statement No. 162, hereafter referred to as Accounting Standards Codification (the “Codification,” or “ASC Topic 105”). ASC Topic 105 is the sole source of authoritative U.S. GAAP recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative US GAAP for SEC registrants. The Codification supersedes all then-existing non-SEC accounting and reporting standards. All other non-grandfathered non-SEC accounting literature not included in the Codification are nonauthoritative. Following the adoption of the Codification, the FASB will issue Accounting Standards Updates, which the FASB will not consider as authoritative in their own right, but which will serve only to update the Codification, provide background information about the guidance, and provide the bases for conclusions on the change(s) in the Codification. We adopted ASC Topic 105 effective with our consolidated financial statements as of September 30, 2009. The

Table of Contents

adoption of ASC Topic 105 did not have a material impact on our consolidated financial statements.

Recently Issued Accounting Pronouncements (Not Effective as of the Date of Adoption of the FASB Codification)

The following FASB accounting standards shall remain authoritative until such time that each is integrated into the Codification: (1) FASB Statement No. 166, Accounting for Transfers of Financial Assets - an amendment of FASB Statement No. 140 (“FAS 166”) and (2) FASB Statement No. 167, Amendments to FASB Interpretation No. 46(R) (“FAS 167”).

In June 2009, the FASB issued FAS 166. The objective of FAS 166 is to improve the relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial statements about a transfer of financial assets; the effects of a transfer on its financial position, financial performance, and cash flows; and a transferor’s continuing involvement, if any, in transferred financial assets. FAS 166 is effective for fiscal years beginning after November 15, 2009, for interim periods within that first annual reporting period and for interim and annual reporting periods thereafter. Earlier application is prohibited. FAS 166 must be applied to transfers occurring on or after the effective date. The adoption of this statement is not expected to have a material impact on our consolidated financial statements.

In June 2009, the FASB issued FAS 167. The objective of FAS 167 is to improve financial reporting by enterprises involved with variable interest entities, in particular to address: (1) the effects on certain provisions of FASB ASC Topic 810 (“ASC Topic 810”), as a result of the elimination of the qualifying special-purpose entity concept in FAS 166 and (2) constituent concerns about the application of certain key provisions of ASC Topic 810, including those in which the accounting and disclosures do not always provide timely and useful information about an enterprise’s involvement in a variable interest entity. This Statement is effective for fiscal years beginning after November 15, 2009, for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter. Earlier application is prohibited. The adoption of this statement is not expected to have a material impact on our consolidated financial statements.

In May 2009, the FASB established general standards for accounting and disclosure of events that occur after the balance sheet date but before the financial statements are issued or are available to be issued. The pronouncement required the disclosure of the date through which an entity has evaluated subsequent events and the basis for that date, whether that date represents the date the financial statements were issued or were available to be issued. In February 2010, the FASB amended this standard whereby SEC filers, like the Company, are required by GAAP to evaluate subsequent events through the date its financial statements are issued, but are no longer required to disclose in the financial statements that the Company has done so or disclose the date through which subsequent events have been evaluated.

(4) DETAIL OF CERTAIN ACCOUNTS

Set forth below is detail of certain accounts as of and for the years ended December 31, 2009 and 2008:

Prepaid expenses, deposits and other

	2009		2008
Prepaid investor relations	$	112,500	$	—
Prepaid insurance	59,155		47,924
Prepaid license fees	7,500		7,500
Inventory deposit	30,212		—
Receivable from contract manufacturer	43,662		—
Prepaid offering costs and other	—		36,344
	$	253,029	$	91,768

Other accrued liabilities

	2009		2008
Accrued director fees	$	159,500	52,500
Preferred stock payable	135,000		—
Accrued vacation	62,734		64,906
Accrued billing adjustments	7,937		36,061
Insurance financing note	17,691		25,330
Accrued legal fees	50,011		56,956
Accrued advisory board fees	44,571		15,829
Accrued royalties	28,656		23,304
Accrued manufacturing costs	22,410		—
Other	3,816		2,551
	$	532,326	$	277,437

Table of Contents

Interest and other expense, net

	2009			2008
Amortization of debt discount	$	528,737		$	1,485,961
Fair value adjustment to exercise price of convertible debt and warrants	—			6,450,384
Interest on debt	1,182,318			925,360
Fair value of warrants issued for amending debt agreements	—			920,091
Other expense, net	(70,402		)	(5,896		)
Interest income	(1,110		)	(17,969		)
	$	1,639,543		$	9,757,931

(5) CONVERTIBLE DEBT

A description of the terms of convertible debt outstanding is as follows:

2006 Debentures

In December 2006, we sold in a private transaction an aggregate of $5,000,000 of convertible debentures (the “2006 Debentures”). We have entered into four amendment agreements with the holders since the original sale as follows:

· The first amendment (the “First Amendment”) dated June 29, 2007;

· The second amendment (the “Second Amendment”) dated November 30, 2007;

· The third amendment (the “Third Amendment”) dated July 1, 2008; and

· The fourth amendment (the “Fourth Amendment”) dated September 25, 2008

As amended, the 2006 Debentures convert into shares of our common stock at a conversion price equivalent to $.80 per common share (subject to adjustment). The 2006 Debentures accrue interest at 12% per annum, payable quarterly. For the period from July 1, 2008 through March 31, 2009, quarterly interest payments were deferred, with accrued interest for the period added to the principal balance. The maturity date of the 2006 Debentures is December 31, 2011 subject to quarterly redemption payments beginning June 30, 2009 (the “Quarterly Redemption Amounts”) which are to be made solely from the Dedicated Revenue Streams (defined below). We made the June 30, 2009 and September 30, 2009 Quarterly Redemption Amount payments in accordance with the terms of the Fourth Amendment. However, the Dedicated Revenue Streams were not sufficient to pay the quarterly interest in full. The unpaid accrued interest for the June and September quarters were added to the debt balance. We have not made the Quarterly Redemption Amount payment that was due on December 31, 2009. The holders of the 2006 Debentures have extended the due date for the December 2009 Quarterly Redemption Amount to April 30, 2010. As of December 31, 2009, the principal balance of the 2006 Debentures was $6,253,468.

Table of Contents

As amended, the terms of the 2006 Debentures require that we make minimum quarterly payments to the holders commencing June 30, 2009 (the “Amended Amortization Schedule”) solely from the following revenue streams (the “Dedicated Revenue Streams”):

· 100% of net revenues (as defined in the amendments) paid or owed to us under the DRL Agreement subsequent to April 1, 2009;

· 100% of net revenue received from any other EpiCeram® commercialization arrangements;

· 50% of the net revenue received from the sale of NeoCeram®;

· 33% of any net revenue received from Ceragenin™ commercialization arrangements; and

· 33% of any net revenue received by us in excess of $250,000 in aggregate excluding any capital raised by the Company through equity investment or the issuance of debt.

Accordingly, all net revenues we receive from the commercialization of EpiCeram® will be utilized to service the existing convertible debt until such time that the debt has been paid in full.

In the event that the Dedicated Revenue Streams are insufficient to make a quarterly interest payment in full, the remedies to the holders are to add the unpaid accrued interest to the outstanding debt balance or receive shares of our common stock in lieu of cash payment. Additionally, in the event that the Dedicated Revenue Streams are not sufficient to make the cumulative Quarterly Redemption Amount payments required by the Amended Amortization Schedule with respect to the 12-month periods ending June 30th, then the remedy to the holders is to have the conversion price of the debt and exercise price of their warrants adjusted downward. Accordingly, until December 31, 2011, the failure to make scheduled interest and/or principal payments in full does not provide the holders the ability to declare the Company in default. However, failure to make a payment that is equal to the Dedicated Revenue Streams would be an event of default.

In the event that we fail to pay interest in full on any due date, the holder shall have the option to receive the unpaid balance in shares of common stock at a price equal to 85% of the average of the five lowest Volume Weighted Average Prices (“VWAPs”) during any 30 consecutive trading day periods during the 365 day period immediately prior to the interest payment date or, in lieu of receiving shares of common stock, may add such unpaid interest to the outstanding principal amount of the 2006 Debentures. In the event that we fail to pay the cumulative Quarterly Redemption Amounts during any 12-month period ending June 30, 2010 and June 30, 2011, the then conversion price of the 2006 Debentures shall be reduced each July 1, 2010 and July 1, 2011, respectively, to the lesser of (i) the then conversion price or (ii) the average of the 10 lowest VWAPs for the 60 consecutive trading day period immediately prior.

Under certain circumstances, we can force the conversion of the 2006 Debentures. However, the 2006 Debentures contain a provision that prohibits the holder from converting the debenture if such conversion would result in the holder owning more than 4.99% of our outstanding common stock at the time of such conversion, which limitation may be waived by the holder under certain conditions to not more than 9.99%. The conversion price of the 2006 Debentures may be adjusted downward in the event that we issue or grant any right to common stock at a price below the conversion price of the 2006 Debentures including a reduction in the price of the Convertible Notes (see more information on the Convertible Notes under the heading “Convertible Notes” below). A reduction in the conversion price of the 2006 Debentures also triggers a reduction in the exercise price of all warrants held by the holders of the 2006 Debentures. Our obligation to repay the 2006 Debentures is secured by a first lien security interest on all of our tangible and intangible assets. Holders of the 2006 Debentures have no voting, preemptive or other rights of shareholders.

Events of default under the 2006 Debentures include: failure to make a redemption or interest payment as scheduled; a breach of a material covenant not cured within five days of written notice or within 10 days after the Company has become or should become aware of such failure; if a default or event of default (subject to any grace or cure periods provided in the applicable agreement) shall occur under any documents that is part of the transaction or any other material agreement, lease, document or instrument to which the Company or any subsidiary is obligated; a breach of any material representations and warranties; the Company or any subsidiary is subject to a bankruptcy event (as defined in the debenture); the Company defaults on any indebtedness in excess of $150,000 which results in such indebtedness becoming or declared due and payable prior to the date it would otherwise become due and payable; a delisting of our common stock or a stop trade action by the SEC that lasts for more than five consecutive days; if the Company shall be party to a change of control transaction (as defined in the debenture) or if the Company shall agree to sell or dispose of 40% of its assets in one related transaction or a series of related transactions; if the effectiveness of the registration statement lapses for any reason or the holders shall not be permitted to resell registrable securities (as defined in the debenture) under the registration statement for a period of more than 25 consecutive trading days or 35 non-consecutive trading days during any 12 month period; if the Company shall fail for any reason to deliver certificates to a holder prior to the fifth trading day after a conversion date; or a monetary judgment in excess of $50,000 is filed against the Company that is not cured within 45 days. Additionally, we are prohibited from paying cash

Table of Contents

dividends on any equity security while the 2006 Debentures are outstanding. In the event that we cannot cure the default under the license agreement with BYU described in Note 2 above, it would constitute a default under the term of the 2006 Debentures.

In connection with the sale of the 2006 Debentures, the holders of the 2005 Notes and the holders of the 2006 Debentures entered into the Amended and Restated Collateral Agent Agreement (the “Collateral Agreement”). Under the terms of the Collateral Agreement, certain actions require an action by a majority in interest (a “Majority Interest Action”). In an event of default, a Majority Interest Action is required to (1) take an action to accelerate payment and/or (2) protect, exercise or enforce any rights or remedies the holders may have under the 2005 Notes and 2006 Debentures. A majority in interest is defined as lenders who hold not less than ninety percent (90%) of the outstanding principal balance. Accordingly, no action can be taken in an event of default unless holders owning at least 90% of the debt balance agree to take such an action.

Purchasers of the 2006 Debentures received five-year warrants to purchase an aggregate of 1,162,212 shares of our common stock at an exercise price of $2.37 per share (the “2006 Debenture Warrants”), but as discussed both above and below, the exercise price and number of shares underlying the warrants have been adjusted several times. As a result of these adjustments, the exercise price of the 2006 Debenture warrants has been reduced to $.80 per share and the number of common shares underlying the warrants has been increased to 3,443,053.

We also issued to placement agents seven-year warrants to purchase an aggregate of 154,867 shares of common stock at an exercise price of $2.26 per share (the “Agent Warrants”) and paid them cash commissions of $425,000.

The anti dilution features of the 2006 Debentures did not meet the definition of “standard” anti dilution features. Therefore, the conversion feature of the 2006 Debentures was considered an embedded derivative. Accordingly, we bifurcated the derivative from the 2006 Debenture (host contract) and recorded the liability at its fair value of $2,831,858 in 2006 with a corresponding entry to debt discount. The fair value of the derivative liability was determined using the Black-Scholes option pricing model.

We evaluated both the Second and Fourth Amendments to determine whether the amendments met the definition of a major modification of debt in accordance with the applicable accounting rules. An amendment is considered a major modification if the present value of the cash flows under the terms of the amended debt instrument are greater than 10% different from the present value of the remaining cash flows under the terms of the original instrument. We did not evaluate the First and Third Amendments as those amendments did not impact future cash flows. Based on our analysis, the Fourth Amendment was not considered a major modification of the debt while the Second Amendment was considered a major modification. Accordingly, in connection with the Second Amendment, the outstanding unamortized discount balance of $1,899,747 related to the debt conversion feature was written off and the fair value of the conversion feature of the amended 2006 Debentures was recorded at its fair value of $1,527,389 with a corresponding entry to debt discount. The fair value of the derivative liability was determined using the Black-Scholes option pricing model. The difference between the unamortized discount balance associated with the original debt, and the fair value of the conversion feature of the new debt was included in the calculation of loss on extinguishment of debt. The debt discount is reflected as a reduction to the 2006 Debentures on the accompanying consolidated balance sheet. The debt discount is being amortized on a straight-line basis over the remaining term of the 2006 Debentures.

The 2006 Debenture Warrants also meet the definition of a derivative due to the cashless exercise provision. Accordingly, we bifurcated the derivative from the 2006 Debenture Warrants (host contract) and recorded the liability at its fair value of $1,793,293 with a corresponding entry to debt discount. The 2006 Debenture Warrants were valued using the Black-Scholes option pricing model. The debt discount is being amortized on a straight-line basis over the remaining term of the 2006 Debentures.

The Agent Warrants also meet the definition of a derivative due to the cashless exercise provision. We recorded a derivative liability at its fair value of $268,230 with a corresponding entry to debt placement costs. The Agent Warrants were valued using the Black-Scholes option pricing model. We also recorded the cash compensation paid to the placement agents as well as all transaction related costs such as legal and road show expenses as debt placement costs. Debt placement costs, which totaled $938,380, were being amortized on a straight-line basis over the three year life of the 2006 Debentures. However, in connection with the Second Amendment described above, the outstanding unamortized debt offering cost balance was written off and was included in the loss on extinguishment of debt. Accordingly, there has been no amortization of debt placement costs during 2009 or 2008.

For the years ended December 31, 2009 and 2008, we amortized $528,737 and $1,057,470, respectively, of debt discount associated with the 2006 Debentures and 2006 Debenture Warrants which is included in interest expense in the accompanying consolidated statements of operations.

Table of Contents

In connection with the First, Second and Fourth Amendments, we provided the holders the following consideration:

· First Amendment — Issued five- year warrants to acquire 400,000 shares of our common stock at an initial exercise price of $2.25 per share (the “First Amendment Warrants”). All other terms of the warrants are identical to the 2006 Debenture Warrants. Accordingly, they also meet the definition of a derivative. We valued these warrants using the Black-Scholes option pricing model. As a result of several adjustments (most recently the Fourth Amendment), the exercise price of the First Amendment Warrants has been reduced to $.80 per share and the number of common shares underlying the warrants has been increased to 1,125,000;

· Second Amendment — We agreed to increase the outstanding principal balance of the 2006 Debentures by 10% ($500,000). As discussed above, the Second Amendment was considered the issuance of new debt.

· Fourth Amendment — In addition to the revision of the terms of the 2006 Debentures described above, we issued new five-year warrants to the holders giving them the right to purchase up to 1,718,750 shares of the Company’s common stock at an initial exercise price of $.80 per share (subject to adjustment) (the “Fourth Amendment Warrants”). All other terms of the warrants are identical to the 2006 Debenture Warrants. Accordingly, they also meet the definition of a derivative. We valued these warrants using the Black-Scholes option pricing model.

During the year ended December 31, 2008, we recorded the fair value of the Fourth Amendment as a charge to interest expense and a corresponding increase to derivative liability on the accompanying consolidated financial statements. We used the Black-Scholes option pricing model to determine fair value. The fair value of the Fourth Amendment is comprised of the following:

Fourth Amendment Warrants	$	708,125
Reduction in conversion price of 2006 Debentures	1,436,875
Reduction in exercise price of 2006 Debenture Warrants and First Amendment Warrants	424,983
	$	2,569,983

Table of Contents

During the years ended December 31, 2009 and 2008, $418,518 and $334,950, respectively, of accrued interest was added to the 2006 Debenture principal balance.

Convertible Notes

In November 2005, we sold in a private transaction an aggregate of $3,200,000 of promissory notes convertible into shares of our common stock (the “Convertible Notes”). We have modified the Convertible Note agreements with the holders three times since the original sale as follows:

· An amendment dated November 28, 2007 (the “November 2007 Amendment”);

· A consent and waiver agreement dated June 30, 2008 (the “June 2008 Waiver”); and

· An amendment dated August 20, 2008 (the “August 2008 Amendment”).

As amended, the Convertible Notes convert into shares of our common stock at a conversion price equivalent to $.80 per common share (subject to adjustment). The Convertible Notes accrue interest at 12% per annum, payable quarterly. For the period from July 1, 2008 through March 31, 2009, quarterly interest payments were deferred with accrued interest for the period added to the principal balance. The maturity date of the Convertible Notes is December 31, 2011 subject to quarterly redemption payments beginning June 30, 2009 (the “Quarterly Redemption Amounts”) which are to be made solely from the Dedicated Revenue Streams. The Dedicated Revenue Streams are identical to those defined above for the 2006 Debentures. We made the June 30, 2009 and September 30, 2009 Quarterly Redemption Amount payments in accordance with the August 2008 Amendment. However, the Dedicated Revenue Streams were not sufficient to pay the quarterly interest in full. The unpaid accrued interest for the June and September quarters were added to the debt balance. The Company did not make the Quarterly Redemption Amount payment originally due on December 31, 2009. The holders of the Convertible Notes have extended the due date for the December 2009 Quarterly Redemption Amount payment to April 30, 2010. As of December 31, 2009, the principal balance of the Convertible Notes was $3,485,344.

In the event that the Dedicated Revenue Streams are insufficient to make a quarterly interest payment in full on any due date, the holder shall have the option to receive the unpaid balance in shares of common stock at a price equal to 85% of the average of the 5 lowest VWAPs during any 30 consecutive trading day periods during the 365 day period immediately prior to the interest payment date or, in lieu of receiving shares of common stock, may add such unpaid interest to the outstanding principal amount of the Convertible Notes. Additionally, in the event that the Dedicated Revenue Streams are not sufficient to make the cumulative Quarterly Redemption Amount payments required by the Amended Amortization Schedule with respect to the 12-month periods ending June30th, then conversion price of the Convertible Notes shall be reduced each July 1st to the lesser of (i) the then conversion price or (ii) the average of the 10 lowest VWAPs for the 60 consecutive trading day period immediately prior. Accordingly, until December 31, 2011, the failure to make scheduled interest and/or principal payments in full does not provide the holders with the ability to declare the Company in default. However, failure to make a payment that is equal to the Dedicated Revenue Streams would be an event of default.

We can force the conversion of the Convertible Notes provided (i) we have registered the common shares underlying the Convertible Notes and (ii) the closing bid price of our common stock has equaled or exceeded $1.60 (as adjusted) for 20 consecutive trading days. However, the Convertible Notes contain a provision that prohibits a holder from converting the note if such conversion would result in the holder owning more than 4.99% of our outstanding common stock at the time of such conversion and certain other restrictions based on the trading volume of our stock. The conversion price of the Convertible Notes was to be adjusted downward if either a “default” or “milestone default” (both defined in the agreements) were to occur. However, in order for the conversion price to be adjusted, both (i) a default or milestone default would have to occur and (ii) the volume weighted average price of our common stock for the five days preceding the default (the “Five Day VWAP”) would have to be less than the stated conversion price. If the Five Day VWAP was less than the conversion price, then the conversion price would be adjusted to the Five Day VWAP. An adjustment to the conversion price due to a default could take place at any time during the year. An adjustment due to a milestone default could only take place on a Reporting Date (the date we file an Annual Report on Form 10-K or a Quarterly Report on Form 10-Q). There are no further potential milestone defaults under the Convertible Notes. Our obligation to repay the Convertible Notes is secured by a first lien security interest on all of our tangible and intangible assets.

Upon filing our Quarterly Report on Form 10-QSB for the periods ended March 31, 2007 and June 30, 2007 and our Annual Report on Form 10-K for the year ended December 31, 2007, we had milestone defaults and the Five Day VWAP was below the conversion price. Accordingly, the conversion price of the Convertible Notes was reduced from $2.05 per share to $1.92 per share, from $1.92 per share to $1.57 per share, and then from $1.57 per share to $.96 per share. The reduction in conversion price of the Convertible Notes also triggered a reduction in the conversion price of the 2006 Debentures, the 2006 Debenture Warrants and the First Amendment Warrants to $.96 per share. For the year ended December 31, 2008, we recorded $2,624,629 for the fair value of the reductions in conversion price resulting from milestone defaults which is included in interest expense on the accompanying consolidated statements of operations with a corresponding increase to derivative liability. We determined fair value using the Black-Scholes option pricing model.

Table of Contents

Events of default include failure to pay principal or interest in a timely manner; a breach of a material covenant not cured within 10 days of written notice; a breach of any material representations and warranties; non-payment of any one or more obligations aggregating in excess of $100,000 for more than 20 days after the due date unless the Company is contesting the validity in good faith; the appointment of a receiver or trustee for a substantial part of our property or business without prior written consent; a money judgment filed against us in excess of $75,000; bankruptcy; a delisting of our common stock; and a stop trade action by the SEC that lasts for more than five consecutive days. In the event that we cannot cure the default under the license agreement with BYU described in Note 2 above, it would constitute a default under the term of the Convertible Notes.

Purchasers of the Convertible Notes received warrants exercisable to purchase an aggregate of 780,488 shares of our common stock at an exercise price of $2.255 per share (the “Convertible Note Warrants”). As a result of the August 2008 Amendment, the warrant shares have been increased by 1,326,219 shares and the exercise price reduced to $.80 per share (except for 48,780 warrants held by a holder that previously converted all of their Convertible Notes). We also issued to a placement agent and finder, five-year warrants exercisable to purchase an aggregate of 156,098 shares of common stock at an exercise price of $2.05 per share (the “Placement and Finder Warrants”) and paid them cash commissions of $320,000.

The anti dilution features of the Convertible Notes did not meet the definition of “standard” anti dilution features. Therefore, the conversion feature of the Convertible Notes was considered an embedded derivative. Accordingly, we bifurcated the derivative from the Convertible Notes (host contract) and recorded the liability at its fair value of $1,792,000 in 2005 with a corresponding entry to debt discount. The fair value of the derivative liability was determined using the Black-Scholes option pricing model.

The Convertible Note Warrants also meet the definition of a derivative due to the cashless exercise provision. Accordingly, we bifurcated the derivative from the Convertible Note Warrants (host contract) and recorded the liability at its fair value of $1,237,073 with a corresponding entry to debt discount. The Convertible Note Warrants were valued using the Black-Scholes option pricing model.

We evaluated both the November 2007 and August 2008 Amendments to determine whether the amendments met the definition of a major modification of debt in accordance with the applicable accounting rules. We did not evaluate the June 2008 as it did not impact future cash flows. Based on our analysis, the August 2008 Amendment was not considered a major modification of the debt while the November 2007Amendment was considered a major modification. As a result, the November 2007 Amendment was considered the issuance of a new debt instrument. We recorded the amended Convertible Notes at fair value as of the amendment date. We used the Black-Scholes option pricing model to determine fair value. The difference between the fair value of the amended Convertible Notes and the fair value of the Convertible Notes prior to the amendment was recorded as a loss on extinguishment of debt.

The debt discount associated with the Convertible Notes was amortized over the life of the Convertible Notes as amended by the November 2007 Amendment. The debt discount associated with the Convertible Note Warrants was amortized over the original life of the Convertible Notes. For the years ended December 31, 2009 and 2008, we amortized $0 and $428,491, respectively, of debt discount associated with the Convertible Notes which is included in interest expense in the accompanying consolidated statements of operations.

The Placement and Finder Warrants also meet the definition of a derivative due to the cashless exercise provision. We recorded a derivative liability at its fair value of $252,254 with a corresponding entry to debt placement costs. The Placement and Finder Warrants were valued using the Black-Scholes option pricing model. We also recorded the cash compensation paid to the placement agent as well as all transaction related expenses such as legal fees as debt placement costs. Debt placement costs, which totaled $610,087, were amortized on a straight-line basis over the original two year life of the Convertible Notes. Accordingly, we did not amortize any debt placement costs during 2009 or 2008.

In addition to revising the terms of the Convertible Notes as described above, in connection with the August 2008 Amendment, we issued new five-year warrants to the holders giving them the right to purchase up to 514,481 shares of the Company’s common stock at an initial exercise price of $.80 per share (subject to adjustment) (the “August 2008 Amendment Warrants”). All other terms of the warrants are identical to the Convertible Note Warrants. Accordingly, they also meet the definition of a derivative. We valued these warrants using the Black-Scholes option pricing model.

During the year ended December 31, 2008, we recorded the fair value of the August 2008 Amendment as a charge to interest expense and a corresponding increase to derivative liability on the accompanying financial statements. We used the Black-Scholes option pricing model to determine fair value. The fair value of the August 2008 Amendment is comprised of the following:

August 2008 Amendment Warrants	$	211,966
Reduction in conversion price of Convertible Notes	1,314,553
Reduction in exercise price of Convertible Note Warrants	649,344
	$	2,175,863

Table of Contents

During the years ended December 31, 2009 and 2008, $232,769 and $150,386, respectively, of accrued interest was added to Convertible Notes principal balance. Further, during the year ended December 31, 2008, holders converted $40,000 of accrued interest into 50,000 shares of common stock.

Including the related party note payable described below in Note 9, maturities of debt that could require cash are as follows as of December 31, 2009:

Year	Amount
2010	1,190,898
2011	8,726,342
2012	102,705
2013	112,898
2014	12,723
	10,145,566
Less debt discount	(1,057,473		)
	$	9,088,093

(6) STOCKHOLDERS’ EQUITY

Preferred Stock

Our articles of incorporation authorizes our board of directors (the “Board”) to issue up to 5,000,000 shares of preferred stock and allows the Board to determine preferences, conversion and other rights, voting powers, restrictions, limitations as to distributions, qualifications, and other terms and conditions.

Series A Preferred Stock

In connection with our merger transaction with Ceragenix Corporation in May 2005 (the “Merger”), the Board authorized the issuance of 1,000,000 shares of Series A Preferred Stock to Osmotics. The issuance of the Series A Preferred Stock was in exchange for identical shares of preferred stock issued by Ceragenix Corporation to Osmotics in January 2005. The Series A Preferred Stock had a stated value of $4.00 per share and accrued dividends at a rate of 6% per annum. In May 2008, all of the Preferred Stock and $240,000 of accrued dividends were converted into 1,304,569 shares of common stock.

Series B Preferred Stock

The Board has also authorized the issuance of 495,000 shares of Series B Preferred Stock (“Series B”). Series B has a stated value of $2.25 per share and does not accrue dividends. Series B is convertible into shares of the Company’s common stock at the option of the holder at a rate of one share of common stock for each share of Series B. In the event of liquidation, Series B ranks junior to all debt of the Company.

In June 2009, we entered into an agreement with an investor relations firm to provide certain services over a three month period which was subsequently renewed for two additional three month periods. Accordingly, the agreement expired in March 2010. Under the terms of the agreement, we agreed to issue 60,000 shares of Series B as consideration for the services for each three month period of service. As of December 31, 2009, we had not issued the 60,000 shares that are owed for the latest renewal period. We have valued the Series B shares at $2.25 per share which represents the liquidation preference value of the shares. We believe that the liquidation preference is the best measurement of fair value for the securities. For the year ended December 31, 2009, we recognized $292,500 of expense for these services which is included in general and administrative expense on the accompanying consolidated statements of operations. We have recorded an accrued liability of $135,000 for the 60,000 shares of Series B which have not been issued which are included in other accrued liabilities on the accompanying consolidated balance sheet at December 31, 2009. The holder of these shares has converted 60,000 shares of Series B into common stock.

In September 2007, we entered into an agreement with an investor relations firm to provide certain services over a twelve month period. Under the terms of the agreement, we issued 300,000 shares of Series B as consideration for the services. We valued these shares at $675,000 which represents the liquidation preference value of the Series B shares that were issued. We recorded a prepaid expense equal to the value of these shares with a corresponding entry to stockholders’ equity. We amortized the prepaid expense over the term of the agreement. For the year ended December 31, 2008, we recognized $450,000 of expense for these services which is included in general and administrative expense on the accompanying consolidated statements of operations. The 300,000 shares of Series B were converted into 240,000 and 60,000 shares of common stock during 2009 and 2008, respectively.

Table of Contents

In September 2007, we renewed an agreement with an investor relations firm to provide certain services over a twelve month period. Under the terms of the agreement, we issued 75,000 shares of Series B as consideration for the services. We valued these shares at $168,750 which represents the liquidation preference value of the Series B shares that were issued. We recorded a prepaid expense equal to the value of these shares with a corresponding entry to stockholders’ equity. We amortized the prepaid expense over the term of the agreement. For the year ended December 31, 2008, we recognized $119,531 of expense for these services which is included in general and administrative expense on the accompanying consolidated statements of operations. The 75,000 shares of Series B were converted into 75,000 shares of common stock during 2009.

Equity Incentive Plan

On May 29, 2008, our shareholders approved the Ceragenix Pharmaceuticals, Inc. 2008 Omnibus Incentive Plan (the “2008 Plan”). The purpose of the 2008 Plan is to enhance our ability to attract and retain officers, directors, key employees and other persons, and to motivate such persons to serve the Company by providing to such persons an opportunity to acquire or increase a direct proprietary interest in the operations and future success of the Company. To this end, the 2008 Plan provides for the grant of stock options, stock appreciation rights, restricted stock, stock units, unrestricted stock, dividend equivalent rights, and cash bonus awards. Stock options granted under the 2008 Plan may be non-qualified stock options or incentive stock options, except that stock options granted to outside directors and any consultants or advisors shall in all cases be non-qualified stock options. The 2008 Plan is administered by the Compensation Committee of the Board. The number of common shares reserved for issuance under the 2008 Plan is 3,000,000. During 2008, the Compensation Committee awarded 699,000 incentive stock options and 192,000 non-qualified stock options under the 2008 Plan. There have been no other awards issued under the 2008 Plan.

For the year ended December 31, 2009 and 2008, we recorded compensation expense related to employee stock options of $533,730 and $806,402, respectively. The stock option compensation expense is included in general and administrative expense in the accompanying consolidated statements of operations. We did not issue any stock options during the year ended December 31, 2009. The weighted average fair value of stock options at the date of grant issued to employees during the year ended December 31, 2008 was $.36 per share. We determine fair value using the Black-Scholes option pricing model. We used the following assumptions to determine the fair value of stock option grants during the year ended December 31, 2008:

Year Ended December 31, 2008
Volatility	50	% - 51%
Dividend yield	0
Risk-free interest rate	2.4	% - 3.2%
Expected term (years)	5.0

The expected volatility was based on the historical price volatility of our common stock. The dividend yield represented our anticipated cash dividend on common stock over the expected life of the stock options. We utilized the U.S. Treasury bill rate for the expected life of the stock options to determine the risk-free interest rate. The expected term of stock options represents management’s estimation of the period of time that the stock options granted are expected to be outstanding.

A summary of stock option activity for the year ended December 31, 2009 is presented below. Except for 699,000 shares, all options presented below are non-qualified.

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value

Balance, January 1, 2009	5,796,750		$	1.50
Options granted	—		$	—
Options exercised	—		—
Options canceled	(185,000	)	1.07
Outstanding at December 31, 2009	5,611,750		$	1.51	5.9 years	$	—
Exercisable at December 31, 2009	4,760,750		$	1.58	5.9 years	$	—

Table of Contents

The total fair value of stock options that vested during the years ended December 31, 2009 and 2008 was $715,556 and $894,741, respectively. The intrinsic value of stock options exercised during the years ended December 31, 2009 and 2008 was $0 as there were no options exercised during these periods. As of December 31, 2009, we had $253,952 of unrecognized compensation cost related to stock options that will be recorded over a weighted average period of approximately 1.1 years.

Additionally, in periods prior to 2008, we issued stock options to new scientific advisory board members. We valued these grants using the Black-Scholes pricing model. The compensation expense is being amortized to general and administrative expense over the three year vesting period of the options. For the years ended December 31, 2009 and 2008, we amortized $5,766 and $16,779, respectively of compensation expense related to scientific advisory board options.

Warrants

In December 2008, we entered into an agreement with a financial advisor whereby we agreed to issue warrants to acquire 200,000 shares of common stock as partial compensation for the services. The warrants have an exercise price of $.80 per share and expire in December 2013. The warrants were valued at $17,600 using the Black-Scholes option pricing model. We are amortizing the cost of the warrants on a straight line basis over the one year term of the agreement. For the years ended December 31, 2009 and 2008, we amortized $16,133 and $1,467, respectively, which is reflected in general and administrative expense on the accompanying consolidated statements of operations.

For a description of warrants issued in connection with debt transactions please see Note 5 above.

(7) INCOME TAXES

The Company did not incur any income tax expense or benefit during the years ended December 31, 2009 and 2008.

A reconciliation of the statutory federal income tax rate to the effective rate is as follows for the years ended December 31, 2009 and 2008:

	2009		2008
Federal income tax rate	34.00	%	34.00	%
State income taxes, net of Federal income tax effect	1.18	%	4.54	%
Nondeductible expenses and other	(23.83	)%	4.61	%
Valuation allowance	(11.13	)%	(43.15	)%
Other	(0.22	)%	0.00	%
	0.00	%	0.00	%

Deferred tax assets and liabilities represent the future impact of temporary differences between the financial statement and tax bases of assets and liabilities and are as follows as of December 31, 2009 and 2008:

	2009			2008
Deferred tax assets:
Net operating loss carry forwards	$	4,380,566		$	5,025,892
Accrued expenses and other	2,750,013			1,773,885
Total deferred tax assets	7,130,579			6,799,777

Deferred tax liabilities:	—			—
Net deferred tax assets before valuation allowance	7,130,579			6,799,777
Valuation allowance	(7,130,579		)	(6,799,777		)

Net deferred tax	$	—		$	—

The Tax Reform Act of 1986 contains provisions that limit the utilization of net operating loss (“NOL”) and tax credit carryforwards if there has been a change of ownership as described in Section 382 of the Internal Revenue Code. We have not prepared an analysis to determine if a change of ownership has occurred. Such a change of ownership may limit the utilization of our net operating losses.

Total deferred tax assets and the valuation allowance increased by $330,802 during 2009. As of December 31, 2009, we had an estimated NOL carryforward of approximately $13.2 million for federal income tax purposes which is available to offset future

Table of Contents

taxable income, if any, through 2029. The ultimate realization of these assets is dependent upon the generation of future taxable income sufficient to offset the related deductions and loss carryforwards within the applicable carryforward period.

(8) FAIR VALUE

The applicable accounting rules require that we determine the fair value of financial assets and liabilities using a fair value hierarchy utilizing three levels of inputs that may be used to measure fair value, as follows:

· Level 1—Quoted prices in active markets for identical assets or liabilities.

· Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

· Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table represents the fair value hierarchy for our financial liabilities measured at fair value on a recurring basis as of December 31, 2009. We had no financial assets subject to fair value measurement at December 31, 2009.

			Fair Value Measurements at December 31, 2009 Using
Description	Balance at December 31, 2009		Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Derivative liabilities:
Debt conversion features	$	2,386,009	—	—	$	2,386,009
Warrant obligations	1,988,161		—	—	1,988,161
Total derivative liabilities	$	4,374,170	—	—	$	4,374,170

The following table presents the changes in fair value for liabilities that have no significant observable inputs (Level 3):

	Level 3 Convertible Debt And Warrant Obligations
Balance at January 1, 2009	$	819,226
Loss on fair value	3,554,944
Balance at December 31, 2009	$	4,374,170

Table of Contents

(9) COMMITMENTS, CONTINGENCIES AND RELATED PARTY TRANSACTIONS

License and Technology Agreements

We have an exclusive license agreement, as amended, with Brigham Young University (the “BYU License”) with respect to the Ceragenin™ technology. The BYU License requires us to pay quarterly research and development support fees of $22,500 and royalty payments equal to 2% - 10% of adjusted gross sales (as defined in the agreement) on any product we sell using the licensed technology. The royalty is subject to an annual minimum royalty. The minimum annual royalty was $100,000 in 2008, $200,000 in 2009, and $300,000 in 2010 and each year thereafter. As of December 31, 2009, we had not made the payment which was due in 2009 nor have we made the quarterly support fee payments that were due on August 1, 2009 and November 1, 2009. These delinquent payments represent a technical default under the terms of the BYU License. The $245,000 balance is reflected as accrued licensing fees on the accompanying consolidated balance sheet as of December 31, 2009. We are also obligated to reimburse BYU for any legal expenses associated with patent protection and expansion. For the years ended December 31, 2009 and 2008, we were charged $117,684 and $75,678, respectively, for legal expenses by BYU. These legal fees are included in general and administrative expense in the accompanying consolidated statements of operations. During the year ended December 31, 2009, we did not reimburse BYU for these legal fees in accordance with the required timeframes set forth in the BYU License agreement. These delinquent payments also represent a technical default under the terms of the BYU License. As of December 31, 2009, we have recorded $94,663 in unpaid legal fees owed to BYU which are included in accounts payable and other accrued liabilities on the accompanying consolidated balance sheet. The term of the BYU license is for the life of the underlying patents which expire commencing in 2022. On April 7, 2010, BYU declared us in breach of the agreement. Under the terms of the BYU License, we have 30 days to cure the breach. If we cannot cure the breach, the BYU License will be terminated.

We also have an exclusive license agreement with the Regents of the University of California (the “UC Agreement”) with respect to our Barrier Repair technology. The UC Agreement requires us to pay a royalty of 5% of net sales as defined in the agreement. The royalty is subject to an annual minimum royalty of $50,000. Upfront and milestone payments received from sub-licensed products are subject to a 15% royalty. The UC Agreement is for the life of the underlying patents which expire in 2014. In addition, the UC Agreement requires reimbursement for legal expenses associated with patent protection and expansion. During the years ended December 31, 2009 and 2008, we were charged $14,430 and $14,440, respectively, for legal fees associated with the UC Agreement. These legal fees are included in general and administrative expense in the accompanying consolidated statements of operations.

Transactions with Osmotics

Osmotics is the former parent company of Ceragenix Corporation and holds 12,222,170 shares of our common stock and warrants to acquire 1,007,161 shares of our common stock at a price of $2.18 per share. Additionally, our Chairman and Chief Executive Officer is a shareholder of Osmotics and his spouse is Osmotics’ Chairperson and Chief Executive Officer. During the years ended December 31, 2009 and 2008, we had or were affected by the following transactions with Osmotics.

Osmotics Sublicense Agreement and Triceram® Acquisition

We obtained our rights to the UC Agreement pursuant to a technology transfer agreement with Osmotics. Osmotics was the exclusive licensee under the UC Agreement until May 2005, at which time it assigned its rights to Ceragenix Corporation. In August 2006, we entered into a sublicense agreement with Osmotics (the “Sublicense Agreement”) whereby we granted Osmotics the right to use the Barrier Repair technology to develop and market cosmetic, non-prescription products (as defined in the agreement). The Sublicense Agreement called for Osmotics to pay us either (1) one-half of the minimum royalty described above or (2) 5% of net sales of Osmotics products using the Barrier Repair technology in the event that royalty payments made by the Company exceed the minimum royalty. The Sublicense Agreement also required Osmotics to pay 50% of all legal expense reimbursements under the UC Agreement. Additionally, the Sublicense Agreement granted us the right, at our sole option, to purchase the formulation for Triceram®, a non prescription product sold by Osmotics using the Barrier Repair technology. The purchase price was $616,000, of which $100,000 was previously paid during 2006. The purchase price was negotiated and approved by the disinterested members of our Board. Under the terms of the DRL Agreement, we were required to purchase the Triceram® formulation by November 2008. We did not purchase Triceram® during 2008 as we did not have sufficient capital resources to do so.

Table of Contents

In March 2009, we amended the Sublicense Agreement as follows:

· The payment terms to purchase Triceram® were revised as follows:

· $16,202 was payable upon exercise of the purchase option;

· Monthly payments of $10,000 commenced on April 1, 2009 and continue until such time that we receive at least $3,500,000 in aggregate net proceeds (as defined in the amendment) from debt or equity transactions and/or upfront and/or milestone payments under commercialization transactions for EpiCeram® or Ceragenins™ ;

· Monthly payments of $40,000 commencing the month following meeting the $3,500,000 net proceed threshold; and

· In the event of certain terminations after a change of control in the Company, or in the event that the Company receives at least $10 million in net proceeds, the outstanding balance shall become payable in a lump sum.

· Osmotics will no longer be responsible for reimbursing us for 50% of all legal expenses under the UC Agreement; and

· Osmotics will no longer be responsible for paying half of the minimum annual royalty under the UC Agreement.

In connection with amending the Sublicense Agreement, we exercised the purchase option to acquire Triceram®. We recorded the purchase at fair value. We do not intend on marketing Triceram® as we believe that its highest and best use is as a “defensive asset.” We have allocated the purchase price of $516,000 to a long-lived intangible asset which is reflected as an other asset on the accompanying consolidated balance sheets. We are amortizing the asset over the remaining life of the patent underlying the UC Agreement at the time of the acquisition (64 months). For the year ended December 31, 2009, we amortized $80,625 which is included in general and administrative expenses on the accompanying consolidated statements of operations.

In connection with acquiring Triceram®, we issued to Osmotics a promissory note. The note bears interest at 9.5% per annum and the payment terms are described above. We applied three outstanding receivables from Osmotics totaling $49,606 to the purchase price and note balance (inclusive of the $16,202 described above). The note is reflected as note payable, related party on the accompanying consolidated balance sheet.

For the years ended December 31, 2009 and 2008, we charged Osmotics $3,084 and $7,716, respectively, for legal expenses under the UC Agreement. We have recorded these charges to Osmotics as a reduction of general and administrative expense on the accompanying consolidated statements of operations. Additionally, for the year ended December 31, 2008, licensing fees were reduced by $25,000 for the portion of the minimum royalty previously borne by Osmotics.

Shared Services Agreement

Given the early stage of our business, management has determined that it is more practical for us to utilize existing Osmotics resources rather than procure them on our own. Accordingly, the Company and Osmotics entered into a shared services agreement (the “Shared Services Agreement”) whereby Osmotics provides office space and other back office support for accounting, human resources, payroll, systems, and information technology. The charge for such services is $5,000 per month. The Shared Services Agreement has been extended until December 31, 2010. The Shared Services Agreement also contemplates that Osmotics may ask certain of our officers to assist them with certain projects. In the event that our officers spend any time on the business of Osmotics, the Shared Services Agreement allows us to charge Osmotics for the cost of these services which is offset against the monthly charge described above. In certain instances, we have not charged Osmotics for the time spent by an executive. However, the Company believes that the time not charged is nominal and not material to the Company’s financial statements. For the years ended December 31, 2009 and 2008, we recorded $59,584 and $60,000, respectively, net, under the Shared Services Agreement. We have recorded such charges as general and administrative expense in the accompanying consolidated statements of operations.

Litigation

From time to time, we may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management would provide for them if upon the advice of counsel, losses are determined to be both probable and estimable.

Table of Contents

(10) GEOGRAPHIC INFORMATION

Revenue by geographic region as determined by where the product is sold was as follows for the years ended December 31, 2009 and 2008:

	2009		2008
United States	$	1,942,494	$	756,224
Canada	128,195		—
Asia	35,616		—
	$	2,106,305	$	756,224

We had no long-lived assets or operations outside of the United States as of and for the years ended December 31, 2009 and 2008.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

We have had no disagreements with our independent registered public accounting firm on accounting and financial disclosure.

Item 9A. Controls and Procedures

This Form 10-K includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 9A includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

The Company’s principal executive and financial officers reviewed and evaluated the Company’s disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Form 10-K. Based on that evaluation, the Company’s principal executive and financial officers concluded that the Company’s disclosure controls and procedures are effective in timely providing them with material information relating to the Company, as required to be disclosed in the reports the Company files under the Exchange Act.

Management’s Annual Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f).

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2009 based on the framework in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2009.

This Form 10-K does not include an attestation of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Form 10-K.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2009 that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

Item 9B. Other Information

None.

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The name, age, and position with our company of each director and executive officer is as follows:

Name	Age	Position	Director/Officer Since
Steven S. Porter	60	Chief Executive Officer, Chairman and Director	2005
Jeffrey S. Sperber	45	Chief Financial Officer and Director	2005
Russell L. Allen	63	Vice President of Corporate Development	2005
Alberto J. Bautista	59	Director	2005
Michel Darnaud	59	Director	2005
Philippe J.C. Gastone	55	Director and Chair of Compensation Committee	2005
Cheryl A. Hoffman-Bray	53	Director and Chair of Audit Committee	2005

Jeffrey S. Sperber has served as the Company’s Chief Financial Officer since May 2005. Prior to joining us, he served as the Chief Financial Officer of Osmotics Corporation from June 2004 until May 2005. He has served as Chief Financial Officer of Ceragenix Corporation since June 2004. From January 2004 through May 2004, Mr. Sperber worked as an independent consultant for various companies, including Osmotics Corporation. From March 2001 through January 2004, Mr. Sperber served as the Vice President and Controller of TeleTech Holdings, Inc., a $1 billion, global, public company which provides outsourced call center services primarily to the Fortune 1000. From October 1997 through March 2001, he served as the Chief Financial Officer of USOL Holdings, Inc., a publicly traded broadband provider focused on multi-family housing communities. At USOL, Mr. Sperber led a successful public offering of USOL’s common stock. From August 1995 through September 1997, Mr. Sperber served as a business unit controller for Tele Communications, Inc., which was subsequently acquired by Comcast. From September 1991 through August 1995, he served in various financial positions for Concord Services, Inc., an international conglomerate, most recently as the Chief Financial Officer of its manufacturing and processing business unit where he oversaw both public and private entities. From September 1986 through September 1991, Mr. Sperber was employed by Arthur Andersen LLP in Denver, Colorado. Mr. Sperber received a CPA license in the State of Colorado, which has since expired. Mr. Sperber was appointed as an outside director of Omni Bio Pharmaceutical Corporation in October 2009 where he also serves as Audit Committee Chair.

Alberto J. Bautista was elected as a director of our company in June 2005. Mr. Bautista has been a Sector Partner for 3i, an international private equity firm, since October 2006. From January 2004 until October 2006, Mr. Bautista worked as the Founder and Principal Consultant of AJB Consulting since January 2004. AJB Consulting was a health care consulting practice based in Singapore, focused on small and medium-sized companies in the life science, medical device, and biotech spaces. From June 1975 to December 2003 he worked at Baxter International in various senior executive positions, including as Vice President and Consultant of Global Renal at Baxter Japan, President of the Asian Division of Baxter Healthcare, President of Worldwide Exports for Baxter World Trade, and General Manager of various branch locations. Mr. Bautista received his M.S. in Management at the Sloan School (Massachusetts Institute of Technology) and his B.S. in Industrial Engineering at the University of the Philippines.

Table of Contents

Michel Darnaud was elected as a director of our company in June 2005. Since February 2008, he has served as President of the Cardiopulmonary Business Unit and Intercontinental for Sorin (Italy). From October 2005 through January 2008, Mr. Darnaud served as Consultant - Medical Technology for Europe with Spencer Stuart (Paris). He served as President of the European Division (Paris) of Boston Scientific Corporation, a producer of medical device products, from 1998 through June 2005. From 1992 until 1997, he worked for Baxter International. Mr. Darnaud was the European President of the Baxter Cardio Vascular Group from 1996 until 1997. From 1994 to 1996 he served as the Vice President of the Renal Division; and from 1992 to 1994 he served as the Area Vice President of the Renal Division. During 1991, Mr. Darnaud served as the General Manager of Diagnostica Stago, a company that manufactures specialty diagnostic products. From 1977 to 1990, he worked with Baxter International. Mr. Darnaud has been a member of the European Medical Device Industry Association since 2002 and its President since October 2004. He graduated from Ecole des Hautes Etudes Commerciales du Nord in 1973.

Philippe J.C. Gastone was elected as a director of our company in June 2005. Since October 2008, he has served as Managing Director, Investment Banking for Violy and Company. From May 2008 to October 2008, Mr. Gastone served as Corporate Director, Development and Mergers & Acquisitions for Votorantim (Brazil). From February 2008 through May 2008, Mr. Gastone served as an independent consultant. From September 2000 until February 2008 he served as the Senior Vice President in Charge of Corporate Business Development for Europe and Americas of Cemex. From 1999 to 2000, he served as a partner of Dome & Cie, a French investment bank. From 1997 to 1999, Mr. Gastone served as a director of Merrill Lynch (London and Paris). From 1994 to 1997, he was the Executive Director, in charge of the Mergers and Acquisitions Origination Group for Europe, of Union Bank of Switzerland (London). From 1984 to 1994, Mr. Gastone worked at Booz, Allen & Hamilton, focusing on strategy and mergers & acquisitions advisory. From 1977 to 1982, he worked as a consultant for The Boston Consulting Group. In 1983, Mr. Gastone received his MBA from INSEAD in Fontainebleau, France in 1983. He graduated from the Ecole des Hautes Etudes Commerciales in 1977 with a BA.

Cheryl A. Hoffman-Bray was elected as a director of the Company in June 2005. Since August 2006, Ms. Hoffman-Bray has served as the Chief Financial Officer and Vice President of the Education Development Center, Inc., a non-profit organization that manages projects addressing world-wide education and health care needs. From October 2004 through March 2006, she served as the Senior Advisor to the Executive Dean of Harvard University. She served as the Dean of Finance and Chief Financial Officer of Harvard’s Faculty of Arts and Sciences from March 2000 until October 2004. Ms. Hoffman Bray served as Chief Financial Officer and Senior Vice President of Finance at the Beth Israel Deaconess Medical Center in Boston, Massachusetts from May 1998 to May 1999, and from October 1996 until May 1998, she served as the Medical Center’s Vice President of Finance. Prior to its merger with Beth Israel, Ms. Hoffman Bray served as the Senior Vice President and Chief Financial Officer of the New England Deaconess Hospital beginning in January 1995. From June 1984 to December 1994, she worked for Albany Memorial Health Systems, Inc., serving as their Vice President and Chief Financial Officer from July 1989 until December 1994 and as the Controller and Director of Fiscal Services from June 1984 until July 1989. From 1980 until May 1984, she was employed by Coopers & Lybrand. Ms. Hoffman Bray graduated from the State University of New York at Albany 1979 with a Bachelor of Science in Accounting and received her Master of Science from the University in 1980. Ms. Hoffman Bray is a director of the Boston Club and a director of the Harvard Cooperative Society.

All directors serve until their successors have been duly elected and qualified, unless they earlier resign.

Directors are elected by a plurality of the shareholders at annual or special meetings of shareholders held for that purpose. In connection with our acquisition of Ceragenix Corporation, we issued to Osmotics an aggregate of 11,191,768 shares of our common stock and 1,000,000 shares of non-voting Series A Preferred Stock. In May 2008, Osmotics converted all shares of the Series A Preferred Stock and $240,000 in accrued dividends into 1,304,569 shares of common stock. There have been no material changes to the way in which shareholders may recommend nominees to the board of directors.

Effective November 7, 2005, Osmotics adopted a Plan of Distribution pursuant to which it plans to exchange approximately 12,004,569 shares of our common stock for shares of its common stock or preferred stock. As part of that Plan of Distribution, Osmotics entered into an escrow agreement with Corporate Stock Transfer, Inc. as Escrow Agent to hold the 12,004,569 shares of common stock. Under the terms of the escrow agreement, Osmotics concurrently granted to our Board an irrevocable proxy to vote all of the escrowed shares. As a result of this series of transactions, our Board in effect, exercises voting control over future elections of members of our Board until such time as Osmotics completes its exchange transaction.

The holders of certain convertible notes have the right to appoint one member to our Board. As of the date of the Report 10-K, they have not exercised this right.

Scientific Advisory Board

Peter Elias, M.D., Professor of Dermatology at the University of California, San Francisco.

Table of Contents

Henry F. Chambers, M.D., Professor of Medicine, University of California, San Francisco and Chief, Division of Infectious Diseases, San Francisco General Hospital.

Richard Gallo, M.D., Professor of Medicine and Pediatrics, and Chief of Division of Dermatology, University of California, School of Medicine.

Tomas Ganz, Ph.D.,M.D., Professor of Medicine and Pathology, and Director, Will Rogers Pulmonary Research Laboratory, David Geffen School of Medicine, University of California, Los Angeles.

Sean P. Gorman, Ph.D., Head of School and Chair in Pharmaceutical Microbiology, Queens University, Belfast, U.K.

Michael S. Niederman, M.D., FACP, FCCP, FCCM, Professor of Medicine and Chairman of the Department of Medicine at the State University of New York, Stony Brook, and Chairman of the Department of Medicine at Winthrop Hospital, Mineola, New York.

Michael J. Rybak, PharmD, MPH, FCCP, FIDSA, Associate Dean for Research, Professor of Pharmacy at the Eugene Applebaum College of Pharmacy and Sciences, and an Adjunct Professor of Medicine in the Division of Diseases at the School of Medicine at Wayne State University, Detroit, Michigan.

Board and Committee Information

During the Company’s 2009 fiscal year, the Board of Directors (the “Board”) conducted two regular meetings. The Board consists of six members of whom four (Ms. Hoffman-Bray and Messrs. Bautista, Gastone, and Darnaud) are independent directors as defined under the rules promulgated by the SEC and the Nasdaq Stock Market. The Board also took three actions by written consent. Each director attended more than 67% of the total number of meetings of the Board and Committees on which he or she served. It is not the policy and practice of the Company that all directors and all nominees for election to the Board attend the Annual Meeting of Stockholders. The Company did not hold an annual meeting of shareholders in 2009. The standing committees of the Board are the Audit and Compensation Committees.

Audit Committee

The Company’s Audit Committee (“Audit Committee”) is comprised of Ms. Hoffman-Bray and Messrs. Gastone and Darnaud, all of whom are independent directors under the rules promulgated by the SEC and the Nasdaq Stock Market. The Audit Committee reviews the independent registered public accounting firm’s reports and audit findings, the scope and plans for future audit programs, independence of the independent registered public accounting firm, and annual financial statements. The Audit Committee also recommends the choice of independent registered public accounting firm to the full Board. The Audit Committee has the sole authority to retain and terminate the Company’s independent registered public accounting firm, approve all auditing services and related fees and the terms thereof, and pre-approve any non-audit services to be rendered by the Company’s independent registered public accounting firm. Six Audit Committee meetings were held in 2009. The Company’s Board of Directors has adopted a written charter for the Audit Committee, which is available on the Company’s web site at www.ceragenix.com under the Investor Relations section. The Board of Directors has determined that Ms. Hoffman-Bray and Mr. Gastone are “audit committee financial experts,” as defined under SEC rules, and satisfy the Nasdaq financial sophistication requirements, as a result of their knowledge, abilities, and experience.

Compensation Committee

The Company’s Compensation Committee (“Compensation Committee”) is currently comprised of Messrs. Bautista, Darnaud and Gastone, all independent directors. The Compensation Committee reviews and makes recommendations to the Board concerning the compensation paid to the Company’s officers. The Compensation Committee held two meetings in 2009. The Company’s Board of Directors has adopted a written charter for the Compensation Committee, which is available on the Company’s web site at www.ceragenix.com under the Investor Relations section.

Nominating Committee

The Company does not currently have a Nominating Committee. The Company has not added any new directors since June 2005 and accordingly has not had a need for a Nominating Committee. In the event that the Company determined it was desirable to add a new director, the entire Board of Directors would oversee the process of identifying potential directors.

Table of Contents

Code of Business Conduct and Ethics

The Company has adopted a Code of Business Conduct and Ethics (“Code”) applicable to its officers, directors, and employees, which includes the principal executive officer, principal financial officer and principal accounting officer. The Code is available on the Company’s website at www.ceragenix.com under the Investor Relations section. The purpose of the Code is to provide legal and ethical standards to deter wrongdoing and to promote:

1. Honest and ethical conduct;

2. Full, fair, accurate, timely, and understandable disclosures;

3. Compliance with laws, rules, and regulations;

4. Prompt internal reporting of violations of the Code; and

5. Accountability for adherence to the Code.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act requires our executive officers, our directors, and persons who own more than ten percent of a registered class of our equity securities, to file changes in ownership on Form 4 or Form 5 with the SEC. These executive officers, directors, and ten-percent stockholders are also required by SEC rules to furnish us with copies of all Section 16(a) reports they file. Based solely on our review of the copies of these forms, we believe that all Section 16(a) reports applicable to our executive officers, directors, and ten-percent stockholders with respect to reportable transactions during the year ended December 31, 2009 were filed on a timely basis.

Report of the Audit Committee

Notwithstanding anything to the contrary set forth in any of the Company’s previous or future filings under the Securities Act of 1933 or the Securities Exchange Act of 1934 that might incorporate future filings made by the Company under those statutes, the following report shall not be deemed to be incorporated by reference into any prior filings nor future filings made by the Company under those statutes.

The Audit Committee of the Board of Directors has oversight responsibility for the Company’s financial reporting processes and the quality of its financial reporting. In reporting this oversight function, the Audit Committee relied upon information and advice received in discussions with the Company’s management and with the auditors, GHP Horwath, P.C.

Management has the primary responsibility for the system of internal controls and the financial reporting process. The independent accountants have the responsibility to express an opinion on the financial statements based on an audit conducted in accordance with generally accepted auditing standards. The Audit Committee has the responsibility to monitor and oversee these processes.

In connection with the December 31, 2009, financial statements, the Audit Committee: (1) reviewed and discussed the audited financial statements with management including the quality of the accounting principles applied and significant judgments used in preparing the Company’s financial statements, (2) discussed with the auditors the matters required by Statement on Auditing Standards No. 61, including the independent auditor’s judgment of accounting principles applied and significant judgments used in preparing the Company’s financial statements, and (3) received the written disclosures and the letter from the auditors required by Independence Standards Board Statement No. 1 (Communication with Audit Committee) and discussed with the auditors the independence of GHP Horwath, P.C. Based upon these reviews and discussions, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in the Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission.

Audit Committee of the Board of Directors:

Cheryl Hoffman-Bray, Chairperson

Michel Darnaud

Philippe Gastone

Item 11. Executive Compensation

Overview of Compensation Policies

Compensation of the Company’s executive officers is determined by the Board. The Compensation Committee is responsible for considering specific information and making recommendations to the full Board with respect to compensation matters. The Compensation Committee voting membership is comprised of Messrs. Bautista, Darnaud and Gastone (three independent

Table of Contents

directors). The Compensation Committee’s consideration of and recommendations regarding executive compensation are guided by a number of factors described below. The objectives of the Company’s total executive compensation package are to attract and retain the best possible executive talent, to provide an economic framework to motivate the Company’s executives to achieve goals consistent with the Company’s business strategy, to provide an identity of interests between executives and stockholders through employee compensation plans, and to provide a compensation package that recognizes an executive’s individual results and contributions in addition to the Company’s overall business results.

During 2009 there were three key elements used to compensate the Company’s executives consisting of base salary, stock options and cash bonuses. The Compensation Committee makes its recommendation to the Board regarding salary levels of officers and key employees, stock options and cash bonus awards based on information derived from a third party survey. The Board reviews management’s future goals and strategies at least yearly to ensure that they are aligned with those of the stockholders and that they provide a sound growth platform that will enhance stockholder value in both the long and short term. In making its recommendations concerning executive compensation, the Committee reviews individual levels of responsibility, scope and complexity of the executive’s position and an evaluation of each individual’s role and performance in advancing the business strategies of the Company. The individual’s and Company’s performance are compared to the executive salary ranges for other companies of similar size and industry.

The Compensation Committee recommends to the Board compensation levels for the Chief Executive Officer, the Chief Financial Officer and other executive officers of the Company. In reviewing individual performance of executives, the Compensation Committee takes into account the full compensation package of each individual, including past compensation levels, past gains on exercises of stock options, and current intrinsic of outstanding options and restricted shares. Additionally, the Committee takes into account the views of the Company’s Chief Executive Officer, who reviews the successes and failures of the Company and its executive officers in light of the goals and strategies for the past year.

Salaries

Salaries for executive officers are determined by evaluating the responsibilities of the position held and the experience of the individual, and by reference to the competitive marketplace for executive talent, including a comparison of salaries for comparable positions at similar companies.

The salary levels of the Chief Executive Officer and other officers of the Company are recommended by the Compensation Committee and approved by the Board of Directors. Specific individual performance, initiative and accomplishments and overall corporate performance are reviewed in determining the compensation level of each individual officer. The Compensation Committee, where appropriate, also considers other performance measures including licensing and financing transactions, future pipeline and compliance with key corporate agreements.

During 2009, there were certain events that the Compensation Committee considered to be important with respect to determining compensation for key executives of the Company. These events included:

· Progress towards commercialization transactions for the Ceragenin™ technology;

· Improvement in the Company’s capital structure;

· Expansion of EpiCeram® into international markets; and

· The financial resources of the Company

The annual base salaries of Steven Porter, the Company’s Chief Executive Officer, Jeffrey Sperber, the Company’s Chief Financial Officer, and Carl Genberg, former Senior Vice President, were $250,000, $210,000, and $230,000, respectively, in 2009. These amounts were unchanged from 2008 and 2007. These officers were not awarded stock option grants or cash bonuses for 2009 due to the financial resources of the Company.

The Compensation Committee believes that the officers of the Company are strongly motivated and dedicated to the growth in stockholder value of the Company. The Compensation Committee further believes that the Chief Executive Officer, as well as the other officers of the Company, are receiving salary compensation in the mid to lower-range of peer-group levels and that their performance incentives are heavily based on their personal shareholding and/or incentive equity holdings in the Company.

Table of Contents

Equity Incentive Compensation

Under existing Company policy, equity-based compensation may be granted to the Company’s key employees and consultants. The Compensation Committee recommends the number and form of the equity-based compensation considering factors including individual performance, CEO recommendations, and gains received on past equity-based grants.

The use of equity-based compensation is intended to align the interests of the executives and other key employees with those of the stockholders. Equity-based compensation also serves to increase management ownership in the Company, provides a level of deferred compensation, aids in employee retention and conserves cash. The Compensation Committee believes that stock options are the best tools to provide for both short term rewards and mid and long term incentive to motivate the executive officers and key employees of the Company to perform at a high level and in the best interest of stockholders.

The Compensation Committee believes that stock options are the best form of long term compensation that rewards management for increasing stockholder value through an increasing stock price. Failure to raise the future stock price will result in a significant loss of potential compensation for executive officers and key employees. The Compensation Committee and the Board do not time the granting of options or shares to the release of important information or quarterly results. The Compensation Committee has previously determined to award annual stock option grants at the June Board meeting.

The following table represents the current status of the outstanding equity compensation awarded pursuant to the policies described above.

EQUITY COMPENSATION PLAN INFORMATION

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants, and rights	Weighted average exercise price of outstanding options, warrants, and rights		Number of securities remaining available for future issuance under equity compensation plan
Equity Compensation awards not subject to a qualified plan	4,855,750	$	1.63	N/A
2008 Ceragenix Pharmaceuticals, Inc. Omnibus Incentive Plan	756,000	$	0.73	2,244,000

Executive Compensation

The following table sets forth the overall compensation earned over each of the past two fiscal years ending December 31, 2009 by (1) each person who served as the principal executive officer of Ceragenix during fiscal year 2009; (2) Ceragenix two most highly compensated executive officers as of December 31, 2009 with compensation during fiscal year 2009 of $100,000 or more; and (3) those two individuals, if any, who would have otherwise been in included in section (2) above but for the fact that they were not serving as an executive of Ceragenix as of December 31, 2009.

Salary Compensation

Name and Principal Position	Fiscal Year	Salary ($)		Bonus ($)(4)		Stock Awards	Options Awards ($)(1)		Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation Compensation ($) (2)(3)	Total ($)
Steven S. Porter	2009	$	250,000	$	—	—	$	93,983	—	—	—	$	343,983
Chief Executive Officer	2008	$	250,000	$	87,500	—	$	114,037	—	—	—	$	451,537

Jeffrey S. Sperber	2009	$	210,000	$	—	—	$	84,078	—	—	—	$	294,078
Chief Financial Officer	2008	$	210,000	$	73,500	—	$	102,061	—	—	—	$	385,561

Carl Genberg(5)	2009	$	230,000	$	—	—	$	89,015	—	—	—	$	319,015
Former Senior Vice President	2008	$	230,000	$	80,500	—	$	108,022	—	—	—	$	418,522

(1) Reflects dollar amount expensed by the Company during applicable fiscal year for financial statement reporting purposes pursuant to ASC 718-10-25. ASC 718-10-25 requires the Company to determine the overall value of the options as of the date of grant based upon the Black-Scholes method of valuation, and to then expense that value over the service period over which the options become exercisable (vest). As a general rule, for time-in-service-based options, the Company will immediately expense any option or portion thereof which is vested upon grant, while expensing the balance on a pro rata basis over the remaining vesting term of the option. For a description ASC 718-10-25 and the assumptions used in determining the value of the options under the Black-Scholes

Table of Contents

model of valuation, see the notes to the consolidated financial statements included with this Report.

(2) Includes all other compensation not reported in the preceding columns, including (i) perquisites and other personal benefits, or property, unless the aggregate amount of such compensation is less than $10,000; (ii) any “gross-ups” or other amounts reimbursed during the fiscal year for the payment of taxes; (iii) discounts from market price with respect to securities purchased from the company except to the extent available generally to all security holders or to all salaried employees; (iv) any amounts paid or accrued in connection with any termination (including without limitation through retirement, resignation, severance or constructive termination, including change of responsibilities) or change in control; (v) contributions to vested and unvested defined contribution plans; (vi) any insurance premiums paid by, or on behalf of, the company relating to life insurance for the benefit of the named executive officer; and (vii) any dividends or other earnings paid on stock or option awards that are not factored into the grant date fair value required to be reported in a preceding column.

(3) Includes compensation for service as a director described under Director Compensation, below.

(4) 2008 cash bonuses are considered earned, have been accrued on the Company’s financial statements, but have not been paid. The bonuses will be paid at such time that the Board determines that the Company has sufficient cash to pay the bonuses.

(5) Mr. Genberg’s employment was terminated effective March 29, 2010.

No outstanding common share purchase option or other equity-based award granted to or held by any named executive officer were repriced or otherwise materially modified, including extension of exercise periods, the change of vesting or forfeiture conditions, the change or elimination of applicable performance criteria, or the change of the bases upon which returns are determined, nor was there any waiver or modification of any specified performance target, goal or condition to payout.

We did not issue any stock options during the year ended December 31, 2009. The weighted average fair value of stock options at the date of grant issued to employees during the year ended December 31, 2008 was $.36 per share. We determine fair value using the Black-Scholes option pricing model. We used the following assumptions to determine the fair value of stock option grants during the year ended December 31, 2008:

Year Ended December 31, 2008
Volatility	50	% - 51%
Dividend yield	0
Risk-free interest rate	2.4	% - 3.2%
Expected term (years)	5.0

The following table provides certain information concerning any common share purchase options, stock awards or equity incentive plan awards held by each of our named executive officers that were outstanding as of December 31, 2009

	Option Awards					Stock Awards
Name	Number of Securities Underlying Unexercised Options(#) Exercisable	Number of Securities Underlying Unexercised Options(#) Unexercisable	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested
Steven S. Porter (1)	1,196,200	151,000	151,000	$.73 - $2.25	2015 - 2018	—	—	—	—

Jeffrey S. Sperber (2)	620,300	135,000	135,000	$.73 - $2.25	2015 - 2018	—	—	—	—

Carl Genberg (3)	783,200	143,000	143,000	$.73 - $2.25	2015 - 2018	—	—	—	—

Russell Allen (4)	470,300	135,000	135,000	$.73 - $3.80	2015 - 2018	—	—	—	—

Table of Contents

(1) Common share purchase options to acquire 950,000 shares of common stock at $1.00 per share were granted on May 10, 2005 in connection with the Merger. These options were fully exercisable (vested) upon grant. Includes 475,000 shares that Mr. Porter is entitled to purchase through a currently exercisable option and 475,000 shares that his spouse, Mrs. Francine Porter, is entitled to purchase through a currently exercisable option. On June 30, 2006, Mr. Porter received common share purchase options to acquire 95,200 shares of common stock at $2.25 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 6, 2007, Mr. Porter received common share purchase options to acquire 151,000 shares of common stock at $1.83 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 6, 2008, Mr. Porter received common share purchase options to acquire 151,000 shares of common stock at $.73 per share. These options vest over a three year period (1/3 each one year anniversary date from grant).This table does not include the shares issued in the Merger that may become beneficially owned by Mr. Porter upon distribution by Osmotics as described under the section titled “Certain Relationships, Related Transactions, and Director Independence.”

(2) Common share purchase options to acquire 400,000 shares of common stock at $1.00 per share were granted on May 10, 2005 in connection with the Merger. These options were fully exercisable (vested) upon grant. On June 30, 2006, Mr. Sperber received common share purchase options to acquire 85,300 shares of common stock at $2.25 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 6, 2007, Mr. Sperber received common share purchase options to acquire 135,000 shares of common stock at $1.83 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 6, 2008, Mr. Sperber received common share purchase options to acquire 135,000 shares of common stock at $.73 per share. These options vest over a three year period (1/3 each one year anniversary date from grant).

(3) Common share purchase options to acquire 550,000 shares of common stock at $1.00 per share were granted on May 10, 2005 in connection with the Merger. These options were fully exercisable (vested) upon grant. On June 30, 2006, Mr. Genberg received common share purchase options to acquire 90,200 shares of common stock at $2.25 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 6, 2007, Mr. Genberg received common share purchase options to acquire 143,000 shares of common stock at $1.83 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 6, 2008, Mr. Genberg received common share purchase options to acquire 143,000 shares of common stock at $.73 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). Mr. Genberg’s employment was terminated effective March 29, 2010.

(4) Common share purchase options to acquire 250,000 shares of common stock at $3.80 per share were granted on June 15, 2005 in connection with Mr. Allen’s commencing employment with the Company. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 30, 2006, Mr. Allen received common share purchase options to acquire 85,300 shares of common stock at $2.25 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 6, 2007, Mr. Allen received common share purchase options to acquire 135,000 shares of common stock at $1.83 per share. These options vest over a three year period (1/3 each one year anniversary date from grant). On June 6, 2008, Mr. Allen received common share purchase options to acquire 135,000 shares of common stock at $.73 per share. These options vest over a three year period (1/3 each one year anniversary date from grant).

Director Compensation

Stock Options

All outside directors will receive options to acquire 70,000 shares of our common stock upon joining our Board. Such options will vest 100% on the first anniversary of the date of grant. Outside directors may also each receive annual grants of options to purchase shares of our common stock, the timing and other terms to be determined by the Compensation Committee of our Board. All options shall be priced at fair market value on the date of grant. In June 2006, the Compensation Committee approved granting options to acquire 33,000 shares of common stock (each) to Mr. Gastone and Ms. Hoffman-Bray and options to acquire 30,000 shares of common stock (each) to Messrs. Bautista and Darnaud. These options have an exercise price of $2.25 per share and vest over a three year period (1/3 on each one year anniversary from the date of grant). In June 2007, the Compensation Committee approved granting options to acquire 48,000 shares of common stock to each of the outside directors. These options have an exercise price of $1.83 per share and vest over a three year period (1/3 on each one year anniversary from the date of grant). In June 2008, the Compensation Committee approved granting options to acquire 48,000 shares of common stock to each of the outside directors. These options have an exercise price of $.73 per share and vest over a three year period (1/3 on each one year anniversary from the date of grant).The Compensation Committee has set the June Board meeting as the date to issue annual option grants.

Table of Contents

Cash Compensation

All outside directors are compensated $1,000 per meeting day for meetings attended in person and $500 per telephonic board meeting. All outside directors receive an annual retainer of $25,000. The Chairperson of the Audit Committee also receives an additional retainer of $5,000 per year. Annual retainers are payable quarterly in arrears. Further, each Audit Committee member is paid $500 per Audit Committee meeting attended whether in person or by telephone. Travel time shall not be considered a meeting day. Under the terms of the Amended Convertible Debt Agreements, the annual retainers are to be accrued, but not paid, until the earlier of (i) June 30, 2010 and (ii) the date that 50% of the initial aggregate principal amount of such debt is no longer outstanding and has been redeemed. Accordingly, we have not made any quarterly retainer payments subsequent to June 30, 2008. As of December 31, 2009, we have accrued $157,500 in unpaid annual retainer fees.

Travel Expenses

All directors shall be reimbursed for their reasonable out of pocket expenses associated with attending the meeting. For domestic travel, only coach airfare will be reimbursed; for international travel we will reimburse for business class.

The following table shows the overall compensation earned for the 2009 fiscal year with respect to each person who was a director as of December 31, 2009, with the exception of Mr. Porter and Mr. Sperber, who are not compensated for their director responsibilities.

DIRECTOR COMPENSATION

Name and Principal Position	Fees Earned or Paid in Cash ($)(4)		Stock Awards ($)	Option Awards ($) (1)		Non-Equity Incentive Plan Compensation ($) (2)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($) (3)	Total ($)
Michel Darnaud (5) Director	$	29,000	—	$	29,800	—	—	—	$	58,800

Cheryl A. Hoffman Bray (6)	$	35,000	—	$	30,660	—	—	—	$	65,660
Director and Chair of Audit Committee

Philippe J.C.Gastone (7)	$	29,000	—	$	30,660	—	—	—	$	59,660
Director and Chair of Compensation Committee

Alberto J. Bautista (8) Director	$	26,000	—	$	29,800	—	—	—	$	55,800

(1) Reflects dollar amount expensed by the Company during applicable fiscal year for financial statement reporting purposes pursuant to FAS 123R. FAS 123R requires the Company to determine the overall value of the options as of the date of grant based upon the Black-Scholes method of valuation, and to then expense that value over the service period over which the options become exercisable (vest). As a general rule, for time-in-service-based options, the Company will immediately expense any option or portion thereof which is vested upon grant, while expensing the balance on a pro rata basis over the remaining vesting term of the option. For a description FAS 123R and the assumptions used in determining the value of the options under the Black-Scholes model of valuation, see the notes to the consolidated financial statements included with this Report.

(2) Excludes awards or earnings reported in preceding columns.

(3) Includes all other compensation not reported in the preceding columns, including (i) perquisites and other personal benefits, or property, unless the aggregate amount of such compensation is less than $10,000; (ii) any “gross-ups” or other amounts reimbursed during the fiscal year for the payment of taxes; (iii) discounts from market price with respect to securities purchased from the company except to the extent available generally to all security holders or to all salaried employees; (iv) any amounts paid or accrued in connection with any termination (including without limitation through retirement, resignation, severance or constructive termination, including change of responsibilities) or change in control; (v) contributions to vested and unvested defined contribution plans; (vi) any insurance premiums paid by, or on behalf of, the company relating to life insurance for the benefit of the director; (vii) any consulting fees earned, or paid or payable; (viii) any annual costs of payments and promises of payments pursuant to a director legacy program and similar charitable awards program; and (ix) any dividends or other earnings paid on stock or option awards that are not factored into the grant date fair value required to be reported in a preceding column.

(4) Includes $25,000 of cash compensation accrued but not paid for Messrs. Bautista and Gastone, $26,000 of accrued but unpaid cash compensation for Mr. Darnaud, and $31,000 of accrued but unpaid cash compensation for Ms. Hoffman-Bray.

(5) Includes 126,000 shares that Mr. Darnaud is entitled to purchase through stock options granted on June 30, 2006 and June 6,

Table of Contents

2007 and 2008 in connection with the annual director grants of which 78,000 shares are currently exercisable.

(6) Includes 129,000 shares that Ms. Hoffman-Bray is entitled to purchase through stock options granted on June 30, 2006 and June 6, 2007 and 2008 in connection with the annual director grants of which 81,000 shares are currently exercisable.

(7) Includes 129,000 shares that Mr. Gastone is entitled to purchase through stock options granted on June 30, 2006 and June 6, 2007 and 2008 in connection with the annual director grants of which 81,000 shares are currently exercisable.

(8) Includes 126,000 shares that Mr. Bautista is entitled to purchase through stock options granted on June 30, 2006 and June 6, 2007 and 2008 in connection with the annual director grants of which 78,000 shares are currently exercisable.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth information, as of April 1, 2010, with respect to beneficial ownership of our common stock by each person known by us to be the beneficial owner of more than 5% of our outstanding stock, by each of our directors and nominees for director, by certain executive officers, and by all officers and directors of the Company as a group. Unless otherwise noted, each stockholder has sole investment and voting power over the shares owned.

Name & Address(1)	Shares Beneficially Owned
of Beneficial Owner	Number(1)(2)	Percent(3)
Steven S. Porter(4)	1,202,867	6.2	%
Jeffrey S. Sperber(5)	620,300

CERAGENIX PHARMACEUTICALS, INC. 10-K